0001354488-14-001177.txt : 20140314 0001354488-14-001177.hdr.sgml : 20140314 20140314173013 ACCESSION NUMBER: 0001354488-14-001177 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20140310 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140314 DATE AS OF CHANGE: 20140314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAURIGA SCIENCES, INC. CENTRAL INDEX KEY: 0001142790 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 651102237 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53723 FILM NUMBER: 14695554 BUSINESS ADDRESS: STREET 1: 39 OLD RIDGEBURY ROAD CITY: DANBURY STATE: CT ZIP: 06180 BUSINESS PHONE: 917-796-9926 MAIL ADDRESS: STREET 1: 39 OLD RIDGEBURY ROAD CITY: DANBURY STATE: CT ZIP: 06180 FORMER COMPANY: FORMER CONFORMED NAME: Immunovative, Inc. DATE OF NAME CHANGE: 20120503 FORMER COMPANY: FORMER CONFORMED NAME: Novo Energies Corp DATE OF NAME CHANGE: 20090626 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC WINE AGENCIES INC DATE OF NAME CHANGE: 20040622 8-K 1 taug_8k.htm CURRENT REPORT taug_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):

March 10, 2014
 
Commission File #: 000-53723
 
TAURIGA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
 
Florida
(State or other jurisdiction of incorporation)

65-1102237
(IRS Employer Identification Number)

39 Old Ridgebury Road
Danbury, Connecticut 06180
 (Address of principal US executive offices)

 Tel: (917) 796-9926
(Registrant’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
 
 
 

 

ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Merger Agreement

On March 10, 2014, Tauriga Sciences, Inc., a Florida corporation, (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Doc Greene’s Acquisition Sub, LLC, a California limited liability company and wholly-owned subsidiary of the Company (“Merger Sub”), Honeywood, LLC, a California limited liability company (“Honeywood”), and the members of Honeywood (together with Honeywood, the “Sellers”).  Pursuant to the Merger Agreement, Merger Sub will merge with and into Honeywood (the “Merger”), with Honeywood surviving the Merger as a wholly-owned subsidiary of the Company.

At the effective time of the Merger (the “Effective Time”), each membership interest of Honeywood will be converted into the right to receive restricted shares of the Company’s common stock such that the members of Honeywood shall receive, in the aggregate, the number of shares of the Company’s common stock equal to 32.0% of the aggregate number of shares of the Company’s common stock outstanding on a fully-diluted basis as of the date immediately preceding the date of the closing of the transactions contemplated by the Merger Agreement.

The obligation of the Sellers to consummate the Merger is subject to a condition that the Company shall have raised $1,000,000 (the “Financing”) to be held in escrow pending the closing of the Merger and to be used following the Merger for the general corporate and working capital purposes of the surviving entity.  Any moneys paid by the Company to Honeywood in advance of the closing of the Merger, including the $175,000 of deposits described below, will be credited toward the aggregate amount of financing that must be raised to meet this condition.  The obligation of the Company to consummate the Merger is subject to a condition that the Company shall have received a notice of effectiveness from the Securities and Exchange Commission (the “Commission”) with respect to a Registration Statement on Form S-1 that the Company intends to file pursuant to the Securities Purchase Agreement described below (the Registration Statement”). The consummation of the Merger is also subject to the satisfaction of other customary conditions, including completion of due diligence, obtaining requisite consents and approvals and performance in all material respects by the parties of their covenants and agreements under the Merger Agreement.

The Merger Agreement contains representations and warranties customary for transactions of this type.  Subject to certain limitations, the parties agreed to indemnify each other for breaches of representations, warranties and agreements and certain other items.

Honeywood has entered into customary covenants and agreements, including, among others, agreements to conduct its business in all material respects in the ordinary course between the execution of the Merger Agreement and the Effective Time and not to engage in specified kinds of transactions during this period.  In addition, the parties have agreed to terminate any and all existing activities, discussions and negotiations with respect to any offer or proposal to acquire all or a majority of any party’s capital stock or equity interests or all or 10% or more of the assets or business of any party, whether by merger, consolidation, reorganization, purchase of stock/interests, purchase of assets, tender offer, exchange offer or otherwise (an “Alternative Proposal”).  In addition, each party has agreed not to solicit, initiate or knowingly encourage the submission of any Alternative Proposal.  From the date of the execution of the Merger Agreement until 120 days following the closing of the Merger, the Company has agreed not to utilize securities drawn under its common stock purchase agreement (“ATM”) entered into between the Company and Hanover Holdings I, LLC on June 13, 2013, without the prior written consent of the other parties to the Merger Agreement, which consent shall not be unreasonably withheld.  The Company has further covenanted to use at up to one half of the remaining shares under the ATM to fund the surviving entity’s business operations, expansion or other working capital needs between the closing of the Merger and July 30, 2016, if necessary.

 
2

 
 
Each party is required to use commercially reasonable efforts, among other things, to take all action and to do all things necessary, proper, or advisable in order to consummate and make effective the transactions contemplated by the Merger Agreement.

On March 11, 2014, the Company paid a nonrefundable deposit to Honeywood on the Merger of $75,000.  In addition, the Company is obligated to pay Honeywood an additional deposit of $100,000 on or before March 24, 2014.  If the Merger is not consummated for any reason, then these amounts, as well as any other amounts paid by the Company to Honeywood (exclusive of payments of rent on Honeywood’s corporate offices that the Company has agreed to pay and certain legal fees), will be converted into an equity ownership interest in Honeywood by the Company based on a pre-transaction valuation of Honeywood of $3,000,000.

The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, attached hereto as Exhibit 2.1, and incorporated herein by reference. The foregoing summary has been included to provide investors with information relating to the terms of the Merger Agreement and is qualified in its entirety by the terms and conditions of the Merger Agreement. It is not intended to provide any other factual information about the Company, Honeywood or their respective subsidiaries or affiliates.

Securities Purchase Agreement

On March 10, 2014, the Company entered into a Securities Purchase Agreement, dated as of March 7, 2014 (the “Securities Purchase Agreement”) by and between the Company and the investor identified therein (the “Investor”) for the private placement of warrants (the “Warrants”) to purchase up to $1,000,000 of the Company’s common stock, par value $0.00001 per share (“Common Stock”).  The aggregate purchase price for the Warrants is $1,000,000, $250,000 of which was deposited into escrow prior to entry into the Securities Purchase Agreement, $250,000 of which will be deposited to escrow no later than one day prior to the closing of the Merger, and the remaining $500,000 of which will be paid within 90 days after the closing of the Merger.

The exercise price for the Warrants is the lower of $0.05 per share or the average of the volume weighted average price of the Common Stock for the five trading days immediately prior to such exercise, with a discount no greater than 35% of such five-day volume weighted average price.  The Warrants will be exercisable at any time from the closing date through and including the 24-month anniversary of the closing date.  The Warrants are subject to customary protections against stock dividends and splits as well as fundamental transactions.

 
3

 
 
As promptly as possible, and in any event within 45 days after the date of the Securities Purchase Agreement, the Company will prepare and file with the Commission the Registration Statement.  The Company has agreed to use commercially reasonable efforts to cause the Registration Statement to be declared effective, and to use its commercially reasonable efforts to keep the Registration Statement continuously effective, subject to certain exceptions, until the earlier of the date that all underlying shares of Common Stock covered by the Warrants have been sold or can be sold publicly pursuant to Commission Rule 144 without compliance with its current public information requirements or volume or manner-of-sale restrictions.

The Securities Purchase Agreement contains representations and warranties customary for transactions of this type.  Furthermore, the obligation of the Investor to purchase the Warrants, and the obligation of the Company to issue the Warrants, are subject to conditions precedent customary for transactions of this type, including the declaration of effectiveness by the Commission of the registration statement.

The foregoing description of the Securities Purchase Agreement, the Warrants and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Securities Purchase Agreement, attached hereto as Exhibit 10.1, and incorporated herein by reference. The foregoing summary has been included to provide investors with information relating to the terms of the Securities Purchase Agreement and the Warrants and is qualified in its entirety by the terms and conditions of the Securities Purchase Agreement. It is not intended to provide any other factual information about the Company, the investors or their respective subsidiaries or affiliates.

Cautionary Note on Forward-Looking Statements

Except for statements of historical fact, this Current Report on Form 8-K (this “Form 8-K”) contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on the Company’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those identified in the Company’s filings with the Commission, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which the Company has little or no control. Such forward-looking statements are made only as of the date of this Form 8-K, and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances, except as required by law. Readers should not place undue reliance on these forward-looking statements.

 
4

 
 
Item 8.01. Other Events.
 
On March 11, 2014, the Company issued a press release announcing the entry into the Merger Agreement and the Securities Purchase Agreement. The press release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
 
ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
 
(d)           Exhibits

The following exhibits are furnished or filed as part of this Current Report on Form 8-K:
 
2.1
Agreement and Plan of Merger, dated March 10, 2014
10.1
Securities Purchase Agreement, dated March 7, 2014.
99.1
Press Release of Tauriga Sciences, Inc., dated March 11, 2014.

 
5

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
TAURIGA SCIENCES, INC
 
       
Date: March 14, 2014
By:
/s/ Stella M. Sung, Ph.D  
   
Stella M. Sung, Ph.D
 
    Chief Executive Officer  
       
 
 
 
6

 
EX-2.1 2 taug_ex21.htm AGREEMENT AND PLAN OF MERGER, DATED MARCH 10, 2014 taug_ex21.htm
Exhibit 2.1
 
EXECUTION COPY
 
AGREEMENT AND PLAN OF MERGER
 
DATED AS OF March 10, 2014
 
BY AND AMONG
 
TAURIGA SCIENCES, INC.,
 
DOC GREENE’S ACQUISITION SUB, LLC,
 
HONEYWOOD, LLC,
 
AND
 
THE OTHER SELLERS FROM TIME TO TIME PARTY HERETO
 

 
 
 

 
 
Table of Contents
 

 
Page
 
EXHIBITS
 
Exhibit A                      Release and Covenant Not to Sue
 
Exhibit B                      Standstill and Voting Agreement
 
Exhibit C                      Form of Joinder
 
SCHEDULES
                    
Schedule 1.1(d):  
Managers and Officers of the Surviving Entity
Schedule 2.2
Capitalization
Schedule 2.4
Seller Consents and Approvals
Schedule 2.5:
Financial Statements
Schedule 2.6(b):
Operation of Business
Schedule 2.7:
No Undisclosed Liabilities
Schedule 2.8:
Litigation; Compliance with Law; Licenses
Schedule 2.9:
Employee Benefit Plans
Schedule 2.10(a):
Doc Green’s IP
Schedule 2.10(j):
Licenses of Doc Green’s, including any City, State and Federal licenses, permits, approvals, contracts and the similar items
Schedule 2.11(a):
Material Contracts
Schedule 2.13(a):
Affiliated Party Transactions – Obligations and Proceedings
Schedule 2.13(b):
Affiliated Party Transactions – Loans and Advances
Schedule 2.13(c):
Affiliated Party Transactions – Ownership
Schedule 2.14(a):
Real Property
Schedule 2.14(c):
Environmental Laws
Schedule 2.16:
Insurance
Schedule 2.18(a):
Employees and Independent Contractors
Schedule 2.18(b):
Directors and Managers
Schedule 2.18(d):
Compliance with Employment Law
Schedule 2.19:
Accredited Investors
Schedule 3.3:
Purchaser Consents and Approvals
Schedule 5.5:    
Preservation of Business
                                       
 
 
2

 
 
AGREEMENT AND PLAN OF MERGER
 
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made as of March 10, 2014, by and among Tauriga Sciences, Inc., a Florida corporation (“Tauriga”), Doc Greene’s Acquisition Sub, LLC, a California limited liability company and wholly-owned subsidiary of Tauriga (“Acquisition Sub” and together with Tauriga, the “Purchasers”), Honeywood, LLC, a California limited liability company (“Honeywood”) and the current limited liability company members of Honeywood LLC (which are Elie Green, Daniel Kosmal and Ramona  Rubin) as of the date hereof and Parties hereto in accordance the terms of this Agreement (“Members”, and together with Honeywood, collectively referred to as “Sellers”, or each a “Seller”).  Tauriga, Acquisition Sub, Honeywood, and, upon their execution hereof, the Members party hereto are each referred to herein as a “Party” or collectively as the “Parties”.
 
RECITALS
 
WHEREAS, Honeywood is engaged in the business of developing therapeutic healing creams harnessing the pain relieving and healing power of cannabis (the “Product”).
 
WHEREAS, Honeywood desires Tauriga to, and Tauriga desires to, assist in the expanded commercialization, increased sales of and revenues generated by the Product and Honeywood.
 
WHEREAS, for the purposes thereof, the Parties desire that Tauriga acquire Honeywood through a merger of Acquisition Sub with and into Honeywood, with Honeywood being the surviving entity (the “Merger”).
 
WHEREAS, the board of directors of Tauriga and board of managers of Honeywood believe that a business combination of Acquisition Sub and Honeywood would be in the best interests of the stockholders or members of both entities.
 
WHEREAS, as a result of the Merger, Honeywood will become a wholly-owned subsidiary of Tauriga and the members of Honeywood will receive shares of Common Stock in Tauriga.
 
NOW, THEREFORE, in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties, and covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound hereby, the Parties agree as follows.
 
ARTICLE I

THE MERGER; CERTAIN DEFINITIONS.
 
1.1 The Merger.
 
(a) Structure.  Subject to the terms and provisions of this Agreement, and in accordance with the California Revised Uniform Limited Liability Company Act (popularly known as RULLCA, and codified at Cal. Corp. Code §§17701.01-17713.13 - the “CA Code”), at the Effective Time, Acquisition Sub shall be merged with and into Honeywood.  Honeywood will be the surviving entity of the Merger (sometimes hereinafter called the “Surviving Entity”) and will continue its corporate existence under the laws of the State of California as a subsidiary of Tauriga.  At the Effective Time, the separate corporate existence of Acquisition Sub shall cease.
 
 
 
3

 
 
(b) The Closing.  The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place at the offices of Nixon Peabody LLP, 437 Madison Avenue, New York, New York 10022, commencing at 11:00 a.m. local time on the earlier to occur of (a) the business day following the date on which all the conditions set forth in Sections 4.1 and 4.2 have been satisfied or waived (other than conditions with respect to actions the respective Parties will take at the Closing itself), or (b) within one-hundred twenty (120) days immediately following the execution of this Agreement or (c) such other date as the parties may mutually determine in writing, including by extension for a period of sixty (60) additional days in the event that the Securities and Exchange Commission should provide comments to Tauriga’s Form S-1 resale registration statement (relating to such institutional investor(s) Warrant exercisable for shares of Tauriga’s common stock in exchange for its/their $1MM investment related to the Merger and pursuant to that certain Securities Purchase Agreement between Tauriga and such investor(s)) (the “Closing Date”).
 
(c) Actions at the Closing.  At the Closing, (i) Tauriga and Acquisition Sub will deliver to Honeywood the various certificates, instruments, and documents referred to in Section 4.2 below, (ii) Honeywood will deliver to Tauriga the various certificates, instruments, and documents referred to in Section 4.1 below, and (iii) the Surviving Entity shall file with the Secretary of State of the State of California a properly executed Certificate of Merger.
 
(d) Effect of Merger.
 
(i) General.  The Merger shall become effective at the time (the “Effective Time”) the Surviving Entity files the Certificate of Merger with the Secretary of State of the State of California.  The Merger shall have the effect set forth in the CA Code.
 
(ii) Articles of Organization.  The Articles of Organization of the Surviving Entity will be the Articles of Organization of Acquisition Sub in effect immediately prior to the Merger.
 
(iii) Operating Agreement.  The Operating Agreement of the Surviving Entity will be the Operating Agreement of the Acquisition Sub in effect immediately prior to the Merger.
 
(iv) Conversion of Membership Interests of Acquisition Sub.  At and as of the Effective Time, all issued and outstanding membership interests of Acquisition Sub will be canceled and retired and shall cease to exist and neither membership interests of the Surviving Entity nor any cash, property, rights, other securities or obligations of the Surviving Entity shall be issued therefor, except as provided in Section 1.2 below.
 
(v) Managers and Officers.  From and after the Effective Time, the managers and officers of the Surviving Entity shall be as set forth on Schedule 1.1(d) hereto.
 
(vi)   Abandonment of Merger.  Subject to Article VIII, at any time before the Effective Time, this Agreement may be terminated and the Merger may be abandoned for any reason whatsoever by the board of managers of Tauriga, notwithstanding the approval of this Agreement by its board of Directors.
 
 
4

 
 
1.2 Merger Consideration.
 
(a) Merger Deposit.  Upon the execution and delivery of this Agreement, in contemplation of and consideration for the transactions contemplated hereby, Tauriga shall pay Honeywood by wire transfer or other delivery of immediately available funds to the bank account specified by Honeywood in writing, (i) an amount equal to seventy five thousand dollars ($75,000), payable on the business day following the date hereof, to serve as an irrevocable deposit for the Merger, and as to which Honeywood shall have immediate access and use solely for working capital purposes of its Doc Green’s product line, and (ii) one-hundred thousand dollars ($100,000), payable within ten (10) business days following the date hereof, to serve as additional consideration for the Merger to be used solely for working capital purposes of its Doc Green’s product line.
 
(b) Break-up Fee. Notwithstanding the terms of Section 1.2(a), it is understood and acknowledged by the parties hereto that should the Closing of the Merger contemplated hereunder not be consummated for any reason, then the $75,000 and (if then paid) the additional $100,000 (if then paid) paid by Tauriga to Honeywood (in addition to any other monies paid, wired or otherwise forwarded by Tauriga to Honeywood  out of the WC Financing (as defined in Section 5.10, but excluding any Rent Payments paid by Tauriga pursuant to Section 5.19 and the legal fees paid for by Tauriga on Sellers’ behalf) in the period between the date of this Agreement and the Closing Date will be exchanged (as a break-up fee) for an equity ownership interest in Honeywood by Tauriga promptly following the termination of this Agreement, which percentage of ownership shall be based on a pre-transaction valuation of Honeywood LLC of three million USD ($3,000,000).
 
(c) Issuance of Tauriga Common Stock.  At the Closing, the sole and single class of issued and outstanding membership interests of Honeywood (collectively, the “Honeywood Interests”) shall be converted into the right to receive up to such number of restricted shares of Tauriga’s common stock, $.00001 par value per share (the “Merger Shares”) determined in accordance with the Conversion Ratio.  The Merger Shares shall be allocated among the holders of Honeywood Interests in accordance with his or its respective proportional holdings of Honeywood Interests as of the Closing; provided, however, for the avoidance of doubt, no Person will be entitled to Merger Shares unless such Person has been admitted as a Member of Honeywood prior to the Effective Time and is a Party to this Agreement, or unless any of the Members have gifted a portion of their Merger Shares to such Persons at Closing.  No fractional shares of Tauriga Common Stock will be issued in the Merger upon the surrender for exchange of the Honeywood Interests, and any such fractional share interests will not entitle the owner thereof to any rights of a stockholder of Tauriga.  Each Member who is entitled to one-half or more of a Merger Share will receive a full Merger Share, and any fractional interests of less than one-half of a Merger Share will be canceled.
 
(d) Cancellation of Honeywood Interests.  All Honeywood Interests converted in accordance with this paragraph will no longer be outstanding and will automatically be cancelled and retired and shall cease to exist, and Honeywood and its Members shall cease to have any rights with respect thereto, except the right to receive Merger Shares in accordance with the Conversion Ratio in accordance with Section 1.2(b).  At and as of the Effective Time, each issued and outstanding unit of Honeywood Interests and any other equity interest in Honeywood issued and outstanding or held in Honeywood’s treasury shall automatically be canceled and extinguished and no payment shall be made in respect thereof except according to the provisions of this Agreement.  No unit of Honeywood Interests outstanding prior to the Effective Time shall be deemed to be outstanding or to have any rights after the Effective Time.  After the Effective Time, there shall be no further registration of transfers of Honeywood Interests outstanding immediately prior to the Effective Time on Honeywood’s membership interest transfer books.
 
(e) Issuance of Interests to Tauriga.  At the Effective Time, all of the membership interests of Acquisition Sub issued and outstanding immediately prior to the Effective Time shall be converted into one (1) fully paid membership interest of the Surviving Entity.  At the Effective Time, Surviving Entity shall issue a membership interest certificate to and in the name of Tauriga for one (1) membership unit.
 
(f) Delivery of Honeywood Interests.  At the Effective Time, Honeywood shall, and Honeywood shall cause each Member to, transfer to Tauriga, the Honeywood Interests owned by it and such Member, free and clear of all Encumbrances and competing claims, and each Member shall deliver to Tauriga any membership interest certificates evidencing the Honeywood Interests and such instruments of transfer and other documents as Purchaser shall reasonably request together with any and all necessary membership interest transfer Tax stamps.
 
 
5

 
 
1.3 [Reserved]
 
1.4 Appraisal Rights.  It shall be a condition to the Closing that no rights of dissension or appraisal under the CA Code shall have been asserted or exercised by Honeywood or any other Member.  Each Member party hereto hereby waives any appraisal rights under the CA Code arising out of the transactions contemplated in this Agreement and shall take all actions necessary or desirable under the CA Code to waive such rights.
 
1.5 Certain Definitions.  As used in this Agreement:
 
(a) Affiliate” means, with respect to any Person, any other Person that controls, is controlled by, or is under common control with such Person.  As used herein, the term “control” shall mean possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through ownership of securities, by contract or otherwise.
 
(b) Confidential Information” means (whether disclosed in writing or orally) any and all non-public and/or proprietary information with respect to the business, services, operations, assets, properties, financial condition, plans and prospects of a Party and its Subsidiaries and Affiliates including Intellectual Property and information relating to acquisition targets and acquisition strategies, pricing for acquisitions, financial information or projections and other information concerning acquisition targets and potential acquisition targets, proposed financing arrangements, customers and vendors, business strategies, plans and prospects, agreements, business records, information relating to intellectual property, marketing and sales strategies, pricing strategies, programs, source codes, object codes, algorithms and the related documentation, software designs (in each case regardless of the medium in which it is maintained or stored), internet strategies, URL designations and any other information which a Party designates that it has received pursuant to a confidentiality obligation to another Person, together with all derivative works, copies, reports, summaries, studies, compilations and other documentation which contain or otherwise reflect or are generated from any of the foregoing.
 
(c) Contract” means any note, bond, mortgage, indenture, guarantee, other evidence of indebtedness, license, lease, option, employment agreement, contract, undertaking, understanding, covenant, agreement or other instrument, whether oral or written.
 
(d) Contaminant” means any waste, pollutant, hazardous substance, toxic substance, hazardous waste, medical waste, special waste, asbestos, petroleum or petroleum-derived substance, radioactive material or waste, or any constituent of any such substance or waste and including any substance which any Governmental Entity or lawful representative thereof requires to be controlled, removed, monitored, encapsulated or remediated or otherwise addressed for the purposes of protection of the environment or public or worker health and safety.
 
(e) Conversion Ratio” shall equal such number of shares of Tauriga’s common stock equal to 32.0% of the aggregate number of shares of Tauriga’s common stock outstanding on a fully-diluted basis as of the date immediately preceding the Closing Date.
 
(f) Employee Benefit Plan” means (a) any “employee pension benefit plan” (as defined in Section 3(2) of ERISA); (b) any “employee welfare benefit plan” (as defined in Section 3(1) of ERISA); and (c) any other written or oral plan, agreement, program, policy, practice, contract, understanding, or other arrangement or commitment of any kind providing for, either directly or indirectly, compensation, bonuses, vacation, termination pay, performance awards, fringe benefits, insurance coverage, severance benefits, disability benefits, deferred compensation, stock options, stock purchase, phantom stock, stock appreciation or any type of stock-related awards, early retirement benefits, welfare benefits, one or more severance plans, any other form of incentive compensation or post-retirement compensation or any other employee benefit of any kind, whether formal or informal, funded or unfunded, and whether or not legally binding, which currently is or has been sponsored, maintained, contributed to, or required to be contributed to, by a Party, any Subsidiary of a Party, or any ERISA Affiliate, or for which a Party, any Subsidiary of a Party, or any ERISA Affiliate has or has had any obligation or any liability of any nature, contingent or otherwise, or for which there is a reasonable expectation of such obligation or liability, on or before the Closing for the benefit of any present or former employees, retirees, directors or independent contractors (or their beneficiaries, dependents or spouses) of a Party, any Subsidiary of a Party, or any ERISA Affiliate.
 
 
6

 
 
(g) Employee Pension Benefit Plan” has the meaning set forth in Section 3(2) of ERISA.
 
(h) Employee Welfare Benefit Plan” has the meaning set forth in Section 3(1) of ERISA.
 
(i) Encumbrance” means a claim, lien, mortgage, encumbrance, pledge, security interest, easement, encroachment, option, right of occupation, litigation, conditional sale or other title retention Contract, restrictive covenant, charge, defect in title or other restriction of any kind, whether arising by Contract or Legal Requirements.
 
(j) Environmental Laws” means any federal, state or local law or ordinance or regulation pertaining to the protection of the environment, natural resources, safety or health of human beings or other living organisms (as such relates to exposure to any Hazardous Substance), or to the manufacture, distribution in commerce, use or Release of any Hazardous Substance, including the Comprehensive Environmental Response, Compensation and Liability Act, 42 USC ss.9601 et seq., the Emergency Planning and Community Right-to-Know Act, 42 USC ss.  11001 et seq., and the Resource Conservation and Recovery Act, 42 USC ss.  6901 et seq.
 
(k) ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
 
(l) ERISA Affiliate” means any entity which with respect to a Party or Subsidiary of a Party is or was a member of (i) a controlled group of corporations (as defined in Section 414(b) of the Code); (ii) a group of trades or businesses under common control (as defined in Section 414(c) of the Code); or (iii) an affiliated service group (as defined under Section 414(m) of the Code or the regulations under Section 414(o) of the Code), any of which includes or included a Party or any Subsidiary of a Party.
 
(m) GAAP” means United States generally accepted accounting principles, consistently applied.
 
(n) Governmental Authorizations” means any approval, consent, license, permit, waiver, or other authorization issued, granted, given, or otherwise made available by or under the authority of any Governmental Entity or pursuant to any Legal Requirement.
 
(o) Governmental Entity” means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature.
 
(p) Hazardous Substance” means (i) those substances defined in or regulated under the Hazardous Materials Transportation Act, the Resource Conservation and Recovery Act, Comprehensive Environmental Response, Compensation and Liability Act, Comprehensive Environmental Response, Compensation and Liability Act, the Clean Water Act, the Safe Drinking Water Act, the Atomic Energy Act, the Federal Insecticide, Fungicide, and Rodenticide Act and the Clean Air Act, and their state counterparts, as each may be amended from time to time, and all regulations thereunder, (ii) petroleum and petroleum products, including crude oil and any fractions thereof, (iii) natural gas, synthetic gas, and any mixtures thereof; (iv) polychlorinated biphenyls, asbestos and radon, (v) any other pollutant or Contaminant; and (vi) any substance, material or waste regulated by any Governmental Entity pursuant to any Environmental Law.
 
 
 
7

 
 
(q) Indebtedness” of any Person means: (i) all indebtedness for borrowed money, (ii) all obligations issued, undertaken or assumed as the deferred purchase price of property or services other than trade accounts arising in the Ordinary Course of Business, (iii) all reimbursement obligations with respect to surety bonds, letters of credit (to the extent not collateralized with cash or cash equivalents), bankers’ acceptances and similar instruments (in each case, whether or not matured), (iv) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (v) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to property acquired by the Person, (vi) all obligations of such Person as lessee which should be capitalized in accordance with GAAP, (vii) all indebtedness referred to in clauses (i) through (vi) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Encumbrance upon or in property (including accounts and contracts rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such Indebtedness, and (viii) all Contracts, undertakings or arrangements by which any Person guarantees, endorses or otherwise becomes or is contingently liable for (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to, or otherwise to invest in, a debtor, or otherwise assure a creditor against loss) the Indebtedness, similar obligation or any other similar liability of any other Person, or guarantees the payment of dividends or other distributions upon the equity securities or interests of any other Person.
 
(r) Intellectual Property” means with respect to any Party and its Subsidiaries, collectively all (i) United States and foreign patents and patent applications and industrial design registrations, including provisional patent applications, patent disclosures, continuations, continuations-in-part, divisions, reissues, reexaminations, extensions, utility models, certificates of invention and design patents, registrations, and applications for registration, (ii) United States, state and foreign trademarks and service marks, internet domain names, uniform resource locators (URLs), and any variants thereof (for example, .net, .biz, .info), logos, words, designs, slogans, product and service names, product descriptions, trade dress, trade names, corporate names, assumed names, and other trade designations whether the foregoing are registered or unregistered, and all United States, state and foreign registrations and applications to register the foregoing, (iii) United States and foreign copyrights, maskwork rights and other rights in original works of authors, whether registered or unregistered, and pending applications to register the same, (iv) computer software programs or applications (in both source and object code versions), including any related technical documentation, (v) trade secret rights and other similar rights in confidential ideas, know-how, concepts, inventions, methods, processes, formulae, technical data, specifications, research and development information, confidential business information, technology, product roadmaps, reports, data, customer lists, mailing lists, business plans, and other proprietary information, all of which derive value, monetary or otherwise (actual or potential), from being maintained in confidence and not known to such Party’s competitors, (vi) inventions, confidential business information, whether patentable or nonpatentable and whether or not reduced to practice, know-how and general intangibles of like nature, together with all goodwill, registrations and applications related to any of the foregoing whether or not protectable as a matter of law, (vii) other proprietary rights relating to any of the foregoing (including remedies against infringements thereof and rights of protection of interest therein under the laws of all jurisdictions), and (viii) copies and tangible embodiments thereof.  In the case of Honeywood, the “Intellectual Property” of Honeywood for the purposes of this Agreement be deemed to include the Honeywood IP.
 
(s) Knowledge of Honeywood” means the knowledge of Elie Green, Daniel Kosmal and Ramona Rubin and each individual Seller, where any such Person is actually aware of the fact or matter or a prudent individual in a similar position could be expected to discover.
 
(t) Legal Requirement” means any federal, state, local, municipal, foreign, international, multinational, or other administrative order, constitution, law, ordinance, principle of common law, regulation, statute, or treaty or order or decree of any court or arbitral body.
 
(u) License” means a license, permit, certification, qualification, or franchise issued by any Governmental Entity.
 
(v) Material Adverse Effect” means an event, occurrence or development that, individually or in the aggregate together with any other events, occurrences or developments, has a material adverse effect upon (i) the business, assets, liabilities, condition (financial or otherwise), property or results of operations of Honeywood or (ii) the ability of the Company or the Purchasers to consummate the Merger, except in each case any adverse effect related to or resulting from (a) the announcement, pendency or consummation of the Merger, or the execution of this Agreement or the performance of obligations hereunder, including the impact of any of the foregoing on relationships with customers, suppliers or employees, (b) conditions affecting the global or United States economy or financial markets as a whole, or generally affecting the industries in which Honeywood conducts its business, (c) any changes or proposed changes in GAAP or any interpretation thereof, (d) the commencement, occurrence or continuation of any war, armed hostilities or acts of terrorism, or (e) earthquakes, hurricanes, floods or other natural disasters, provided, however, that in the cases of clause (b) and (c) above, that Honeywood is not disproportionately affected thereby as compared to other businesses in the industry in which Honeywood operates.
 
 
8

 
 
(w) Member Approval” means approval of each of the Members in a meeting duly called pursuant to and upon the notice required by the CA Code.
 
(x) Ordinary Course of Business” means the ordinary course of business consistent with past custom and practice.
 
(y) Person” means any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, or other entity or Governmental Entity.
 
(z) Proceeding” means a claim, suit, action, litigation, arbitration, dispute, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Entity or any arbitral body, whether at law or in equity.
 
(aa) Release” means any release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal, leaching or migration into the indoor or outdoor environment or into, out of or under  any real property, plant, building, facility, structure, underground storage tank or other similar asset owned, used, leased or operated by Honeywood, together with all rights, privileges and easements appurtenant thereto of any Hazardous Substance or Contaminant, including the movement of Hazardous Substances or Contaminants through or in the air, soil, surface water, groundwater or such real property.
 
(bb) Required Consents” means the consents, approvals, orders, authorizations, notifications, notices, estoppel certificates, releases, registrations, ratifications, declarations, filings, waivers, exemptions or variances with respect to any License, Legal Requirement or Contract or otherwise as are set forth on Schedule 2.4 hereof with respect to Seller, and Schedule 3.3 with respect to Purchasers.
 
(cc) SEC” means the United States Securities and Exchange Commission.
 
(dd) Subsidiary” means any Person with respect to which a specified Person (or a Subsidiary thereof) owns a majority of the equity interests or has the power to vote or direct the voting of sufficient securities to elect a majority of the directors.
 
(ee) Tax” means any tax (including any income tax, capital gains tax, value-added tax, sales tax, property tax, gift tax, or estate tax), levy, assessment, tariff, duty (including any customs duty), deficiency, or other fee, and any related charge or amount (including any fine, penalty, interest, or addition to tax), imposed, assessed, or collected by or under the authority of any Governmental Entity or payable pursuant to any tax-sharing agreement.
 
(ff) Tax Return” means any return (including any information return), report, statement, schedule, notice, form, or other document or information filed with or submitted to, or required to be filed with or submitted to, any Governmental Entity in connection with the determination, assessment, collection, or payment of any Tax or in connection with the administration, implementation, or enforcement of or compliance with any Legal Requirement relating to any Tax.
 
(gg) Transaction Documents” means this Agreement and each other agreement, instrument, document, and certificate to be executed and delivered by the Parties pursuant to this Agreement.
 
 
9

 
 
1.6 Cross-References.  For reference purposes only, the following capitalized terms are defined in the Sections of this Agreement set forth below:
 
Term
Section
Acquisition Sub
Preamble
Agent” or “Agents
Article VII
Agreement
Preamble
Alternative Proposal
Section 5.9(b)
Closing
Section 1.1(b)
Closing Date
Section 1.1(b)
Code
Section 1.3
Costs
Section 6.1
Effective Time
Section 1.1(d)
Exchange Act
Section 3.5
Indemnitee
Section 6.4(a)
Indemnitor
Section 6.4(a)
Indemnity Certificate
Section 6.4(a)
Joinder
Section 4.2(o)
Latest Honeywood Balance Sheet
Section 2.5(a)
Leased Property
Section 2.14(a)
Material Contracts
Section 2.11(a)
Member
Preamble
Merger
Recitals
Merger Shares
Section 2.19
CA Code
Section 1.1(a)
Owned Property
Honeywood
Section 2.14(a)
Preamble
Party” or “Parties
Preamble
Honeywood
Preamble
Honeywood Interests
Section 1.2(b)
Honeywood IP
Section 2.10(a)
Honeywood Financial Statements
Section 2.5(a)
Purchasers
Preamble
Real Property
Section 2.14(a)
Real Property Leases
Section 2.14(a)
Representatives
Section 5.9(a)
Restricted Employees
Section 5.11(a)(ii)
Restricted Period
Section 5.11(a)
Securities Act
Section 2.19(b)
Sellers
Preamble
Straddle Period
Section 5.14(a)
Surviving Entity
Section 1.1(a)
Tauriga
Preamble
Tauriga Common Stock
Section 1.2(b)
Tax Liability
Section 2.12(c)
Product
Recitals
 
 
 
10

 
 
1.7 Construction.  In this Agreement, except to the extent otherwise provided or that context otherwise requires:
 
(a) the words “hereby,” “herein,” “hereof,” “hereunder” and words of similar import refer to this Agreement as a whole (including any Exhibits hereto and Schedules delivered herewith) and not merely to the specific section, paragraph or clause in which such word appears;
 
(b) all references herein to Sections, Exhibits and Schedules shall be deemed references to Sections of, Exhibits to and Schedules delivered with this Agreement;
 
(c) the words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation”;
 
(d) the definitions given for terms in Sections 1.6 and elsewhere in this Agreement shall apply equally to both the singular and plural forms of the terms defined;
 
(e) any pronoun shall include the corresponding masculine, feminine and neuter forms;
 
(f) all references to “Dollars” or “$” shall be deemed references to the lawful money of the United States of America;
 
(g) references to any statute, rule or regulation are to the statute, rule or regulation as amended, modified, supplemented or replaced from time to time (and, in the case of statutes, include any rules and regulations promulgated under said statutes) and to any section of any statute, rule or regulation including any successor to said section (and, in the case of statutes, any rules and regulations promulgated under said statutes), in each case, as of such date;
 
(h) “or” has the inclusive meaning represented by the phrase “and/or”;
 
(i) references to agreements and other documents shall be deemed to include all subsequent amendments and other modifications thereto;
 
(j) all references in this Agreement to days shall mean calendar days unless business days are specified; and
 
(k) “shall” and “will” have equal force and effect.
 

 
11

 
 
ARTICLE II
 
REPRESENTATIONS AND WARRANTIES OF SELLERS.
 
Subject to the disclosures set forth in the disclosure letter of Honeywood and the Sellers as provided herein (the “Disclosure Schedules”), Honeywood represents and warrants to Tauriga and Acquisition Sub that each of the following statements (as may be further amended by the Parties) is true and correct as of as of the Finalization Date (except for representations and warranties which address matters only as to a specified date, which representations and warranties shall be true and correct with respect to such specified date) and shall be true and correct as of the Closing Date, and each other Seller severally represents and warrants to Tauriga and Acquisition Sub that each of the statements set forth in Sections 2.1, 2.2, 2.3, 2.4(a) and 2.19 of this Agreement shall be true and correct as of the Finalization Date (except for representations and warranties which address matters only as to a specified date, which representations and warranties shall be true and correct with respect to such specified date) and shall be true and correct as of the Closing Date.  It is further agreed and acknowledged by the Parties hereto that the Disclosure Schedules to this Section 2 will be agreed upon and provided by Honeywood and the Sellers (as applicable) on or before April 11, 2014 (the “Finalization Date”), or if necessary, by an extended date to be mutually agreed upon by the Parties.  The parties further agree and acknowledge, that for the purpose of this Agreement and as of the date hereof, the following representations and warranties are hereby included for illustrative purposes only, are not binding and may not be relied upon by the Purchasers or any of their Affiliates for any purpose whatsoever, including but not limited to the Purchasers’ or their Affiliates’ decision to invest in Honeywood’s membership interests, provided further, that each of the Parties acknowledges and agrees that the following representations and warranties contained in this Article II will not impose any liability on any of the Sellers to the Purchasers, their Affiliates or any other Person for any indemnification obligations of the Sellers under Article VI of this Agreement, nor will any deemed breach of the representations and warranties set forth in this Agreement as of the date hereof give rise to the Purchasers’ right to terminate this Agreement.  The Parties shall work in good faith to amend the Agreement by no later than the Finalization Date in order to reflect the Parties’ agreement regarding Sellers’ representations and warranties to be provided to the Purchasers herein (“Amended Representations and Warranties”).   For the avoidance of any doubt such Amended Representations and Warranties shall be binding upon the Sellers in accordance with the terms of this Agreement as of the Finalization Date.
 
Notwithstanding anything to the contrary contained herein, Honeywood and the Sellers may supplement or amend the Disclosure Schedules prior to the Closing Date with respect to any matter arising as of the Finalization Date which, if existing or occurring at or prior to the Finalization Date, would have been required to be set forth or described in the Disclosure Schedules or in any representation or warranty made by Honeywood or the Sellers which would have been rendered inaccurate by the failure to supplement or amend the Disclosure Schedules.  If in any supplement or amendment of the Disclosure Schedules delivered by the Sellers or Honeywood after the Finalization Date, Honeywood or the Sellers disclose an event, change or circumstance which constitutes a Material Adverse Effect, the Buyer shall have the right to terminate this Agreement as provided in Article VIII and such termination shall be Buyer’s sole and exclusive remedy relating to any matters set forth in such supplement or amendment; provided however, that if Buyer does not terminate this Agreement within the timeframe set forth in such Section, Buyer will be deemed to have accepted such supplement or amendment to the Disclosure Schedules, and the event, change or circumstance so disclosed in such supplement shall not be deemed to constitute a Material Adverse Effect or serve as the basis for termination pursuant to Article  VIII or otherwise
 
2.1 Organization.  Honeywood is a limited liability company duly organized, validly existing and in good standing under the laws of the State of California and has the requisite power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted.  Honeywood is a limited liability company duly organized, validly existing and in good standing under the laws of the State of California and has the requisite power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted.  Honeywood is duly qualified or licensed to do business as a foreign limited liability company and is in good standing in each jurisdiction in which the nature of the business conducted by it makes such qualification or licensing necessary, except where the failure to so qualify would not reasonably be expected to have a Material Adverse Effect on such Seller.  Honeywood has delivered to Tauriga true, correct and complete copies of its Articles or Certificate of Organization, Operating Agreement and other organizational documents, as currently in effect, of such Seller.
 
 
12

 
 
2.2 Capitalization.
 
(a) All membership interests or other equity interests of Honeywood, and the record and beneficial ownership of all membership interests and other equity interests of Honeywood, are set forth on Schedule 2.2.  The Honeywood Interests constitute all of the authorized and issued or outstanding membership interests of Honeywood.  The Honeywood Interests are duly authorized, validly issued and fully paid.  Except as contemplated by this Agreement or set forth on Schedule 2.2, there are no (i) options, warrants, calls, preemptive rights, subscriptions or other rights, convertible securities, agreements or commitments of any character obligating, now or in the future, Honeywood to issue, transfer or sell any membership interests, options, warrants, calls or other equity interest of any kind whatsoever in Honeywood or securities convertible into or exchangeable for such membership interests or other equity interests, (ii) contractual obligations of Honeywood to repurchase, redeem or otherwise acquire any membership interests or other equity interest of Honeywood, (iii) rights of first refusal, rights of first offer, preemptive or similar rights granted by Honeywood in respect of membership interest or any other equity interests of Honeywood, or (iv) voting trusts, proxies or similar agreements to which Honeywood is a party with respect to the voting of the membership interests of Honeywood.
 
(b) Honeywood does not have any direct or indirect Subsidiaries or hold any equity or ownership interest of any kind, whether beneficially or of record, in any Person.
 
(c) Except as set forth on Schedule 2.2(c), Honeywood has no outstanding Indebtedness the holders of which have the right to vote (or which are convertible into or exercisable for securities having the right to vote) with the members of Honeywood on any matter.  There are not any Contracts to which Honeywood is bound or otherwise subject to repurchase, redeem or otherwise acquire any equity interests of Honeywood.  There are no proxies, voting trusts or other Contracts to which either Seller is a party or is bound with respect to the voting of the equity interests of, or other equity interests in, Honeywood.  Except as set forth on Schedule 2.2(c), there are no contractual obligations or commitments of any character to which either Seller is a party or by which either Seller is bound restricting the transfer of, or requiring the registration for sale of, any equity interests of Honeywood.
 
2.3 Authorization; Validity of Agreement.  Each Seller has the requisite power and authority (or in the case of individual Members, the legal capacity) to execute, deliver and perform this Agreement and each of the other Transaction Documents to be executed and delivered by such Person pursuant to this Agreement, and to assume and perform any obligations hereunder and thereunder, and, subject to receipt by Honeywood of Member Approval, to consummate the transactions contemplated hereby and thereby.  This Agreement has been and each of the other Transaction Documents to be executed and delivered by such Person pursuant to this Agreement will at Closing be, duly authorized, executed and delivered by such Person and, assuming the due authorization, execution and delivery by each of Tauriga and Acquisition Sub, constitute a legal, valid and binding obligation of such Seller, enforceable against such Seller in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar laws of general applicability relating to or affecting creditors’ rights or by general equity principles.  Except for the Member Approval on the part of Honeywood, no other limited liability company proceedings on the part of Honeywood or any holders of any of its equity interests are necessary to authorize this Agreement and the Transaction Documents or to consummate the transactions contemplated hereby, including the Merger, other than the filing of the Certificate of Merger pursuant to the CA Code.
 
2.4 No Violations; Consents and Approvals.
 
(a) Except as set forth on Schedule 2.4, the execution, delivery and performance of each of this Agreement and the other Transaction Documents by the Sellers do not, and the consummation by each Seller of the transactions contemplated hereby and thereby will not: (i) in the case of a Seller that is an entity, violate any provision of such Seller’s Articles or Certificate of Organization, Operating Agreement or other organizational documents, (ii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, amendment, cancellation or acceleration) under any of the terms, conditions or provisions of any Contract applicable to such Seller or to which such Seller is a party, after giving effect to any Required Consents, or (iii) violate any Legal Requirement applicable to such Seller or any of its respective properties or assets, except where such failure would not reasonably be expected to result in a Material Adverse Effect.
 
(b) Except as set forth on Schedule 2.4(b), no consents, approvals, orders, or authorizations, exemptions or variances with, to or of any Governmental Entity is required in connection with the execution, delivery and performance of this Agreement or any of the other Transaction Documents by the Sellers or the consummation by the Sellers of the transactions contemplated hereby and thereby, except the Required Consents set forth on Schedule 2.4 hereof.
 
 
13

 
 
2.5 Financial Statements.
 
(a) Attached as Schedule 2.5 are the unaudited balance sheets of Honeywood as of December 31, 2013 (the “Latest Honeywood Balance Sheet”), together with the related unaudited statements of income and statement of changes in members’ equity for the fiscal year or nine-months then ended (collectively, the “Honeywood Financial Statements”).
 
(b) The Honeywood Financial Statements have been prepared by Honeywood and have been derived from, and agree with, the books and records of Honeywood and fairly present the financial position of Honeywood as of the respective dates thereof and the results of operations of Honeywood for the respective periods set forth therein.  The Honeywood Financial Statements have been prepared in accordance with GAAP as of the dates and for the periods involved, subject to the absence of notes.
 
(c) Except as set forth on Schedule 2.5(c), all accounts payable of Honeywood arose in bona fide arm’s length transactions in the ordinary course of business.  All accounts receivable of Honeywood have arisen from bona fide transactions by Honeywood in the ordinary course of business and are not subject to counterclaims or setoffs.  All of the accounts receivable reflected on the Latest Honeywood Balance Sheet are good and collectible in the ordinary course of business.
 
(d) Except as set forth on Schedule 2.5(d), Honeywood is not obligated with respect to, and has no liability for, any Indebtedness.
 
2.6 Operation of Business.
 
(a) Since the date of the Latest Honeywood Balance Sheet, Honeywood has not suffered any Material Adverse Effect. Any facts, conditions or threats of conditions that Honeywood is aware of that might reasonably be expected to result in a Material Adverse Effect will be set forth on a Disclosure Schedule and delivered to Tauriga and its counsel prior to the Finalization Date or the Closing Date, as applicable.
 
(b) Except as set forth on Schedule 2.6(b), since December 31, 2012, Honeywood has not taken any of the following actions, and Honeywood has not authorized its Members to take any of the following actions:
 
(i) issued, delivered or agreed (conditionally or unconditionally) to issue or deliver, or granted any option, warrant or other right to purchase, any of membership interests or other equity interest or any security convertible into its equity interests, permitted any transfer of its membership interests by any member, or admitted any Person as a member;
 
(ii) paid any obligation or liability (absolute or contingent) other than current liabilities reflected on the Latest Honeywood Balance Sheet and current liabilities incurred since the date thereof in the ordinary course of business consistent with past practice;
 
(iii) undertaken or committed to undertake capital expenditures exceeding five thousand USD ($5,000) for any single project or related series of projects;
 
(iv) sold, leased, transferred or otherwise disposed of, or mortgaged or pledged, or imposed or suffered to be imposed any Encumbrance on, any of the assets reflected on the Latest Honeywood Balance Sheet or any assets acquired after the date thereof;
 
(v) made any acquisition or disposition of any assets or become involved in any other material transaction, including, without any limitation, any merger or consolidation with, purchase of all or part of the assets of, or acquisition of any business of any proprietorship, firm, association, corporation or other business organization or division thereof;
 
(vi) cancelled any debts owed to Honeywood or claims held by Honeywood, including the settlement of any claims or litigation, or waived any rights;
 
 
14

 
 
(vii) created, incurred, guaranteed or assumed any Indebtedness or entered into any capitalized leases;
 
(viii) accelerated collection of any note or account receivable to a date prior to the date such collection would have occurred in the Ordinary Course of Business;
 
(ix) delayed payment of any account payable or other liability of Honeywood, beyond its due date or the date when such liability would have been paid in the Ordinary Course of Business;
 
(x) granted any bonus or other special compensation or increased the compensation or benefits payable or to become payable to any managers, officers or employees, or instituted any profit sharing, bonus, incentive, deferred compensation, insurance, pension, retirement, medical, hospital, disability, welfare or other employee benefit plan;
 
(xi) hired or terminated any employees or independent contractors;
 
(xii) increased or reduced any compensation or benefits payable to any manager, officer, employee or independent contractor or made any other change in the terms of engagement, employment or service of any such Person;
 
(xiii) encountered any labor difficulties or labor union organizing activities;
 
(xiv) sold, assigned, licensed or otherwise transferred any Intellectual Property or other similar intangible assets, or disclosed any proprietary or confidential information to any Person (other than Tauriga and its agents);
 
(xv) made any change in accounting methods or practices or in the method of maintaining books, accounts or business records;
 
(xvi) declared, set aside or paid any dividend or made any other distribution (whether in cash, stock or other property) to any holders of the membership interests or any other equity interests of Honeywood;
 
(xvii) purchased, redeemed, called for purchase or redemption or otherwise acquired any equity interests of Honeywood;
 
(xviii) made any write-offs as uncollectible of any notes or accounts receivable;
 
(xix) entered into, amended, modified, accelerated or terminated any Contract, or suffered the other party to any Contract to amend, modify, accelerate or terminate such Contract, or, except as otherwise contemplated herein, entered into any transaction other than in the Ordinary Course of Business or any transaction involving commitments for expenditures in excess of five thousand USD ($5,000);
 
(xx) suffered any material physical damage, destruction or loss (whether or not covered by insurance) affecting its properties, business or prospects;
 
 
15

 
 
(xxi) prepared or filed any Tax Return inconsistent with past practice or, on any such Tax Return taken any position, made any election, or adopted any method that is inconsistent with positions taken, elections made or methods used in preparing or filing similar Tax Returns in prior periods (including positions, elections or methods which would have the effect of deferring income to periods ending after the Closing Date or accelerating deductions to periods ending on or prior to the Closing Date);
 
(xxii) made or pledged to make any charitable contribution or other capital contribution outside the Ordinary Course of Business;
 
(xxiii) violated any Legal Requirement, if such violation would reasonably be expected to have a Material Adverse Effect on Honeywood, or failed to maintain all Licenses required to operate its business as it is currently being conducted or proposed to be conducted; or
 
(xxiv) agreed or committed to do or authorized any of the foregoing.
 
2.7 No Undisclosed Liabilities.  Except as set forth on Schedule 2.7, Honeywood has no liabilities, Indebtedness or obligations of any kind, whether known or unknown, absolute, accrued, contingent, matured, unmatured or otherwise, and whether due or to become due, and whether or not required by GAAP to be recorded or reflected on a balance sheet of Honeywood, and there is no existing condition or situation which could be reasonably expected to result in any such liabilities, Indebtedness or obligations, other than those that (i) are set forth or reserved against on the Latest Honeywood Balance Sheet; or (ii) were incurred in the Ordinary Course of Business since the date of the Latest Honeywood Balance Sheet and which would not reasonably be expected to have a Material Adverse Effect on Honeywood.
 
2.8 Litigation; Compliance with Law; Licenses.
 
(a) Except as set forth on Schedule 2.8, there is no Proceeding pending, nor, to the Knowledge of Honeywood, threatened, that involves or affects Honeywood, by or before any Governmental Entity, court, arbitration panel or any other Person.  There is no judgment, decree, injunction, ruling or order of any Governmental Entity or arbitral body outstanding against Honeywood.
 
(b) Except as set forth in Schedule 2.8, Honeywood is and has, at all times since the date of its limited liability formation, been in compliance with all applicable Legal Requirements, except where such violation has not and would not reasonably be expected to result in a Material Adverse Effect.  Except as set forth on Schedule 2.8, since inception, Honeywood has not received any written notice of any violation or alleged violation of any Legal Requirement.
 
(c) Except as set forth on Schedule 2.8(c), Honeywood has every License by any Person required for it to conduct its business as presently conducted and as contemplated to be conducted, except would it would not reasonably be expected to result in a Material Adverse Effect.  All such Licenses are in full force and effect, and Honeywood has not received notice of any pending cancellation or suspension of any thereof nor, to the Knowledge of Honeywood, is any cancellation or suspension thereof threatened.
 
2.9 Employee Benefit Plans; ERISA.
 
(a) Schedule 2.9 lists each Employee Benefit Plan that Honeywood maintains or to which Honeywood contributes.
 
2.10 Intellectual Property.
 
(a) Schedule 2.10(a) sets forth all: (i) United States and foreign patents and patent applications and industrial design registrations, including prepared and unfiled provisional patent applications or non-provisional patent applications, provisional patent applications, patent disclosures, continuations, continuations-in-part, divisions, reissues, reexaminations, extensions, utility models, certificates of invention and design patents, registrations, and applications for registration, (ii) United States, state and foreign trademarks and service marks, internet domain names, uniform resource locators (URLs), and any variants thereof (for example, .net, .biz, .info), logos, designs, product and service names, trade dress, trade names, corporate names, and other trade designations whether the foregoing are registered or unregistered, and all United States, state and foreign registrations and applications to register the foregoing, and (iii) United States and foreign registered copyrights, and pending applications to register the same, all of the foregoing Intellectual Property being owned by, or licensed or sublicensed to Honeywood, or being used by Honeywood in its business as presently conducted and as contemplated to be conducted (“Honeywood IP”).
 
(b) The Honeywood IP set forth in Schedule 2.10(a) sets forth all Intellectual Property necessary for the operation of Honeywood, as its business as presently conducted or as is contemplated to be conducted.
 
 
16

 
 
(c) Honeywood has not received any written notice or Proceeding challenging the validity or enforceability of such Honeywood IP or alleging any misuse of such Honeywood IP.
 
(d) Except as set forth on Schedule 2.10(d)(i), (i) to the Knowledge of Honeywood, no Honeywood IP is being infringed, misappropriated or otherwise violated by any third party, and (ii) to the Knowledge of Honeywood, it is not infringing, misappropriating or otherwise violating any Intellectual Property owned by any third party.  Honeywood has not received written notice of any Proceedings described in subsection (i) or (ii) above since inception, and there are no Proceedings against Honeywood presently pending or, to the Knowledge of Honeywood, threatened, alleging infringement, misappropriation or other violation of any third party Intellectual Property.  Except as set forth on Schedule 2.10(d)(1) and to the knowledge of Honeywood, there is no outstanding consent decree, settlement, order, injunction, judgment or ruling restricting the use or ownership of Honeywood IP used by Honeywood, and Honeywood is not a party to any such outstanding consent decree, settlement, order, injunction, judgment or ruling and, to its Knowledge, Honeywood is not otherwise subject to any such outstanding consent decree, settlement, order, injunction, judgment or ruling.
 
(e) To the Knowledge of Honeywood, there is no threatened Proceeding regarding or disputing the ownership, registrability, validity, or enforceability of, or use by Honeywood of, any Honeywood IP, except with respect to office actions in connection with applications in the ordinary course of prosecution of any applied-for Honeywood IP.  To the Knowledge of Honeywood, it is in material compliance with and has not breached, violated or defaulted under, or received written notice that it has breached, violated or defaulted under, any of the material terms or conditions of any license or sublicense relating to any of the Honeywood IP, except with respect to any non-compliance, breach, violation or default which has been cured or which would not have a Material Adverse Effect.
 
(f) Except as set forth on Schedule 2.10(f), Honeywood has obtained from all parties (including current or former employees, consultants and subcontractors) who have created any portion of, or to the Knowledge of Honeywood, who would otherwise have any rights in or to, the Honeywood IP, valid and enforceable written assignments of any such work, invention, improvement or other rights to the Honeywood IP.  All amounts payable by Honeywood to consultants and former consultants involved in the development of any Honeywood IP have been paid in full.
 
(g) Except as set forth on Schedule 2.10(g), Honeywood has taken commercially reasonable measures to protect its ownership of, and rights in, all Honeywood IP and, without limiting the foregoing, Honeywood has not made any Honeywood IP trade secrets, confidential information or proprietary information that it intended to maintain as confidential available to any other Person except pursuant to written agreements requiring such Person to maintain the confidentiality of such information.
 
(h) Except as set forth on Schedule 2.10(h), Honeywood has not transferred ownership of any Honeywood IP or granted any license or sublicense for the use of Honeywood IP.
 
2.11 Material Contracts.
 
(a) Except as set forth on Schedule 2.11(a) Honeywood is not party to or bound by:
 
(i) any Contract that includes any exclusive dealing arrangement or any arrangement that grants any material right of first refusal, right of first offer, preemptive right or similar right or that limits or purports to limit in any material respect the ability of Honeywood (or that, following the consummation of the Merger, would materially restrict the ability of the Surviving Entity or its Affiliates) to own, operate, sell, transfer, pledge or otherwise dispose of any assets or participate in any business anywhere in the world;
 
(ii) any Contract for the acquisition, sale, lease or license of properties or assets of Honeywood with a value in excess of $5,000 (by merger, purchase or sale of assets or stock or otherwise) entered into since January 1, 2007;
 
(iii) any Contract for any acquisition or disposition pursuant to which Honeywood is subject to continuing indemnification or earn-out obligations (whether related to environmental matters or otherwise), in each case, that would reasonably be likely to result in payments by Honeywood in excess of five thousand USD ($5,000);
 
(iv) any collective bargaining Contract;
 
(v) any Contract that is a local marketing, joint sales, shared services, management services, independent sales agent, joint development, commercialization, distribution or similar Contract;
 
 
17

 
 
(vi) any employment or similar Contract providing for compensation, severance or a fixed term of employment in respect of services performed by any employee or independent contractor of Honeywood;
 
(vii) any partnership, limited liability company or joint venture Contract where Honeywood directly or indirectly owns an equity interest in the partnership, limited liability company or joint venture;
 
(viii) any Contract for capital expenditures in excess of five thousand USD ($5,000) for any single item and ten thousand USD ($10,000) for any project consisting of multiple items;
 
(ix) any Real Property Lease or other Contract relating to Real Property;
 
(x) any Contract relating to Indebtedness;
 
(xi) any Contract entered into by Honeywood with an officer, manager, employee, independent contractor or Affiliate of Honeywood;
 
(xii) any Contract relating to Intellectual Property;
 
(xiii) any Contract (other than any Contract of the type described in clauses (1) through (13) above) that: (A) involves the payment or potential payment by or to Honeywood of more than ten thousand USD ($10,000) per annum or twenty thousand USD ($20,000) in the aggregate, or (B) cannot be terminated within twelve (12) months after giving notice of termination and without resulting in any material cost, penalty or liability to Honeywood.
 
Each Contract to which Honeywood is a party of the type described in clauses (1) through (14) of this Section 2.11(a) is referred to in this Agreement as a “Material Contract.”
 
(b) Honeywood has delivered or made available to Tauriga true, correct and complete copies of each Material Contract and all amendments, modifications and side letters with respect thereto.  Except to the extent that it has previously expired in accordance with its terms, each Material Contract is valid and in full force and effect in all material respects, and is enforceable against Honeywood, and to the Knowledge of Honeywood, is enforceable against each other party thereto, in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or similar laws of general applicability relating to or affecting creditors’ rights generally, or by general equity principles.
 
(c) Except as set forth on Schedule 2.11(c), and except as would not reasonably be expected to have a Material Adverse Effect on Honeywood: Honeywood is not, and to the Knowledge of Honeywood no other party thereto is, in breach or violation of, or in default under, any Material Contract.
 
(d) No Consent from or to any Governmental Entity or other Person is required in order to maintain in full force and effect any of the Material Contract, other than such consents that have been obtained and are in full force and effect or that have been duly given and, in each case copies of such consents have been delivered to Tauriga and Acquisition Sub.
 
 
18

 
 
2.12 Taxes.
 
(a) Honeywood has filed all Tax Returns or permissible extensions related thereto that it was required or permitted to file, as the case may be.  All such Tax Returns were correct and complete in all respects.  Except as set forth on Schedule 2.12(a), all Taxes owed by Honeywood have been paid except for those not yet due.  To its Knowledge, no claim has ever been made by any Governmental Entity in a jurisdiction where Honeywood does not file Tax Returns that it is or may be subject to taxation by that jurisdiction.  To its Knowledge, there are no Encumbrances on any of the assets of Honeywood that arose in connection with any failure (or alleged failure) to pay any Tax.
 
(b) Honeywood has withheld and paid all Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party.
 
(c) To Honeywood’s Knowledge, no Governmental Entity plans to assess any additional Taxes for any period for which Tax Returns have been filed.  There is no dispute or claim concerning any liability with respect to any Taxes (a “Tax Liability”) of Honeywood either: (A) claimed or raised by any Governmental Entity, or (B) as to which Honeywood has Knowledge.
 
(d) Honeywood has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency.
 
(e) To the Knowledge of Honeywood, (i) Honeywood has no transferee or successor liability for any unpaid material Taxes of any other Person, (ii) Honeywood is not subject to any closing agreement, request to change a method of accounting, subpoena or request for information with or by any Governmental Entity with respect to its business, and (iii) Honeywood is not subject to any private letter ruling of the IRS or comparable rulings of other taxing authorities.
 
(f) Honeywood has not been a beneficiary of or participated in any “listed transaction” described in Treasury Regulations Section 1.6011-4(b)(2) (or any corresponding provision of state or local Law), and Honeywood has properly disclosed all reportable transactions as required under Treasury Regulations Section 1.6011-4 (or any corresponding provision of state or local Law).
 
(g) Honeywood is not a party to any Contract providing for the allocation or sharing of Taxes with a Person (other than customary Tax gross-up or Tax indemnification provisions in credit agreements, derivatives, leases and other commercial Contracts entered into in the Ordinary Course of Business).
 
(h) Honeywood is not a party to any joint venture, partnership or other arrangement that is treated as a partnership for federal Income Tax purposes.
 
(i) There is no Contract covering any employee or independent contractor of Honeywood that individually, or collectively, could give rise to a payment that would result in a nondeductible expense to Honeywood by reason of Section 280G (determined without regard to Section 280G(b)(4)) nor an excise tax to the recipient of such payment under Section 4999 of the Code.
 
(j) Honeywood has not, and nor has it ever had, a permanent establishment in any foreign country and does not engage and has not engaged in a trade or business in any foreign country.
 
 
19

 
 
2.13 Affiliated Party Transactions.
 
(a) Except as listed on Schedule 2.13(a) and except for obligations arising under the Transaction Documents, no Affiliate of Honeywood has, directly or indirectly, any obligation to or Proceeding or claim against Honeywood.
 
(b) Except as listed on Schedule 2.13(b) Honeywood has not made any loan or advance to any member, officer, manager, employee or independent contractor of Honeywood or guaranteed any Indebtedness of such Person.
 
(c) Except as listed on Schedule 2.13(c), no officer or manager of Honeywood or any Affiliate of Honeywood has, either directly or indirectly:
 
(i) an equity interest of five percent (5%) or more in any Person that purchases from or sells or furnishes to Honeywood any goods or otherwise does business with Honeywood; or
 
(ii) a beneficial interest in any Contract to which Honeywood is a party or under which Honeywood is obligated or bound or to which the property of Honeywood may be subject, other than Contracts between Honeywood and such Persons in their capacities as employees, officers or directors of Honeywood; provided, however, that such representation and warranty shall not apply to the ownership, as a passive investment, by any such manager, officer or Affiliate of less than one percent (1%) of a class of securities listed for trading on a national securities exchange, automated quotation system or publicly traded in the over-the-counter market.
 
2.14 Real Property; Environmental Matters.
 
(a) Schedule 2.14(a) identifies, as of the date hereof: (i) all real properties (by name and location) owned by Honeywood (the “Owned Property”), (ii) all material leases, subleases and occupancy Contracts for real properties and interests in real properties leased, subleased, occupied or operated by Honeywood as lessee, sublessee or occupant (the “Leased Property”).  The Owned Property and the Leased Property are referred to herein collectively as the “Real Property”.  Schedule 2.14(a) also identified all leases, subleases and occupancy Contracts for Real Property to which Honeywood is a party or pursuant to which it occupies Real Property (the “Real Property Leases”).
 
(b) Except as set forth on Schedule 2.14(b), Honeywood has a valid leasehold interest in, subleasehold interest in, or other occupancy right with respect to, the Leased Property, sufficient to allow Honeywood to conduct its business as and where currently conducted. Except as set forth in Schedule 2.14(b), all of the buildings, fixtures and other improvements located on the Real Property are adequate and suitable in all material respects for the purpose of conducting the business of Honeywood as presently conducted and as contemplated to be conducted.  There are no pending, or to the Knowledge of Honeywood, threatened condemnation, eminent domain or similar proceedings affecting any of the Real Property.
 
 
20

 
 
(c) Except as set forth in Schedule 2.14(c), the operation of Honeywood’s business is in compliance and has been since inception, in compliance with all applicable Environmental Laws and orders or directives of any Governmental Entity having jurisdiction under such Environmental Laws, including any Environmental Laws or orders or directives with respect to any cleanup or remediation of any release or threat of release of Hazardous Substances, and to Honeywood’s Knowledge, no actions are presently required to comply with any such applicable Environmental Laws.  There is no Proceeding pending or, to the Knowledge of Honeywood, threatened asserting any liability under any Environmental Law against Honeywood.  Honeywood has not received any written citation, directive, letter or other written notice of any Proceeding arising out of or relating to any Environmental Laws, from any Person arising out of the ownership of its properties or the conduct of its operations.  Honeywood is not a party to or otherwise subject to any judicial or administrative judgment, decree, order, consent order, settlement stipulation or Contract relating to any violation or alleged violation of any Environmental Law by Honeywood or the investigation, removal, remediation, monitoring or payment of penalties, costs or damages, including natural resource damages, related to or arising out of the actual or alleged Release of any Hazardous Substance or Contaminant which would reasonably be expected to have a Material Adverse Effect on Honeywood.
 
(d) There has been no Release of any Hazardous Substance at, on, under or from any Real Property or, during the period of ownership, lease or operation by Honeywood, any real property formerly owned, leased or operated by Honeywood or any present or former Affiliate of Honeywood that would reasonably be expected to have a Material Adverse Effect on Honeywood.  Honeywood has not caused or allowed, or contracted with any party for, the generation, use, transportation, treatment, storage or disposal of any Hazardous Substances in connection with the operation of its business or otherwise.
 
(e) To its Knowledge, Honeywood has not been named as a responsible party or potentially responsible party under the Comprehensive Environmental Response, Compensation and Liability Act or any other Environmental Law.
 
(f) Set forth on Schedule 2.14(f) are copies of all of Honeywood’s environmental reports, Contracts, audits, studies, investigations, and other written or electronic environmental information created within the past five (5) years in its custody, possession or control concerning Honeywood, their respective businesses, operations and products, or any Real Property or any other real property formerly owned, leased or operated by Honeywood or any current or former Affiliate of Honeywood.
 
2.15 Title and Sufficiency of Assets.  Except as set forth on Schedule 2.15, Honeywood has good, valid and marketable title to all of the assets reflected on the Latest Honeywood Balance Sheet as being owned by it (except to the extent that such assets have been disposed of after the date of such balance sheet in the Ordinary Course of Business), free and clear of all Encumbrances.  The assets, properties and rights owned, leased or licensed by Honeywood and the Contracts to which Honeywood is a party relating to its business, constitute all of the assets, properties, rights and Contracts required to conduct its business as presently conducted and as contemplated to be conducted.
 
2.16 Insurance.  Set forth in Schedule 2.16 is a list of all insurance policies of any kind covering Honeywood.  Tauriga and Acquisition Sub have been provided copies of all such policies.  Since inception, Honeywood has not been denied any insurance coverage which it has requested.
 
2.17 Delivery of Documents; Corporate Records.  The minute books of Honeywood contain true, correct and complete copies of the records of all meetings and consents in lieu of meetings of Honeywood’s board of managers (and all committees thereof) and the members of Honeywood since the date of its incorporation or organization.  The membership interest record of Honeywood contains true, correct and complete copies of the records of all issuances and transfers of membership interests and other equity interests of Honeywood since its inception.  True, correct and complete copies of all such minute books and membership interest record books have been provided to Tauriga and Acquisition Sub.
 
 
21

 
 
2.18 Labor and Employment Matters.
 
(a) Set forth on Schedule 2.18(a) is a true, correct and complete list of all employees and independent contractors of Honeywood as of the date hereof and their respective positions and hire dates.  Honeywood has provided Tauriga and Acquisition Sub current annual salary and bonus information for all Honeywood employees, officers and directors.  Honeywood is not aware of any employee or independent contractor who intends to terminate his or her employment relationship with Honeywood or Surviving Entity as a result of the transactions contemplated hereby or otherwise.
 
(b) Set forth on Schedule 2.18(b) is a true, correct and complete list of the names and title of each director and manager of Honeywood and such Person’s compensation during Honeywood’s most recently ended fiscal year.
 
(c) (i) Honeywood is not a party to or bound by any collective bargaining agreement or similar agreement with any labor organization, or work rules or practices agreed to with any labor organization or employee association applicable to employees of Honeywood, (ii) none of the employees of Honeywood are represented by any labor organization and there are no organizational campaigns, demands, petitions or proceedings pending or, to the Knowledge of Honeywood, threatened by any labor organization or group of employees seeking recognition or certification as collective bargaining representative of any group of employees of Honeywood, (iii) there are no union claims to represent the employees of Honeywood, and (iv) there are no strikes, controversies, slowdowns, work stoppages, lockouts or labor disputes pending or, to the Knowledge of Honeywood, threatened against or affecting Honeywood, and there have not been any such actions at any time since inception.
 
(d) Except as set forth on Schedule 2.18(d), Honeywood is, and has at all times since inception been, in compliance with all applicable Legal Requirements respecting immigration, employment and employment practices, and the terms and conditions of employment, including employment standards, equal employment opportunity, family and medical leave, wages, hours of work and occupational health and safety, and is not engaged in any unfair labor practices as defined in the National Labor Relations Act or any other applicable Legal Requirement.  There are no employment or service Contracts, severance Contracts or retention Contracts with any employees or independent contractors of Honeywood and no personnel policies, rules or procedures applicable to employees of Honeywood, other than those listed in Schedule 2.18(d), true and correct copies of which have been provided to Tauriga and Acquisition Sub.  Except as set forth in Schedule 2.18(d): there are no Proceedings related to Honeywood pending, or, to the Knowledge of Honeywood, threatened, in any court or with any Governmental Entity responsible for the enforcement of federal, state, local or foreign labor or employment laws regarding breach of any express or implied contract of employment, any Legal Requirement or regulation governing employment or the termination thereof or other illegal, discriminatory, wrongful or tortious conduct in connection with the employment relationship, the terms and conditions of employment, or applications for employment with Honeywood.
 
(e) Honeywood’s characterization and treatment of consultants and contractors as independent contractors satisfies all Requirements of Law. Honeywood has complied in all material respects with all Requirements of Law relating to payment of wages and overtime compensation and is not liable for any arrears of wages or benefits, or any Taxes or penalties for failure to comply with any of the foregoing.
 
2.19 Investment in Tauriga Securities; Tax Advice.
 
(a) Each Member represents and warrants that such Member is acquiring restricted shares of Tauriga’s common stock as Merger consideration for its own account for investment purposes only and not with a view to or for distributing or reselling such Merger Shares or any part thereof.
 
 
22

 
 
(b) Except as set forth on Schedule 2.19 hereto, at the time such Member was offered the Merger Shares, it was, and as of the date of the Member Approval and the Closing Date, it will be, an “accredited investor” as defined in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”).
 
(c) Each Member acknowledges that it has reviewed the reports filed by Tauriga under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) of the Exchange Act and has been afforded: (A) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, Representatives of Tauriga concerning such materials, (B) access to information about Tauriga and its financial condition, results of operations, business, properties, management and prospects sufficient to enable Honeywood to evaluate its investment, and (C) the opportunity to obtain such additional information that Tauriga possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the Merger, the merger consideration the Merger Shares and the transactions contemplated in this Agreement and any Transaction Document. Notwithstanding the foregoing, each Member has independently evaluated the merits of its decision to enter into the transactions contemplated hereby including investment in and ownership of the Merger Shares, and no Member has relied on the business or legal advice of Tauriga or its Representatives in making its investment decision hereunder, and confirms that no such Person has made any representations or warranties to Honeywood in connection with the transactions contemplated hereby other than as set forth herein.
 
(d) Each Member, either alone or together with its representatives has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the proposed transactions including investment in the Merger Shares, and has so evaluated the merits and risks of such investment.  Each Member understands that it must bear the economic risk of the investment in the Merger Shares indefinitely, and is able to bear such risk and is able to afford a complete loss of such investment.
 
(e) Each Member understand that the Merger Shares are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from Tauriga in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances, and each Member understands that the certificates evidencing the Merger Shares may bear a legend to this effect.
 
(f) Notwithstanding anything to the contrary contained in this Agreement, each Party to this Agreement acknowledges that he, she or it has received his, her or its own Tax advice in respect of the Tax consequences of the transactions contemplated by this Agreement and has not and will not rely on any other Party for such Tax advice.
 
2.20 Certain Business Practices.  Neither Honeywood, nor to the Knowledge of Honeywood, any manager, officer, employee, independent contractor, agent or representative of Honeywood (acting in such capacity), has, directly or indirectly: (a) offered, paid, promised to pay, or authorized a payment, of any money or other thing of value (including any fee, gift, sample, travel expense or entertainment) or any commission payment, or any payment related to political activity, to any government official or employee, to any employee of any organization owned or controlled in part or in full by any Governmental Entity, or to any political party or candidate, to influence the official or employee to act or refrain from acting in relation to the performance of official duties, with the purpose of obtaining or retaining business or any other improper business advantage, or (b) taken any action which would cause them to be in violation of the Foreign Corrupt Practices Act of 1977 or any other anti-corruption or anti-bribery Requirements of Law applicable to Honeywood (whether by virtue of jurisdiction or organization or conduct of business).
 
2.21 Takeover Laws.  Honeywood has taken all necessary actions to render inapplicable this Agreement, the Merger and the other transactions contemplated hereby from the provisions of any applicable federal or state takeover statute.
 
 
23

 
 
2.22 No Brokers.  Except as set forth on Schedule 2.22, no Person is entitled to any brokerage, financial, advisory or similar fee or commission payable by any of Honeywood or any Affiliate of Honeywood in connection with the transactions contemplated by this Agreement or any Transaction Document.  It is hereby agreed and acknowledged that to the extent that any such financial advisory, broker, placement agent or similar fees are due and payable, they will remain the obligation of the Sellers to satisfy such fees.
 
2.23 No Misstatements or Omissions.  No representation or warranty by any Seller contained in this Agreement or in any certificate, list, Schedule, Exhibit or other instrument specified or referred to in this Agreement, whether heretofore furnished to Tauriga or Acquisition Sub or hereafter furnished to Tauriga or Acquisition Sub pursuant to this Agreement on the part of any Seller, contains or will contain any untrue statement of a material fact or omits or will omit any material fact necessary to make the statements contained therein, in light of the circumstances under which they were made, not misleading.
 
2.24 Compliance with Laws.  Except as set forth in Schedule 2.24, each of Honeywood and its subsidiaries and affiliates: (A) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by Honeywood (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority (including the Federal Trade Commission (the “FTC”)) alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and Honeywood is not in material violation of any term of any such Authorizations; (D) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, FTC or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations; (E) has not received notice that the FDA, FTC or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA, FTC or any other federal, state, local or foreign governmental or regulatory authority is considering such action; and (F) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.
 
2.25 All Necessary Permits, etc. Except as set forth in Schedule 2.25, Honeywood possesses such valid and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct its businesses except for such certificates, authorizations or permits which the failure to obtain would not result in a Material Adverse Effect, and Honeywood has not received any written notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, could result in a Material Adverse Effect.
 
2.26 Money Laundering Laws.  To the Knowledge of Honeywood, the operations of Honeywood, its affiliates and subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving Honeywood with respect to the Money Laundering Laws is pending or, to the Knowledge of the Honeywood, threatened.
 
2.27 No Other Representations and Warranties
 
.  Except for the representations and warranties contained in this Article II (including the related portions of the Disclosure Schedules), neither Seller, nor Honeywood nor any other Person has made or makes any other express or implied representation or warranty, either written or oral, on behalf of Sellers or Honeywood, including any representation or warranty as to the accuracy or completeness of any information regarding the business of Honeywood furnished or made available to Purchaser and its Representatives or in any other form in expectation of the transactions contemplated hereby) or as to the future revenue, profitability or success of Honeywood’s business, or any representation or warranty arising from statute or otherwise in law.
 
 
24

 
 
ARTICLE III
 
REPRESENTATIONS AND WARRANTIES OF TAURIGA AND ACQUISITION SUB.
 
Purchasers, jointly and severally represent and warrant to the Sellers that each of the following statements is true and correct as of the date of this Agreement (unless stated as of another date) and shall be true and correct as of the Closing Date:
 
3.1 Organization.  Tauriga is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Florida and has the requisite power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted.  Acquisition Sub is a limited liability company duly organized, validly existing and in good standing under the laws of the State of California and has the requisite power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted.  Each of the Purchasers is duly qualified or licensed to do business as a foreign corporation or limited liability company and is in good standing in each jurisdiction in which the nature of the business conducted by it makes such qualification or licensing necessary, except where the failure to so qualify would not reasonably be expected to have a Material Adverse Effect on Purchasers.  Acquisition Sub has delivered to Honeywood true, correct and complete copies of its Certificate of Organization, operating agreement and other organizational documents, as currently in effect, of Acquisition Sub.
 
3.2 Authorization; Validity of Agreement.  Each of the Purchasers has the requisite corporate or limited liability company power and authority to execute, deliver and perform this Agreement and each of the other Transaction Documents to be executed and delivered by such Person pursuant to this Agreement, and to assume and perform any obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby.  This Agreement has been and each of the other Transaction Documents to be executed and delivered by such Person pursuant to this Agreement will at Closing be, duly authorized, executed and delivered by such Person and, assuming the due authorization, execution and delivery by Honeywood, constitutes a legal, valid and binding obligation of such Purchaser, enforceable against such Purchaser in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar laws of general applicability relating to or affecting creditors’ rights or by general equity principles.  No corporate or limited liability company proceedings on the part of the Purchasers or any of their stockholders or members are necessary to authorize this Agreement and the Transaction Documents or to consummate the transactions contemplated hereby or thereby, including the Merger, other than the filing of the Certificate of Merger pursuant to the CA Code.
 
3.3 No Violations; Consents and Approvals.
 
(a) The execution, delivery and performance of each of this Agreement and the other Transaction Documents by the Purchasers do not, and the consummation by each Purchaser of the transactions contemplated hereby and thereby will not: (i) violate any provision of such Purchaser’s Certificate of Incorporation, Articles of Organization, bylaws, operating agreement or other organizational documents, (ii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, amendment, cancellation or acceleration) under any of the terms, conditions or provisions of any Contract applicable to such Purchaser or to which such Purchaser is a party, after giving effect to any Required Consents, or (iii) violate any Legal Requirement applicable to the Purchasers or any of their respective properties or assets.
 
(b) No consents, approvals, orders, authorizations, notifications, notices, estoppel certificates, releases, registrations, ratifications, declarations, filings, waivers, exemptions or variances with, to or of any Governmental Entity or Person is required in connection with the execution, delivery and performance of this Agreement or any of the other Transaction Documents by the Purchasers or the consummation by the Purchasers of the transactions contemplated hereby and thereby, except the Required Consents set forth on Schedule 3.3 hereof.
 
3.4 Tauriga Common Stock.  The Merger Shares to be issued to the Members upon Closing, when issued in accordance with the terms of this Agreement, will be duly authorized, validly issued, fully paid and non-assessable.
 
3.5 SEC Filings; Disclosure.  Tauriga has filed with the SEC all forms, statements, reports and documents required to be filed by it since January 1, 2007 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder all of which, as amended, if applicable, complied when filed in all material respects with the applicable requirements of the Exchange Act and the rules and regulations thereunder.
 
3.6 Acquisition Sub.  Acquisition Sub is a wholly-owned subsidiary of Tauriga organized on March 6, 2014 that has not engaged in any operations through the Closing Date, except as contemplated by this Agreement.
 
3.7 Capitalization.  The number of shares outstanding, options, warrants and notes exercisable for, exchangeable for or convertible into shares of Tauriga’s Common Stock are set forth in the Quarterly Statement on Form 10-Q of Tauriga for the fiscal quarter ended December 31, 2013.
 
3.8 No Brokers.  No Person is entitled to any brokerage, financial, advisory or similar fee or commission payable by any of Tauriga, Acquisition Sub or any Affiliate of Tauriga or Acquisition Sub in connection with the transactions contemplated by this Agreement or any Transaction Document.
 
 
25

 
 
ARTICLE IV
 
CONDITIONS.
 
4.1 Conditions to Obligations of Sellers.  The obligations of Sellers to consummate the transactions contemplated hereby and to make the deliveries contemplated at the Closing shall, in addition to the conditions set forth elsewhere herein, be subject to the satisfactory completion on or prior to the Closing Date of each of the following conditions, any of which may be waived by Honeywood (it being agreed that if any of the following conditions are not satisfied as of the Closing and the Parties nevertheless consummate the transactions contemplated hereby, such conditions shall be deemed waived except to the extent that the Parties agree specifically to the contrary in writing):
 
(a) Correctness of Representations and Warranties.  Each of the representations and warranties of Purchasers contained in this Agreement shall have been true and correct on the date hereof (unless stated as of another date) and shall be true and correct on the Closing Date with the same effect as if made on the Closing Date.
 
(b) Performance of Covenants and Agreements.  All of the covenants and agreements of Purchasers contained in this Agreement and required to be performed by the Purchasers on or before the Closing Date shall have been performed in all material respects.
 
(c) Absence of Material Adverse Effect.  There shall not have occurred any event, occurrence, incident, action, failure to act, or transaction since the date hereof which has had or would reasonably be expected to have a Material Adverse Effect on any of the Purchasers.
 
(d) Officer’s Certificate.  Each of the Purchasers shall have delivered to Honeywood a certificate, dated as of the Closing Date, signed by an officer of such Purchaser certifying as to the satisfaction of the conditions specified in clauses (a) and (b) above.
 
(e) No Proceedings.  No preliminary or permanent injunction or other order by any federal or state court preventing consummation of the transactions contemplated hereby shall have been issued and shall be continuing in effect, and the Merger and the other transactions contemplated hereby shall not be prohibited under any applicable federal or state law or regulation.
 
(f) Financing.  On or before the Closing Date, Tauriga shall have raised one million USD ($1,000,000) (“WC Financing”), which shall be held in the escrow account of the Quick Law Firm (the “Escrow Account”) as of the Closing Date (it being understood and agreed that funds available in escrow pending the Closing of the transactions contemplated by this Agreement shall be considered to be available for the purposes of this Section 4.1(f)).  The remainder of the WC Financing less any Advances (as defined below) will be deposited in a jointly held bank account within one (1) business day following the Closing Date for the general corporate and working capital purposes of the Surviving Entity.  Notwithstanding the provisions of this Section 4.1(f), it is agreed and acknowledged that any monies paid, transferred, wired or delivered by Tauriga to Honeywood prior to the Closing Date (but excluding any Rent Payments paid by Tauriga pursuant to Section 5.19 and the legal fees paid for by Tauriga on Sellers’ behalf), including, but not limited to, the $75,000 and $100,000 described and set forth in Section 1.2(a) of this Agreement (“Advances”), shall be credited towards the aggregate amount of the WC Financing required to be raised by Tauriga for the general corporate and working capital purposes of the Surviving Entity as set forth in this Section 4.1(a) and 5.10.  Any Advances shall not exceed five hundred thousand USD ($500,000) and will be credited to Tauriga against the Balance.  Notwithstanding the provisions of this Section 5.10, it is agreed and understood that the Members of Honeywood will receive an additional twenty thousand USD ($20,000) from Tauriga to pay Buchalter Nemer P.C. for its legal fees incurred solely in connection with this Merger.
 
 
26

 
 
(g) Consents and Approvals.  Honeywood shall have received written evidence satisfactory to it that all Required Consents pursuant to Section 3.3 have been obtained or made.
 
(h) Delivery of Secretary’s Certificate.  Honeywood shall have received a certificate from each of the Purchasers, signed by the respective Secretary or Assistant Secretary of such Purchaser, certifying that the attached copies of its respective Certificate of Incorporation, Articles of Organization, bylaws, operating agreement and resolutions of the board of directors or board of managers approving this Agreement and the transactions contemplated hereby are all true, correct and complete and remain in full force and effect.
 
(i) Employment Agreements.  Tauriga shall have entered into an employment agreement with each of Elie Green, Daniel Kosmal and Ramona Rubin, which shall be in conformity with applicable Federal laws and California laws, and in forms acceptable to each of Elie Green, Daniel Kosmal and Ramona Rubin, as applicable.
 
(j) Amendments to this Agreement and the Disclosure Schedules. Honeywood shall have provided Tauriga with Disclosure Schedules in form acceptable to Honeywood and Tauriga, and any necessary amendment to the Merger Agreement to address changes to Article II of this Agreement as well as any other necessary changes in form acceptable to Honeywood and Tauriga.
 
(k) Operations Committee and Board Seat.  Honeywood shall have received an agreement regarding the scope of Honeywood’s Board of Managers governance and reporting requirements to Tauriga’s operations committee (“Operations Committee”) in a form acceptable to Honeywood and Tauriga.  Further, Daniel Kosmal or another member of Honeywood shall have been offered a position on Tauriga’s Board of Directors effective as of the Closing Date.
 
(l) Rule 10b5-1 Plan.  Tauriga shall have adopted effective stock trading plans in place in accordance with the guidelines established by the Securities and Exchange Commission under Rule 10b5-1 ("Rule 10b5-1") of the Securities Exchange Act of 1934 for the benefit of each of the Sellers.
 
(m) Operating Agreement.  The Members and Tauriga shall have executed an Operating Agreement for the Surviving Entity in form acceptable to the Members and Tauriga.
 
(n) Other Closing Documents.  Honeywood shall have received the executed Certificate of Merger and such other agreements and instruments as Honeywood shall reasonably request, in each case, in form and substance reasonably satisfactory to Honeywood.
 
 
27

 
 
4.2 Conditions to Obligations of Purchasers.  The obligations of Tauriga and Acquisition Sub to consummate the transactions contemplated hereby and to make the deliveries contemplated at the Closing shall, in addition to the conditions set forth elsewhere herein, be subject to the satisfactory completion on or prior to the Closing Date of each of the following conditions, any of which may be waived by Tauriga or Acquisition Sub (it being agreed that if any of the following conditions are not satisfied as of the Closing and the Parties nevertheless consummate the transactions contemplated hereby, such conditions shall be deemed waived except to the extent that the Parties agree specifically to the contrary in writing):
 
(a) Correctness of Representations and Warranties.  Each of the representations and warranties of the Sellers contained in this Agreement shall have been true and correct on the Finalization Date and shall be true and correct on the Closing Date with the same effect as if made on the Closing Date.
 
(b) Performance of Covenants and Agreements.  All of the covenants and agreements of the Sellers contained in this Agreement and required to be performed by the Sellers on or before the Closing Date shall have been performed in all material respects.
 
(c) Absence of Material Adverse Effect.  There shall not have occurred any event, occurrence, incident, action, failure to act, or transaction since the date hereof which has had or would reasonably be expected to have a Material Adverse Effect on Honeywood.
 
(d) Officer’s Certificate.  Each of the Sellers that is an entity shall have delivered to Tauriga a certificate, dated as of the Closing Date, signed by an officer of such Seller certifying as to the satisfaction of the conditions specified in clauses (a), (b) and (c) above.
 
(e) No Proceedings.  No preliminary or permanent injunction or other order by any federal or state court preventing consummation of the transactions contemplated hereby shall have been issued and shall be continuing in effect, and the Merger and the other transactions contemplated hereby shall not be prohibited under any applicable federal or state law or regulation.
 
(f) Consents and Approvals.  Tauriga shall have received written evidence satisfactory to it that all Required Consents pursuant to Section 2.4 have been obtained or made.
 
(g) Member Approval of Merger.  The Members shall have taken all limited liability company action required to: (i) approve the Merger and provide the Member Approval (including any stockholder/members approval under the CA Code), and (ii) waive any rights of first refusal, and Honeywood shall have delivered to the Purchasers at Closing a certificate of Honeywood’s Secretary or Assistant Secretary to that effect.
 
(h) Release.  Each of Honeywood, Chief Executive Officer of Honeywood and the Members from time to time party to this Agreement shall have executed and delivered to Tauriga a Release and Covenant not to Sue substantially in the form of Exhibit B attached hereto.
 
(i) Form S-1 Effectiveness.  Tauriga shall have received notice of effectiveness from the Securities and Exchange Commission regarding the Form S-1 Registration Statement which it will file within forty-five (45) days following the date of this Agreement and pursuant to the terms of that Securities Purchase Agreement between Tauriga and such investor, to register for resale the underlying securities issuable pursuant to a Warrant  being sold to such investor in exchange for its the funding of $1,000,000 related to the merger.
 
 
 
28

 
 
(j) Audited Financials.  Honeywood shall have delivered, and Tauriga shall have received, the financial statements of Honeywood, and Tauriga’s auditor shall have prepared and approved, the consolidated balance sheets, consolidated statements of income, consolidated statements of stockholders’ equity, consolidated statements of cash flows and any notes to the notes to condensed consolidated financial statements, and any other financials related to the Merger under this Agreement that are necessary for Tauriga to comply with its financial, auditing and accounting requirements under the Securities Act of 1933, as amended (the “33 Act”), the Securities and Exchange Act of 1934, as amended, and under the respective rule and regulations thereunder, including Regulation S-X under the 33 Act, the instructions under Form 8-K and Form S-1. Tauriga shall bear the cost of the preparation of the auditing of Honeywood’s financials necessary and directly related to the closing of the Merger and Tauriga’s applicable financials reporting obligations under the Securities Act and Exchange Act.  Honeywood and Tauriga’s auditor will use their best efforts to contain the costs to not more than $30,000 in the preparation of audited financials.
 
(k)  Termination of Employment/Consulting/Agency Agreement.  Any and all employees of Honeywood (and any employees working under the Doc Green’s brand) who have an employment, consulting or agency (or such similar) agreement shall have entered into an agreement with Honeywood in form and substance reasonably satisfactory to Tauriga: (i) terminating such Employment/Consulting/Agency Agreement, and (ii) acknowledging that no amounts are due or payable to such employee/agent pursuant to such agreement from and after the Closing Date and otherwise releasing Honeywood from all liabilities, claims and choses in action.
 
(l) Waiver of Appraisal Rights.  Each of the Members of Honeywood shall have waived, in a manner reasonably satisfactory to Tauriga, any and all dissenters’ rights of appraisal under the CA Code and no such rights shall have been asserted or exercised by any Member.
 
(m) Standstill Agreement. The Honeywood, its executives and its Members shall have entered into a Standstill and Voting Agreement substantially in the form attached as Exhibit C hereto.
 
(n) Operating Agreement.  The Members and Tauriga shall have executed an Operating Agreement for the Surviving Entity in form acceptable to the Members and Tauriga.
 
(o) Joinders.  Each of the Members of Honeywood, as of the Closing Date, shall have entered into a joinder to this Agreement substantially in the form attached as Exhibit D hereto (“Joinder”).
 
(p) Due Diligence.  Tauriga shall have completed its business, regulatory, intellectual property, financial and accounting and legal due diligence review of Honeywood  and its business, regulatory matters, its assets and liabilities and the Product subject to this Agreement, as well as its business arrangements and structure with the not-for-profit companies to which it sells its products, and the results thereof shall be satisfactory to Tauriga and its counsel in its and their sole discretion.
 
(q) Delivery of Secretary’s Certificate.  Tauriga shall have received a certificate from each Seller that is an entity, signed by the respective Secretary or Assistant Secretary of such Seller, certifying that the attached copies of its respective organizational documents, operating agreement and resolutions of its board of directors or managers approving this Agreement and the transactions contemplated hereby are all true, correct and complete and remain in full force and effect.
 
(r) Employment Agreements.  Elie Green, Daniel Kosmal and Ramona  Rubin shall have entered into an employment agreement with Tauriga, which shall be in conformity with applicable Federal laws and California laws.
 
(s) Amendments to this Agreement and the Disclosure Schedules. Honeywood shall have provided Tauriga with Disclosure Schedules in form acceptable to Honeywood and Tauriga, and any necessary amendment to the Merger Agreement to address changes to Article II of this Agreement as well as any other necessary changes in form acceptable to Honeywood and Tauriga.
 
(t) Product Labeling and Advertising. Honeywood’s (Doc Green’s) product labeling, website and other forms of advertising and communications regarding its product and company shall have been revised and amended to the satisfaction of Tauriga and its counsel pursuant to Section 5.19 of this Agreement.
 
(u) Honeywood Tax Returns: Honeywood shall have delivered to Tauriga correct and complete copies of all federal and state income and other material Tax Returns, examination reports, and statements of deficiencies assessed against or agreed to by Honeywood for the last two (2) years.
 
(v) Other Closing Documents.  Tauriga shall have received the executed Certificate of Merger and such other agreements and instruments as Tauriga shall reasonably request, in each case, in form and substance reasonably satisfactory to Tauriga.
 
 
 
29

 
 
ARTICLE V
 
COVENANTS.
 
5.1 Further Assurances.  Each of the Parties will use its commercially reasonable efforts to take all action and to do all things necessary, proper, or advisable in order to consummate and make effective the transactions contemplated by this Agreement (including satisfaction of their respective closing conditions set forth in Article IV).  Each of the parties hereto further agree to continue, between the time of execution of this Agreement and the Closing Date, the due diligence process, as well as finalizing the Disclosure Schedules and any amendments to this Agreement.
 
5.2 Full Access.  From the date hereof through the Closing Date, each Party shall permit representatives of each other Party to have full access to all premises, properties, personnel, books, records (including Tax records), Contracts, and documents of or pertaining to such Party.
 
5.3 Notice of Developments.  From the date hereof through the Closing Date, Honeywood and each of the other Sellers will give prompt written notice to Purchasers of any material adverse development that would reasonably be expected to cause a Material Adverse Effect, and following the Finalization Date until the Closing date, such developments that would reasonably cause a breach of any of the representations and warranties of Honeywood or any of the other Sellers herein.
 
5.4 Regulatory and Other Approvals.
 
(a) Subject to the terms and conditions of this Agreement, each Party will proceed diligently and in good faith to, as promptly as practicable, to: (a) obtain all Required Consents, make any other filings with and give any other notices to Governmental Entities or any other public or private third parties required of a Party to consummate the Merger and the other matters contemplated hereby, and (b) provide such other information and communications to such Governmental Entity or other public or private third parties as any other Party or such Governmental Entity or other public or private third parties may reasonably request in connection therewith.
 
(b) Honeywood and each of the other Sellers will reasonably cooperate with Purchasers in: (A) determining which filings are required to be made prior to the Effective Time with, and which material consents, approvals, Licenses, notices or authorizations are required to be obtained prior to the Effective Time from, the SEC or any other Governmental Entities or third parties in connection with the execution and delivery of this Agreement and Transaction Documents, and consummation of the transactions contemplated hereby and thereby and (B) timely making all such filings and timely seeking all such consents, approvals, Licenses, notices or authorizations.
 
(c) Upon the request of Tauriga and at Tauriga’s expense, Honeywood shall reasonably cooperate with and assist Tauriga and Tauriga’s independent public accountants in the compilation and preparation of all financial statements and financial statement schedules of Honeywood in accordance with GAAP and reports and consents of Honeywood’s independent accountants as may be necessary for Tauriga to comply with SEC or other reporting and disclosure requirements.  If requested by Tauriga, Honeywood shall deliver to Tauriga or Tauriga’s or Honeywood’s independent public accountants all engagement letters and management representation letters as may be reasonably requested by Tauriga (at Tauriga’s cost and expense) or such accountants, which shall cover such periods as Tauriga may reasonably request.  In connection with the foregoing, Honeywood shall use its commercially reasonable best efforts to cause their accountants to cooperate with and assist Tauriga and its independent public accountants in the preparation of the financial statements contemplated by this Section 5.4(c) as may be necessary or applicable under the Securities Act and the Exchange Act, and the rules and regulations thereunder.
 
 
30

 
 
5.5 Preservation of Business.  From the date of this Agreement through the Closing Date, Honeywood shall operate only in the Ordinary Course of Business, and shall use commercially reasonable efforts to: (a) preserve intact its respective business organization, and (b) preserve the good will and advantageous relationships with customers, prospective customers, suppliers, independent contractors, employees and other Persons material to the operation of its business.  Honeywood will use its reasonable best efforts to not and the Members will use each of their reasonable best efforts to not permit Honeywood to (or after the closing, the Surviving Entity, in accordance with the covenants under this Agreement, to not), without the prior written consent of Tauriga, do, permit or suffer the occurrence of any action or omission which would cause any of the representations or warranties of Sellers contained herein to become inaccurate, or any of the covenants or agreements of Sellers to be breached in any material respect.  From the date hereof through the Closing Date, No Member will sell, transfer, convey, deliver or encumber any of its membership interests in Honeywood other than with the prior written consent of Tauriga.
 
5.6 Publicity.  Prior to issuing any public announcement or statement with respect to the transactions contemplated hereby Tauriga and Honeywood will, subject to their respective legal obligations, consult with each other and will allow each other to review the contents of any such public announcement or statement and any such filing.  Subject to the preceding sentence, Tauriga and Honeywood each agree to furnish to the other copies of all other public announcements they may make concerning their respective business and operations promptly after such public announcements are made.
 
5.7 Appointment of Managers and Officers.  Tauriga shall take such actions and make such filings as may be necessary to satisfy the requirements of Section 1.1(d)(v).
 
5.8 Tax Treatment.  For federal income Tax purposes, the Parties intend that the Merger shall be treated as Tauriga acquiring all of the assets of Honeywood and as the Members of Honeywood converting their equity interests in Honeywood into a right to receive the restricted common stock of Tauriga, consistent with Internal Revenue Service Ruling 99-6.
 
5.9 No-Shop.  From the date hereof through the Closing Date:
 
(a) Other than as contemplated in this Agreement, immediately following the execution of this Agreement, the Parties will (and will cause each of their respective employees, officers, directors, managers, stockholders, members, agents and representatives (“Representatives”) to) terminate any and all existing activities, discussions and negotiations with third parties (other than each other) with respect to any Alternative Proposal.
 
(b) Other than as contemplated in this Agreement including the condition for Tauriga to obtain additional financing, no Party will (and each will cause its Representatives not to), directly or indirectly, solicit, initiate or knowingly encourage the submission of any offer or proposal to acquire all or a majority of a Party’s capital stock or equity interests or all or ten percent (10%) or more of the assets or business of a Party, whether by merger, consolidation, reorganization, purchase of stock/interests, purchase of assets, tender offer, exchange offer or otherwise (an “Alternative Proposal”).
 
(c) A Party shall promptly (and in any event by 5:00 p.m. New York City time, on the next business day) communicate to the other Parties in writing the identity of the Person making an Alternative Proposal or any related inquiries, proposals or offers, and the terms and conditions of such Alternative Proposal, inquiry, proposal or offer that it may receive.
 
(d) A Party’s board of directors or managers (or a committee thereof) shall not approve or recommend an Alternative Proposal, or withdraw or modify its approval or recommendation of this Agreement and the transactions contemplated hereby, including the Merger (or publicly propose to do any of the foregoing).
 
(e) Nothing in this Section 5.9 shall permit Honeywood or any other Seller to terminate this Agreement.  For the avoidance of doubt, none of Honeywood or any other Seller may enter into any agreement with respect to an Alternative Proposal during the term of this Agreement.
 
(f) The Sellers shall ensure that their respective Representatives are aware of the provisions of this Section 5.9, and the Sellers acknowledge and agree that any action taken by any Representative of the Sellers that, if taken by the Sellers, would constitute a breach of this Section 5.9, will be deemed to constitute a breach of this Section 5.9 by the Sellers.
 
 
31

 
 
5.10 Financing.  On or before the Closing Date, Tauriga shall have raised one million USD ($1,000,000) (“WC Financing”), which shall be held in the escrow account of the Quick Law Firm (the “Escrow Account”) as of the Closing Date (it being understood and agreed that funds available in escrow pending the Closing of the transactions contemplated by this Agreement shall be considered to be available for the purposes of this Section 4.1(f)).  The remainder of the WC Financing less any Advances (as defined below) will be deposited in a jointly held bank account within one (1) business day following the Closing Date for the general corporate and working capital purposes of the Surviving Entity.  Notwithstanding the provisions of this Section 4.1(f), it is agreed and acknowledged that any monies paid, transferred, wired or delivered by Tauriga to Honeywood prior to the Closing Date (excluding any Rent Payments paid by Tauriga pursuant to Section 5.19 and the legal fees paid for by Tauriga on Sellers’ behalf), including, but not limited to, the $75,000 and $100,000 described and set forth in Section 1.2(a) of this Agreement (“Advances”), shall be credited towards the aggregate amount of the WC Financing required to be raised by Tauriga for the general corporate and working capital purposes of the Surviving Entity as set forth in Sections 4.1(f) and 5.10.  Any Advances shall not exceed five hundred thousand USD ($500,000) and will be credited to Tauriga against the Balance.  Notwithstanding the provisions of this Section 5.10, it is agreed and understood that the Members of Honeywood will receive an additional twenty thousand USD ($20,000) from Tauriga to pay Buchalter Nemer P.C. for its legal fees incurred solely in connection with this Merger.
 
5.11 ATM Lock-up.  Following the Closing Date and for a period of one-hundred twenty (120) days thereafter (the “Lock-up Period”), Tauriga covenants not to utilize its EEP securities drawn under its common stock purchase agreement (“ATM”) entered into between Tauriga and Hanover Holdings I, LLC, a New York limited liability company on June 13, 2013, without the prior written consent of the Parties to this Agreement, which consent shall not be unreasonably withheld. Tauriga covenants to utilize up to one-half of the ATM (“Surviving Entity’s ATM Shares”), for purposes of funding the Surviving Entity’s business operations, expansion or other working capital needs from the ATM between the Closing Date and July 30, 2016, if necessary, and Members covenant that any funds drawn under and from the ATM will be utilized solely for the Surviving Entity’s business operations, expansion or other working capital needs.  Following the Lock-up Period, and through July 30, 2016, any request by the Surviving Entity for a sale under the ATM exceeding an aggregate of two million (2,000,000) shares of Tauriga’s common stock within a consecutive ten (10) day period will require the prior written consent of Tauriga, which consent shall not be unreasonably withheld.  For the avoidance of any doubt, any request by the Surviving Entity for a sale of shares under the ATM for Surviving Entity’s working capital needs which does not exceed an aggregate of two million ($2,000,000) shares of Tauriga’s common stock within a consecutive ten (10) day period will not require the prior written consent the Operations Committee.  Tauriga hereby covenants and agrees to refrain from use or sale of Surviving Entity’s ATM Shares from the date of this Agreement until the Closing Date.
 
5.12 Transfer Taxes.  All stock transfer, real estate transfer, documentary, stamp, recording and other similar Taxes (including interest, penalties and additions to any such Taxes) incurred in connection with the transactions contemplated by this Agreement, including the Merger, shall be borne and paid shall be borne and paid by the Purchasers as a group.
 
5.13 Taxes.
 
(a) Honeywood shall be liable for and shall pay, and pursuant Article VI shall indemnify and hold harmless Purchasers from and against any and all Costs incurred by Purchasers in connection with or arising from all Tax liabilities  (whether assessed or unassessed) of Honeywood attributable to periods or portions thereof ending on or prior to the Closing Date other than Taxes accrued for on the Latest Honeywood Balance Sheet.  The Purchasers shall be liable for and shall pay, and pursuant to Article VI shall indemnify and hold harmless the Sellers party hereto from and against any and all Costs incurred by Sellers in connection with or arising from all Tax liabilities (whether assessed or unassessed) of Surviving Entity and/or Honeywood (as applicable) attributable to periods (or portions thereof) beginning on or after the Closing Date.  For purposes of this Section 5.14(a), any period beginning before and ending after the Closing Date (a “Straddle Period”) shall be treated as two partial periods, one ending on the Closing Date and the other beginning after the Closing Date, except that any property Taxes imposed on a periodic basis shall be allocated on a daily basis.
 
(b)           The Purchasers, on the one hand, or Honeywood, on the other hand, as the case may be, shall provide reimbursement for any Tax paid by one Party, all or a portion of which is the responsibility of the other Party in accordance with the terms of Section 5.12 or this Section 5.14.  Within a reasonable time prior to the payment of any said Tax, the Party paying such Tax shall give notice to the other Party of the Tax payable and the portion which is the liability of each party, although failure to do so will not relieve the other Party from its liability hereunder.
 
(c)           Honeywood shall prepare or cause to be prepared and file or cause to be filed all income or franchise Tax Returns that are required to be filed with respect to Honeywood for all Taxable periods ending on or prior to the Closing Date and shall cause the Sellers to pay to Honeywood at least three (3) business days prior to the due date for such payments any and all Taxes due by Honeywood with respect to any such applicable period to the extent they were not fully accrued as liabilities on the Latest Honeywood Balance Sheet.  All such Tax Returns shall be prepared and filed consistent with past practices of Honeywood, to the extent such practices comply with applicable Legal Requirements.
 
 
32

 
 
(d)           Surviving Entity shall file or cause to be filed when due all Tax Returns that are required to be filed by or with respect to Honeywood or the Surviving Entity for all Taxable periods of such Person, ending after the Closing Date, and Surviving Entity shall remit (or cause to be remitted) any Taxes due from such Person in respect of such Tax Returns.  Honeywood shall reimburse Surviving Entity for any Taxes for which Honeywood is liable pursuant to this Section 5.14 but which are payable with respect to any Tax Return to be filed by Surviving Entity upon the written request of Surviving Entity setting forth in detail the computation of the amount owed by Honeywood and, with respect to any such Tax Return as to which Honeywood is required to reimburse Surviving Entity for any periods ending on or before the Closing Date.  Surviving Entity shall provide a copy of such Tax Return to Honeywood at least fifteen (15) business days prior to filing and shall make such revisions to such Tax Return as are reasonably requested by Honeywood prior to filing such Tax Return.
 
(e)           After the Closing Date, each of the Sellers and the Purchasers shall (and shall cause their respective Affiliates to): (i) assist the other Party in preparing any Tax Returns which such other Party is responsible for preparing and filing, (ii) cooperate fully in preparing for and participating in any audits of, requests for information from, or disputes with Taxing authorities regarding, any Tax Returns or Taxes assessed in respect of Honeywood or the Surviving Entity, (iii) make available to the other and to any Taxing authority as reasonably requested all information, records and documents relating to Taxes of Honeywood or the Surviving Entity, (iv) provide timely notice to the other in writing of any pending or threatened Tax audits or assessments relating to Taxes of Honeywood or the Surviving Entity for Taxable periods for which the other may have a liability under this Section 5.14, (v) furnish the other with copies of all correspondence received from any Taxing authority in connection with any Tax audit or information request with respect to any such Taxable period, and (vi) timely provide to the other Parties powers of attorney or similar authorizations necessary to carry out the purposes of this Section 5.14
 
(f)           Within thirty (30) days following the Closing Date, to the extent necessary to satisfy the Member’s respective tax consequences arising solely out of the receipt of the Merger Shares, Tauriga agrees to use its best efforts to enable such Member to sell such number of Merger Shares sufficient to satisfy such Seller’s estimated and unpaid tax liability generated by the receipt of the Merger Shares or other merger consideration by way the filing of a Form S-1 for the resale of the Member’s Merger Shares, but only up to such number of Merger Shares as then necessary to satisfy such tax consequence, and in compliance the Securities Act, the Exchange Act, and the respective rules and regulations thereunder.
 
(g)           The obligations of the Parties set forth in this Section 5.13 shall be unconditional and absolute and shall remain in effect until sixty (60) days after the relevant statute of limitations for assessing the tax has expired.
 
5.14 Records. For four (4) years following the Closing Date, Tauriga shall grant to the Sellers and their authorized representatives at Sellers’ request, reasonable access to the books, records, officers and employees of Tauriga as may be reasonably necessary in connection with the defense of any legal proceeding; provided that (x) Tauriga may redact any portion of, or deny access to, any materials that are subject to attorney-client privilege, work product privilege or any other privilege or confidentiality obligation, and (y) any such access shall be limited to matters arising prior to the Closing Date.
 
5.15 Employment Agreements.  Tauriga shall have, on or before the Closing Date offered Elie Green, Daniel Kosmal and Ramona  Rubin an employment agreement satisfactory to such individual and Tauriga, providing such person is employed by the Surviving Entity as of and after the Closing Date.
 
 
33

 
 
5.16 Bank Account. Tauriga shall have, within three (3) business days following the Closing Date, opened a commercial bank account with a bank of its choice, which account shall be jointly held by Tauriga and the Surviving Entity.  The Surviving Entity agrees and acknowledges to utilize the proceeds provided by Tauriga (both the $1 million initially and any funds thereafter derived from the Surviving Entity’s business or elsewhere) for the Surviving Entity’s working capital, expansion and/or maintenance of its business operations and with the goal of substantial increase in its revenues, and at margins that are acceptable to Tauriga.  Elie Green, Daniel Kosmal and Ramona Rubin shall be appointed as the sole signatories and authorized agents under such bank account, provided that if at any time the funds drawn from such bank account are not being utilized for Surviving Entity’s working capital and other business related needs within the scope of ordinary course of business or other projects as previously approved by the Operations Committee, then Tauriga shall be permitted to appoint an  authorized executive or employee as a joint signatory under such bank account.
 
5.17 Surviving Entity Board of Managers.  On or before the Closing Date, Tauriga and the Sellers will form a Board of Managers of the Surviving Entity (the “Board of Managers”), which will oversee and approve the day to day operations of the Surviving Entity following the closing of the Merger.  The Board of Managers will consist of Elie Green, Daniel Kosmal, Ramona Rubin and Stella Sung.  Any matters that may have a Material Adverse Effect, or shall involve such additional major decisions as may be agreed upon by Honeywood and Tauriga prior to Closing will require the unanimous consent of the Board of Managers.  Any other decisions shall be subject to the majority approval of the Board of Managers.  The parties hereto, and the members of the board of managers that are or become party to this agreement (or by joinder) agree that the Board of Managers will meet at a minimum on a quarterly basis, and that any additional meetings will be called on an as needed basis should a decision concerning any material or substantial matters arise which require the approval of the Board of Managers (as outlined in this Section 5.17) before the next scheduled quarterly meeting.
 
5.18 Labeling, Website and Other Advertising.  Honeywood and the Sellers will diligently and cooperate in good faith with Tauriga in revising Honeywood’s (including Doc Green’s) product labeling, sales, advertising, marketing, website language and other physical and electronic means by which it provides information about its products, its and their uses, claims, intent, warnings, warranties, ingredients, components and the like, which changes must be made, implemented and be deemed acceptable and approved by Tauriga, its counsel and Honeywood on or before the Closing Date, such acceptance and approval to be confirmed in writing (which confirmation is permissible via email, fax or other electronic means).
 
5.19 Rent Payments.  Tauriga covenants and agrees that from the date hereof until the Closing Date, Tauriga shall be solely responsible for any and all rent payments due by Honeywood for its corporate offices located at 1999 Harrison Street, Oakland, California, which payments shall not be credited towards the Advances against the WC Financing or the Break-Up Fee set forth in Section 1.2.  For the avoidance of any doubt, the Surviving Entity shall be responsible for any and all rent payments for the above facility on and after the Closing Date.
 

 
34

 
 
ARTICLE VI
 
INDEMNIFICATION.
 
6.1 Indemnification by Honeywood.
 
(I) Each Seller (in the proportion to such Seller’s Merger Shares issued hereunder) shall severally, and not jointly, indemnify and hold harmless Tauriga, Acquisition Sub, Surviving Entity, their Affiliates and their respective officers, directors, employees, attorneys, agents and controlling persons from any liability, damage (excluding indirect or consequential damages), loss, penalty, cost or expense, including reasonable attorneys’ fees and costs of investigating and defending against lawsuits, complaints, actions or other pending or threatened litigation (collectively, “Costs”), arising from or attributable to:
 
(a) Any breach of any representation, warranty or agreement made by any one or more of the Sellers in this Agreement or any certificate delivered by Sellers pursuant to this Agreement;
 
(b) Any breach by one or more of the Sellers, or other failure by any one or more of the Sellers to perform, any of the covenants or agreements of the Sellers contained in this Agreement;
 
(c) Any Proceeding arising from the management, business or operations of Honeywood on or prior to the Closing Date to the extent not reflected on or reserved against on the Latest Honeywood Balance Sheet; and
 
(d) The principal amount, interest or any Costs arising out or relating to any Indebtedness of Honeywood at or prior to the Closing Date (other than any Indebtedness repaid by WC Financing).
 
(II) Each Seller other than Honeywood shall severally (in the proportion to such Seller’s Merger Shares issued hereunder) indemnify and hold harmless Tauriga, Acquisition Sub, Surviving Entity, their Affiliates and their respective officers, directors, employees, attorneys, agents and controlling persons from any Costs arising from or attributable to any breach of any representation, warranty or agreement made by such Seller in this Agreement, or any certificate delivered by Sellers pursuant to this Agreement.
 
6.2 Indemnification by Tauriga.  Tauriga shall indemnify and hold harmless each of the Sellers party to this Agreement, their Affiliates and their respective officers, directors, managers, employees, attorneys, agents and controlling persons from Costs arising from or attributable to:
 
(a)  Any breach of any representation, warranty or agreement made by any one or more of the Purchasers in this Agreement or any certificate delivered by Purchasers pursuant to this Agreement;
 
(b) Any breach by any one or more of the Purchasers, or other failure by any Purchasers to perform, any of the covenants or agreements of any one or more of the Purchasers contained in this Agreement;
 
(c) Any Proceeding arising from the management, business or operations of Surviving Entity after the Closing Date; and
 
(d) Any Taxes for which the Purchasers are liable pursuant to Sections 5.12. 5.13 or 5.14.
 
6.3 Limitations Period.  No action or claim for Costs pursuant to Section 6.1(I)(a), 6.1(II) or 6.2(a) shall be brought or asserted after the date that is eighteen (18) months from the Closing Date, except that: (a) the indemnification obligations under this Article VI shall continue as to Costs arising from any breach of the representations and warranties set forth in Sections 2.1, 2.2, 2.3, 2.4(a), 2.22, 3.1, 3.2, 3.3, 3.7 and 3.8 indefinitely, (b) the indemnification obligations under this Article VI shall continue as to Costs arising from any breach of the representations and warranties set forth in Sections 2.9 and 2.12 until the date that is sixty (60) days after the expiration of the statute of limitations.
 
 
35

 
 
6.4 Procedures for Resolution and Payment of Claims for Indemnification.
 
(a) If a Person entitled to be indemnified under this Article VI (the “Indemnitee”) shall incur any Costs and believes that it is entitled to be indemnified against such Costs by a Party hereunder (the “Indemnitor”), such Indemnitee shall deliver to the Indemnitor a certificate (an “Indemnity Certificate”) signed by the Indemnitee which Indemnitee Certificate shall:
 
(i) state that the Indemnitee has paid or properly accrued Costs, or anticipates that it will incur liability for Costs for which such Indemnitee is entitled to indemnification pursuant to this Agreement; and
 
(ii) specify in reasonable detail each individual item of Cost included in the amount so stated, the date such item was paid or properly accrued, the basis for any anticipated liability and the nature of the misrepresentation, breach of warranty or breach of covenant to which each such item is related and the computation of the amount to which such Indemnitee claims to be entitled hereunder.
 
(b) In case the Indemnitor shall object to the indemnification of an Indemnitee in respect of any claim or claims specified in any Indemnity Certificate, the Indemnitor shall within thirty (30) days after receipt by the Indemnitor of such Indemnity Certificate deliver to the Indemnitee a written notice to such effect and the Indemnitor and the Indemnitee shall, within the 30-day period beginning on the date of receipt by the Indemnitee of such written objection, attempt in good faith to agree upon the rights of the respective parties with respect to each of such claims to which the Indemnitor shall have so objected.  If the Indemnitee and the Indemnitor shall succeed in reaching agreement on their respective rights with respect to any of such claims, the Indemnitee and the Indemnitor shall promptly prepare and sign a writing setting forth such agreement.
 
(c) Promptly after the assertion by any third party of any claim against any Indemnitee that, in the judgment of such Indemnitee, may result in the incurrence by such Indemnitee of Costs for which such Indemnitee would be entitled to indemnification pursuant to this Agreement, such Indemnitee shall deliver to the Indemnitor a written notice describing in reasonable detail such claim and such Indemnitor may, at its option, assume the defense of the Indemnitee against such claim (including the employment of counsel, who shall be satisfactory to such Indemnitee, and the payment of expenses), which assumption shall not be deemed an admission of liability for indemnification, provided that, Indemnitor shall not be entitled to assume such defense unless: (i) the Indemnitor gives written notice to the Indemnitee within thirty (30) days after the Indemnitee has given notice of the third party claim that the Indemnitor will indemnify the Indemnitee from and against the entirety of any and all Costs the Indemnitee may suffer resulting from such claim, (ii) the Indemnitor provides the Indemnitee with evidence reasonably acceptable to the Indemnitee that the Indemnitor will have adequate financial resources to defend against such claim and fulfill its indemnification obligations hereunder, and (iii) such claim involves only money damages and does not seek an injunction or other equitable relief against the Indemnitee.  Any Indemnitee shall have the right to employ separate counsel in any such action or claim and to participate in the defense thereto, but the fees and expenses of such counsel shall not be at the expense of the Indemnitor unless: (A) any of the conditions in (i) through (iii) above shall not be met, (B) the employment of such counsel has been specifically authorized by the Indemnitor, or (C) the named parties to any such action (including any impleaded parties) include both such Indemnitee and the Indemnitor and such Indemnitee shall have been advised in writing by such counsel that such counsel has a conflict of interest in representing both the Indemnitor and Indemnitee in such action.  No Indemnitor shall be liable to indemnify any Indemnitee for any settlement of any such action or claim effected without the consent of the Indemnitor but if settled with the written consent of the Indemnitor, or if there be a final judgment for the plaintiff in any such action, the Indemnitor shall jointly and severally indemnify and hold harmless each Indemnitee from and against any loss or liability by reason of such settlement or judgment.  If an Indemnitor assumes the defense of an Indemnitee against a claim asserted hereunder, the Indemnitee shall give the Indemnitor access to its books and records as necessary to conduct such defense and cooperate in such defense.
 
(d) Settlement of Third Party Claims. Notwithstanding any other provision of this Agreement, the Indemnitor shall not enter into settlement of any third party claim without the prior written consent of the Indemnitee (which consent shall not be unreasonably withheld or delayed).  If a firm offer is made to settle a third party claim without leading to liability or the creation of a financial or other obligation (including injunctive relief or specific performance) or liability on the part of the Indemnitee and provides, in customary form, for the unconditional release of each Indemnitee from all liabilities and obligations in connection with such third party claim and the Indemnitor desires to accept and agree to such offer, the Indemnitor shall give written notice to that effect to the Indemnitee. If the Indemnitee fails to consent to such firm offer within ten (10) days after its receipt of such notice, the Indemnitee may continue to contest or defend such third party claim and in such event, the maximum liability of the Indemnitor as to such third party claim shall not exceed the amount of such settlement offer. If the Indemnitee fails to consent to such firm offer and also fails to assume defense of such third party claim, the Indemnitor may settle the third party claim upon the terms set forth in such firm offer to settle such third party claim. If the Indemnitee has assumed the defense pursuant to Section 6.4(c), it shall not agree to any settlement without the written consent of the Indemnitor (which consent shall not be unreasonably withheld or delayed).
 
(e) In no event shall any Indemnitor be liable to any Indemnitee for any punitive, incidental, consequential, special or indirect damages.
 
(f) Each Indemnitor shall take, and cause its Affiliates to take, all reasonable steps to mitigate any Costs upon becoming aware of any event or circumstance that would be reasonably expected to, or does, give rise thereto.
 
 
36

 
 
6.5 Limitation on Indemnification.  Notwithstanding any other provision of this Article VI: (i) no Party will have any indemnification obligations for Costs under Section 6.1(I)(a), 6.1(II)(a) or Section 6.2(a) unless and until the Costs exceed seventy-five thousand USD ($75,000) (the “Basket”), and Costs then shall be recoverable from all Costs in excess of such Basket, and (ii) in no event will the aggregate indemnification to be paid by a Party under 6.1(I)(a), 6.1(II) or Section 6.2(a) exceed seven million five hundred thousand USD ($7,500,000); provided, however, that the limitations in this Section 6.5 shall not apply to any claims arising out of fraud, and provided further, that in no event shall each individual Member’s liability under this Article VI exceed the amount calculated by multiplying $0.036 per the total amount of Merger Shares allocated to such Member pursuant to this Agreement.  At his or its discretion, any Member may elect, in lieu of cash, to satisfy any or all of its obligations to any Person under this Article VI by canceling and/or transferring to such Person a portion of his, her or its Merger Shares.  Notwithstanding the other provisions of this Section 6.5, in the event that any Member has an indemnification obligation under this Article VI, and such Member chooses to forfeit his, her or her Merger Shares in lieu of payment of cash, any such Merger Shares forfeited pursuant to this Section 6.5 shall have a value of $0.036 per Merger Share.  All indemnification payments made under this Agreement shall be treated by the Parties as an adjustment to the Merger Consideration for Tax purposes, unless otherwise required by Applicable Law.
 
6.6 Exclusive Remedies The Parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than claims arising from fraud on the part of a party hereto in connection with the transactions contemplated by this Agreement) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this Article VI.
 
ARTICLE VII
 
CONFIDENTIAL INFORMATION.
 
Each Party agrees that it will use the Confidential Information that it receives solely for the purpose of evaluating and implementing the transactions contemplated hereby and for no other purpose.  Each Party shall keep the Confidential Information strictly confidential, and shall not disclose any of the Confidential Information to any Person or use any of the Confidential Information for any other purpose; provided that each Party may disclose the Confidential Information to its accountants and attorneys (each an “Agent” and collectively the “Agents”) who need to know such Confidential Information solely for purposes of assisting such Party in evaluating the transactions contemplated hereby and, provided further, that such Confidential Information may be disclosed where required by applicable law, any rules and regulations of an exchange or automated quotation system, if required by any Governmental Entity or pursuant to an order of a court.  As a condition precedent to disclosing any Confidential Information to any such Agent, the Party will inform such Agent of the confidential nature of the Confidential Information and such Agent will agree to be bound to the terms and provisions hereof, as if such Agent was a party hereto.
 
 
37

 
 
ARTICLE VIII
 
TERMINATION.
 
8.1 Ability to Terminate.  This Agreement may be terminated at any time prior to the Effective Time as follows:
 
(a) By the mutual written consent of Tauriga and Honeywood.
 
(b) By Purchasers: (i) upon written notice to Honeywood that any of the conditions in Section 4.2 have not been fulfilled or waived on or prior to September 10, 2014, (ii) if there has been a breach by any one or more of the Sellers of any representation, warranty or covenant made by it as of the Finalization Date would result in the failure of a condition set forth in Sections 4.1 or 4.2; and such breach has not been cured by Sellers or waived by Tauriga within twenty (20) business days after all other conditions to Closing have been satisfied or are capable of being satisfied, or (iii) if an Alternative Proposal relating to Honeywood has not been rejected within three (3) days after receipt thereof by Honeywood, provided, that Purchasers may not terminate this Agreement pursuant to this Section 8.1(b) if any of the Purchasers are in material breach of this Agreement.
 
(c) By Honeywood: (i) upon written notice to Tauriga that any of the conditions in Section 4.1 have not been fulfilled or waived on or prior to September 10, 2014, (ii) if there has been a breach by any one or more of the Purchasers of any representation, warranty or covenant made by it by it as of the Finalization Date would result in the failure of a condition set forth in Sections 4.1 or 4.2; and such breach has not been cured by the Purchasers within twenty (20) business days after all other conditions to Closing have been satisfied or are capable of being satisfied, (iii) if Honeywood and Tauriga shall have failed to reach an agreement on the Disclosure Schedules, amendment to the Agreement or an agreement pertaining to Tauriga’s Operations Committee’s oversight over the operations of the Surviving Entity.
 
(d) By any Party if any Governmental Entity shall have issued an order, decree or ruling or taken any other action permanently restraining, enjoining or otherwise prohibiting the Merger and such order, decree, ruling or other action shall have become final and nonappealable (provided, however, that the right to terminate this Agreement pursuant to this Section 8.1(d) shall not be available to any Party until such Party has used all commercially reasonable efforts to remove such order, decree, ruling or other action unless such removal is not reasonably likely to be obtained).
 
8.2 Procedure and Effect of Termination.  In the event of termination of this Agreement by any of the Parties pursuant to this Article VIII, written notice thereof will forthwith be given by the terminating Party to the other Parties and this Agreement will terminate and the transactions contemplated hereby will be abandoned, without further action by either Party, whereupon the obligations and liabilities of the Parties hereunder will terminate, except as otherwise expressly provided in this Agreement; provided that Articles VII, VIII and IX shall survive termination.  Upon termination (other than with respect to the Break-up Fee), no Party will have any further obligations to any other Party and the Parties’ sole remedy will be an action for breach of contract or otherwise under law or in equity; provided, however, that the exercise of any termination right under Article VIII will not be an election of remedies and the terminating Party’s right to pursue all remedies at law or in equity will survive such termination unimpaired.
 
 
 
38

 
 
ARTICLE IX
 
MISCELLANEOUS PROVISIONS.
 
9.1 Construction; Governing Law.  This Agreement shall be construed and enforced in accordance with and governed by the laws of the State of Delaware without regard to principles of conflicts of laws, other than the mechanics and effect of the Merger, which shall be governed by the CA Code.
 
9.2 Notices.  All notices, consents, directions, approvals, instructions, requests and other communications required or permitted by the terms of this Agreement shall be in writing, and shall be sent to the applicable Party at the following addresses or facsimile numbers, as applicable:
 
If to the Purchasers, or Honeywood after the Closing Date:

C/o Tauriga Sciences, Inc.
39 Old Ridgebury Road, Suite C4
Danbury, CT 06180
Attn:  Stella M. Sung, Ph.D
Telephone: 514-840-3697
Fax:  514-221-3336

With a copy to:

Nixon Peabody LLP
437 Madison Avenue
New York, New York 10014
Attn: Theodore J. Ghorra, Esq.
Telephone: 212-940-3072
Fax:  855-856-7298
 
 
 
39

 
 
If to Seller prior to the Closing Date:

Honeywood LLC
1999 Harrison Street
Suite 1800
Oakland CA 94707
Attn:  Daniel Kosmal

With a copy to:
 
Buchalter Nemer, PC
1000 Wilshire Boulevard
Suite 1500
Los Angeles, CA 90017
Attn: Jeremy Weitz, Esq. and Tanya Viner, Esq.
Tel: (213) 891-0700
Fax: (213) 630-5793

or to such other address or facsimile number as any Party may have furnished to each other Party in writing in accordance herewith.  All notices, consents, directions, approvals, instructions, requests and other communications hereunder shall be sent and effective as follows: (i) on the business day delivered, when delivered personally, (ii) five (5) business days after mailing if mailed by registered or certified mail, return receipt requested (postage prepaid), (iii) on the next business day if sent by a nationally recognized overnight express courier service with all costs prepaid and provided evidence of delivery is available, or (iv) on the business day of a facsimile transmission if received on a business day before 5:00 p.m., local time, or on the next business day if received after that time, in each case provided that an automatic machine confirmation indicating the time of receipt is generated.
 
9.3 Assignment.  Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof may be assigned by Purchasers on the one hand or Honeywood or any of the other Sellers on the other hand without the prior written consent of the other such Party.  Nothing contained herein, express or implied, is intended to confer upon any Person other than the Parties hereto and their successors in interest and permitted assignees and any Indemnitee hereunder any rights or remedies under or by reason of this Agreement unless so expressly stated herein to the contrary.
 
9.4 Amendments and Waivers.  No breach of any covenant, agreement, warranty or representation shall be deemed waived unless expressly waived in writing by the Party who is entitled to assert such breach.  No waiver of any right hereunder shall operate as a waiver of any other right or of the same or a similar right on another occasion.  This Agreement and the Exhibits and Schedules hereto may be modified only by a written instrument duly executed by the Parties hereto.
 
9.5 Attorneys’ Fees.  In the event that any action or proceeding is commenced by any Party hereto for the purpose of enforcing any provision of this Agreement, the Parties to such action or proceeding may receive as part of any award, judgment, decision or other resolution of such action, proceeding or arbitration their costs and attorneys’ fees as determined by the Person or body making such award, judgment, decision or resolution.  Should any claim hereunder be settled short of the commencement of any such action or proceeding, the Parties in such settlement shall be entitled to include as part of the damages alleged to have been incurred costs of attorneys or other professionals in investigation or counseling on such claim.
 
 
40

 
 
9.6 Binding Nature of Agreement.  This Agreement includes each of the Schedules and Exhibits that are referred to herein or attached hereto, all of which are incorporated by reference herein.  All the terms and provisions of this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective executors, heirs, legal representatives, successors and permitted assigns.
 
9.7 Expenses.  The costs and expenses and the professional fees and disbursements incurred by each Party in connection herewith shall be borne such Party, except as otherwise specifically stated in this Agreement.
 
9.8 Entire Agreement.  This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof, and supersedes all prior representations, agreements and understandings relating to the subject matter hereof.
 
9.9 Severability.  Any provision of this Agreement that is invalid, illegal or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions hereof in such jurisdiction or rendering that or any other provision of this Agreement invalid, illegal or unenforceable in any other jurisdiction.
 
9.10 Counterparts; Signatures; Section Headings.  This Agreement may be executed by the Parties in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute but one and the same instrument.  A facsimile signature shall bind the signatory in the same way that an original signature would bind the signatory.  The headings of each section, subsection or other subdivision of this Agreement are for reference only and shall not limit or control the meaning thereof.
 
9.11 Waiver of Jury Trial.  EACH PARTY HERETO WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY DISPUTE IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND THE RELATED AGREEMENTS, AND AGREES TO TAKE ANY AND ALL ACTION NECESSARY OR APPROPRIATE TO EFFECT SUCH WAIVER.
 
9.12 Submission to Jurisdiction.  All actions or proceedings arising in connection with this Agreement shall be tried and litigated exclusively in the state courts for the State of California.  The aforementioned choice of venue is intended by the Parties to be mandatory and not permissive in nature, thereby precluding the possibility of litigation between the Parties with respect to or arising out of this Agreement.  Each Party hereby waives: (i) any right it may have to assert the doctrine of forum non conveniens or similar doctrine or to object to venue with respect to any proceeding brought in accordance with this Section 9.12, and (ii) the right each may have to a trial by jury.  Each Party stipulates that the state courts for the State of California shall have in personam jurisdiction over each of them for the purpose of litigating any such dispute, controversy or proceeding.  Each Party hereby authorizes and accepts service of process sufficient for personal jurisdiction in any action against it as contemplated by this Section 9.12 by registered or certified mail, return receipt requested, postage prepaid, to its address for the giving of notices as set forth in Section 9.2.  Nothing herein shall affect the right of any party to serve process in any other manner permitted by law.
 
[Remainder of page intentionally left blank]
 
 
41

 
 
IN WITNESS WHEREOF, this Agreement has been duly executed by the Parties hereto as of the date first written above.
 
 
TAURIGA SCIENCES, INC.
 
     
       
 
By:
/s/ Stella M. Sung, Ph.D  
    Name:  Stella M. Sung, Ph.D  
    Title:    Chief Executive Officer  
       
       
 
DOC GREENE’S ACQUISITION SUB, LLC
 
     
       
 
By:
/s/ Stella M. Sung, Ph.D  
    Name: Stella M. Sung, Ph.D  
    Title: Manager  
       
       
 
HONEYWOOD, LLC
 
     
     
       
 
By:
/s/ Daniel Kosmal  
    Name: Daniel Kosmal  
    Title: CFO  
       
 
HONEYWOOD’S MEMBERS
 
     
     
       
 
 
/s/ Elie Green  
    Elie Green  
       
    /s/ Daniel Kosmal  
    Daniel Kosmal   
       
    /s/ Ramona Moonflower Rubin  
    Ramona Moonflower Rubin   

                                                                        
42

 



 
 
EX-10.1 3 taug_ex101.htm SECURITIES PURCHASE AGREEMENT, DATED MARCH 7, 2014. taug_ex101.htm
Exhibit 10.1
 
SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 7, 2014, by and among Tauriga Sciences, Inc., a Florida corporation with headquarters located at 39 Old Ridgebury Road, Danbury, CT 06810 (the “Company”), and each investor identified on the signature pages hereto (individually, an “Investor” and collectively, the “Investors”).
 
BACKGROUND
 
A.             The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act.
 
B.           The Investor wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) a Warrant, in substantially the form attached hereto as Exhibit A (the “Warrant”) to acquire up to that aggregate number of shares of the common stock, par value $0.00001 per share, of the Company (the “Common Stock”) having an aggregate value of up to $1,000,000 (which aggregate amount issuable upon exercise or otherwise shall collectively be referred to herein as the “Warrant Shares”).
 
C.            This Agreement, and the Warrant to be issued hereunder, as entered into in connection with the Company’s execution of that certain Agreement and Plan of Merger, dated March 7, 2014, by and among the Company, Doc Greene’s Acquisition Sub, LLC, Honeywood LLC, and the other sellers (members of Honeywood LLC) from time to time party thereto (the “Merger Agreement”).
 
D.             The Warrant and any Warrant Shares, issued or issuable pursuant to this Agreement and the Warrant are, collectively sometimes are referred to herein as the “Securities.”
 
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Investors agree as follows:
 
ARTICLE I
 
DEFINITIONS
 
1.1 Definitions.  In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated:
 
Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act.
 
 
 

 
 
Agreement” has the meaning set forth in the Preamble.
 
Best Efforts” means the efforts that a prudent person desirous of achieving a result would use in similar circumstances to ensure that such result is achieved as expeditiously as practical; provided, however, that an obligation to use Best Efforts under this Agreement does not require the Company to dispose of or make any change to its business, expend any material funds or incur any other material burden.
 
Business Day” means any day other than Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any day on which banking institutions in The State of New York are authorized or required by law or other governmental action to close.
 
Closing” means the closing of the purchase and sale of the Securities pursuant to Section 2.1.
 
Closing Date” means the date and time of the Closing and shall be on such date and time as is mutually agreed to by the Company and each Investor.
 
Closing Price” means, for any date, the closing price per share of the Common Stock for such date (or, if not a Trading Day, the nearest preceding date that is a Trading Day) on the primary Eligible Market or exchange or quotation system on which the Common Stock is then listed or quoted.
 
Company” has the meaning set forth in the Preamble.
 
Company Counsel” means Nixon Peabody LLP, counsel to the Company.
 
Common Stockhas the meaning set forth in the Preamble.
 
Contingent Obligation” has the meaning set forth in Section 3.1(aa).
 
Convertible Securities” means any stock or securities (other than Options) convertible into or exercisable or exchangeable for Common Stock.
 
Effective Date” means the date that the Registration Statement is first declared effective by the SEC.
 
Effectiveness Period” has the meaning set forth in Section 6.1(b).
 
Disclosure Materials” has the meaning set forth in Section 3.1(f).
 
8-K Filing” has the meaning set forth in Section 4.5.
 
Eligible Market” means any of the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or OTC Bulletin Board.
 
 
2

 
 
Event” has the meaning set forth in Section 6.1(d).
 
Event Payments” has the meaning set forth in Section 6.1(d).
 
Exchange Act” means the Securities Exchange Act of 1934, as amended.
 
Excluded Events” has the meaning set forth in Section 6.1(d)(ii).
 
Filing Date” means the date that is forty-five (45) days after the date of this Agreement or, if such date is not a Business Day, the next date that is a Business Day.
 
GAAP” has the meaning set forth in Section 3.1(g).
 
Indebtedness” has the meaning set forth in Section 3.1(aa).
 
Indemnified Party” has the meaning set forth in Section 6.4(c).
 
Indemnifying Party” has the meaning set forth in Section 6.4(c).
 
Insolvent” has the meaning set forth in Section 3.1(h).
 
Intellectual Property Rights” has the meaning set forth in Section 3.1(t).
 
Investor” has the meaning set forth in the Preamble.
 
Lien” means any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction.
 
Losses” means any and all losses, claims, damages, liabilities, settlement costs and expenses, including, without limitation, reasonable attorneys’ fees.
 
Material Adverse Effect” means (i) a material adverse effect on the results of operations, assets, business, prospects or financial condition of the Company or (ii) material and adverse impairment of the Company's ability to perform its obligations under any of the Transaction Documents, provided, that none of the following alone shall be deemed, in and of itself, to constitute a Material Adverse Effect:  (i) a change in the market price or trading volume of the Common Stock or (ii) changes in general economic conditions or changes affecting the industry in which the Company operates generally (as opposed to Company-specific changes) so long as such changes do not have a disproportionate effect on the Company.
 
Material Permits” has the meaning set forth in Section 3.1(v).
 
 
3

 
 
Options” means any outstanding rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.
 
“Person” has the meaning set forth in Section 3.1(aa).
 
Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, a partial proceeding, such as a deposition), whether commenced or threatened in writing.
 
Prospectus” means the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the Prospectus including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.
 
Registrable Securities” means the Warrant Shares issued or issuable pursuant to the Transaction Documents, together with any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing.
 
Registration Statement” means each registration statement required to be filed under Article VI, including (in each case) the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.
 
Regulation D” has the meaning set forth in the Preamble.
 
Required Effectiveness Date” means (i) if the Registration Statement does not become subject to review by the SEC, the date which is the earliest of (a) one-hundred (100) days after the Closing Date or (b) five (5) Trading Days after the Company receives notification from the SEC that the Registration Statement will not become subject to review, or (ii) if the Registration Statement becomes subject to review by the SEC, the date which is the earliest of (a) one hundred and sixty (160) days after the Closing Date or (b) five (5) Trading Days after the Company receives notification from the SEC that the SEC has no further comment to the Registration Statement.
 
Rule 144,” “Rule 415,” and “Rule 424” means Rule 144, Rule 415 and Rule 424, respectively, promulgated by the SEC pursuant to the Securities Act, as such Rules may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.
 
“SEC” has the meaning set forth in the Preamble.
 
SEC Reports” has the meaning set forth in Section 3.1(f).
 
 
4

 
 
Securities” has the meaning set forth in the Preamble.
 
Securities Act” has the meaning set forth in the Preamble.
 
Shares” means shares of the Company’s Common Stock.
 
Short Sales” has the meaning set forth in Section 3.2(h).
 
Trading Day” means (i) a day on which the Common Stock is traded on a Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed or quoted on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not listed or quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by the Pink Sheets LLC (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day.
 
Trading Market” means whichever of the New York Stock Exchange, the American Stock Exchange, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question.
 
Transaction” has the meaning set forth in Section 3.2(h).
 
“Transaction Documents” means this Agreement, the schedules and exhibits attached hereto, the Warrant and the Transfer Agent Instructions.
 
Transfer Agent” means ClearTrust LLC, 16540 Pointe Village Dr., Suite 206, Lutz, Florida 33558, or any successor transfer agent for the Company.
 
Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in the form of Exhibit C, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.
 
“Warrant” has the meaning set forth in the Preamble.
 
Warrant Shares” has the meaning set forth in the Preamble.
 
 
5

 
 
ARTICLE II
 
PURCHASE AND SALE
 
2.1 Closing.  Subject to the terms and conditions set forth in this Agreement, at the Closing the Company shall issue and sell to each Investor, and each Investor shall, severally and not jointly, purchase from the Company, such number of Warrant Shares for the price set forth on such Investor’s signature page to this Agreement.  The date and time of the Closing and shall be 11:00 a.m., New York City Time, on the Closing Date.  The Closing shall take place at the offices of the Company’s Counsel.
 
2.2 Closing Deliveries.
 
(a) At the Closing, the Company shall deliver or cause to be delivered to each Investor the following:
 
(i) a copy of the Company’s irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, one or more stock certificates, free and clear of all restrictive and other legends (except as expressly provided in Section 4.1(b) hereof), evidencing such number of Warrant Shares set forth on such Investor’s signature page to this Agreement, registered in the name of such Investor;
 
(ii) a Warrant, issued in the name of such Investor, pursuant to which such Investor shall have the right to acquire such number of Warrant Shares set forth on such Investor’s signature page to this Agreement
 
(iii) duly executed Transfer Agent Instructions acknowledged by the Company’s transfer agent;
 
(iv) a legal opinion of The Quick Law Group, in the form of Exhibit B, executed by such counsel and delivered to the Investors and;
 
(v) a certificate of the Secretary of the Company, dated as of the Closing Date, (a) certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Securities, (b) certifying the current versions of the certificate of incorporation, as amended and by-laws of the Company and (c) certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company; and
 
(vi) a certificate of the Chief Executive Officer or Chief Financial Officer of the Company, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in Section 5.1(a) and (b).
 
(b) (i) Prior to the closing, the Investor shall have delivered by wire transfer of $250,000 USD in immediately available funds to the Escrow Account (the “Escrow Account”) held at the Quick Law Group pursuant to that certain Escrow Agreement by and among Investor, the Company and the Quick Law Group; (ii) no less than one day prior to the Closing Date, the Investor shall have delivered by wire transfer of $250,000 USD in immediately available funds to the Escrow; and (iii) within ninety (90) days immediately following the Closing Date, the Investor shall have delivered by wire transfer $500,000 USD in immediately available funds to the Escrow Account.  The Investor’s obligation to deliver the above mentioned funds into the Escrow Account pursuant to this Section 2.2(b) shall not be applicable (as to a particular wire under subsection (i), (ii) or (iii) of this Section 2.2(b), and not as to all obligations in the aggregate hereunder) if the daily closing price of the Company’s Common Stock on the five consecutive trading days immediately preceding such payment must be no less than $.0025 (or as adjusted post-split).
 

 
 
6

 
 
ARTICLE III
 
REPRESENTATIONS AND WARRANTIES
 
3.1 Representations and Warranties of the Company.  The Company hereby represents and warrants to the Investors as follows (which representations and warranties shall be deemed to apply, where appropriate, to each Subsidiary of the Company):
 
(a) Organization and Qualification. The Company is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, with the requisite legal authority to own and use its properties and assets and to carry on its business as currently conducted.  The Company is not in violation of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.  The Company is duly qualified to do business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.
 
(b) Authorization; Enforcement. The Company has the requisite corporate authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.  The execution and delivery of each of the Transaction Documents to which it is a party by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action on the part of the Company and no further consent or action is required by the Company, its Board of Directors or its stockholders.  Each of the Transaction Documents to which it is a party has been (or upon delivery will be) duly executed by the Company and is, or when delivered in accordance with the terms hereof, will constitute, the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
 
(c) No Conflicts.  The execution, delivery and performance of the Transaction Documents to which it is a party by the Company and the consummation by the Company of the transactions contemplated hereby and thereby do not, and will not, (i) conflict with or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company debt or otherwise) or other understanding to which the Company is a party or by which any property or asset of the Company is bound, or affected, except to the extent that such conflict, default, termination, amendment, acceleration or cancellation right would not reasonably be expected to have a Material Adverse Effect, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including, assuming the accuracy of the representations and warranties of the Investors set forth in Section 3.2 hereof, federal and state securities laws and regulations and the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, including all applicable Trading Markets), or by which any property or asset of the Company is bound or affected, except to the extent that such violation would not reasonably be expected to have a Material Adverse Effect.
 
(d) The Securities. The Securities (including the Warrant Shares) are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens and will not be subject to preemptive or similar rights of stockholders (other than those imposed by the Investors).  The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable upon exercise of the Warrants.
 
(e) Capitalization.  The aggregate number of shares and type of all authorized, issued and outstanding classes of capital stock, options and other securities of the Company (whether or not presently convertible into or exercisable or exchangeable for shares of capital stock of the Company) is set forth in Schedule 3.1(f) hereto.  All outstanding shares of capital stock are duly authorized, validly issued, fully paid and nonassessable and have been issued in compliance in all material respects with all applicable securities laws.
 
 
7

 
 
(f) SEC Reports; Financial Statements.  Except as set forth on Schedule 3.1(g), the Company has filed all reports required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding the date hereof on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension and has filed all reports required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof.  Such reports required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, together with any materials filed or furnished by the Company under the Exchange Act, whether or not any such reports were required being collectively referred to herein as the “SEC Reports” and, together with this Agreement and the Schedules to this Agreement, the “Disclosure Materials”.  As of their respective dates (or, if amended or superseded by a filing prior to the Closing Date, then on the date of such filing), the SEC Reports filed by the Company complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed (or, if amended or superseded by a filing prior to the Closing Date, then on the date of such filing) by the Company, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or, if amended or superseded by a filing prior to the Closing Date, then on the date of such filing).  Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements, the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP or may be condensed or summary statements, and fairly present in all material respects the consolidated financial position of the Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments.  All material agreements to which the Company is a party or to which the property or assets of the Company are subject are included as part of or identified in the SEC Reports, to the extent such agreements are required to be included or identified pursuant to the rules and regulations of the SEC.
 
(g) Material Changes; Undisclosed Events, Liabilities or Developments; Solvency.  Since the date of the latest audited financial statements included within the SEC Reports, except as disclosed in the SEC Reports or in Schedule 3.1(h) hereto, (i) there has been no event, occurrence or development that, individually or in the aggregate, has had or that would result in a Material Adverse Effect, (ii) the Company has not incurred any material liabilities other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company's financial statements pursuant to GAAP or required to be disclosed in filings made with the SEC, (iii) the Company has not altered its method of accounting or changed its auditors, except as disclosed in its SEC Reports, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders, in their capacities as such, or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock-based plans.  The Company has not taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so.  The Company is not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the applicable Closing, will not be Insolvent (as defined below).  For purposes of this Section 3.1(h), “Insolvent” means (i) the present fair saleable value of the Company's assets is less than the amount required to pay the Company's total Indebtedness (as defined in Section 3.1(aa)), (ii) the Company is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii) the Company intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or (iv) the Company has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted.
 
(h) Absence of Litigation.  Except as disclosed in the SEC Reports, there is no action, suit, claim, or Proceeding, or, to the Company's knowledge, inquiry or investigation, before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company that could, individually or in the aggregate, to have a Material Adverse Effect.
 
 
8

 
 
(i) Compliance.  Except as would not, individually or in the aggregate, reasonably be expected to have or result in a Material Adverse Effect, (i)  the Company is not in default under or in violation of, (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company nor has the Company received written notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound, (ii) the Company is not in violation of any order of any court, arbitrator or governmental body, or (iii)  the Company is not in violation of any statute, rule or regulation of any governmental authority.
 
(j) Title to Assets.  The Company does not own real property.  The Company has good and marketable title in all personal property owned by them that is material to the business of the Company, in each case free and clear of all Liens, except for Liens that do not, individually or in the aggregate, have or result in a Material Adverse Effect.  Any real property and facilities held under lease by the Company is held by it under valid, subsisting and enforceable leases of which the Company is in material compliance.
 
(k) No General Solicitation.  Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged in any form of unlawful general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities.  The Company shall be responsible for the payment of any financial advisory fees, or brokers’ commission (other than for persons engaged by any Investor or its investment advisor) relating to or arising out of the issuance of the Securities pursuant to this Agreement.  The Company shall pay, and hold each Investor harmless against, any liability, loss or expense (including, without limitation, reasonable attorney's fees and out-of-pocket expenses) arising in connection with any such claim for fees arising out of the issuance of the Securities pursuant to this Agreement.
 
(l) Private Placement; Investment Company; U.S. Real Property Holding Corporation.  Neither the Company nor any of its Affiliates nor, any Person acting on the Company’s behalf has, directly or indirectly, at any time within the past six months, made any offer or sale of any security or solicitation of any offer to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause the offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market.  Assuming the accuracy of the representations and warranties of the Investors set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Investors as contemplated hereby. The sale and issuance of the Securities hereunder does not contravene the rules and regulations of any Trading Market on which the Common Stock is listed or quoted.  The Company is not required to be registered as, and is not an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.  The Company is not required to be registered as a United States real property holding corporation within the meaning of the Foreign Investment in Real Property Tax Act of 1980.
 
(m) Listing and Maintenance Requirements.  The Company has not, in the twelve months preceding the date hereof, received notice (written or oral) from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market.  The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
 
(n) Registration Rights.  Except as described in Schedule 3.1(p), the Company has not granted or agreed to grant to any Person any rights (including “piggy-back” registration rights) to have any securities of the Company registered with the SEC or any other governmental authority that have not expired or been satisfied or waived.
 
 
9

 
(o) Disclosure.  The Company confirms that neither it nor any officers, directors or Affiliates, has provided any of the Investors (other than any investors who signed a confidentiality agreement with the Company) or their agents or counsel with any information that constitutes or might constitute material, nonpublic information (other than the existence and terms of the issuance of Securities, as contemplated by this Agreement).  The Company understands and confirms that each of the Investors (other than any investors who signed a confidentiality agreement with the Company) will rely on the foregoing representations in effecting transactions in securities of the Company.  All disclosure provided by the Company to the Investors regarding the Company, its business and the transactions contemplated hereby, including the Schedules to this Agreement furnished by or on behalf of the Company, are true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.  To the Company's knowledge, except for the transactions contemplated by this Agreement, no event or circumstance has occurred or information exists with respect to the Company or its businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed.  The Company acknowledges and agrees that no Investor makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those set forth in the Transaction Documents.
 
(p) Acknowledgment Regarding Investors' Purchase of Securities.  Based upon the assumption that the transactions contemplated by this Agreement are consummated in all material respects in conformity with the Transaction Documents, the Company acknowledges and agrees that each of the Investors is acting solely in the capacity of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby.  The Company further acknowledges that no Investor is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given by any Investor or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Investors’ purchase of the Securities.  The Company further represents to each Investor that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its advisors and representatives.
 
(q) Patents and Trademarks.  The Company owns, or possesses adequate rights or licenses to use, all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights (“Intellectual Property Rights”) necessary to conduct their respective businesses as now conducted.  None of the Company’s Intellectual Property Rights that is currently material to its business have expired or terminated, or are expected to expire or terminate within three years from the date of this Agreement.  The Company does not have any knowledge of any infringement by the Company of Intellectual Property Rights of others.  Except as disclosed in the SEC Reports, there is no claim, action or proceeding being made or brought, or to the knowledge of the Company, being threatened, against the Company regarding its Intellectual Property Rights.
 
(r) Insurance.  The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses and locations in which the Company is engaged.
 
(s) Regulatory Permits.  The Company possesses all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as presently conducted and described in the SEC Reports (“Material Permits”), except where the failure to possess such permits does not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.
 
(t) Sarbanes-Oxley Act. The Company is in compliance in all material respects with applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder, except where such noncompliance would not have, individually or in the aggregate, a Material Adverse Effect.
 
(u) Foreign Corrupt Practices.  The Company, nor to the knowledge of the Company, any director, officer, agent, employee or other Person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee or to any foreign or domestic political parties or campaigns from corporate funds; (iii) violated or is in violation in any material respect of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.
 
(v) Labor Matters.   The Company is in compliance in all material respects with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
 
 
10

 
 
(w) Tax Status.  The Company (i) has made or filed all foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.  There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.
 
3.2 Representations and Warranties of the Investors.  Each Investor hereby, as to itself only and for no other Investor, represents and warrants to the Company as follows:
 
(a) Organization; Authority.  Such Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite corporate, partnership or other power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.  The purchase by such Investor of the Securities hereunder has been duly authorized by all necessary corporate, partnership or other action on the part of such Investor.  This Agreement has been duly executed and delivered by such Investor and constitutes the valid and binding obligation of such Investor, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
 
(b) No Public Sale or Distribution.  Such Investor is (i) acquiring the Warrant and (ii) upon exercise of the Warrants will acquire the Warrant Shares issuable upon exercise thereof in the ordinary course of business for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities laws, and such Investor does not have a present arrangement to effect any distribution of the Securities to or through any person or entity; provided, however, that by making the representations herein, such Investor does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to an exemption under the Securities Act.
 
(c) Investor Status.  At the time such Investor was offered the Securities, it was, at the date hereof it is and on the date which it exercises any Warrants it will be an “accredited investor” as defined in Rule 501(a) under the Securities Act or a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.  Such Investor is not a registered broker dealer registered under Section 15(a) of the Exchange Act, or a member of the FINRA, Inc. or an entity engaged in the business of being a broker dealer.  Except as otherwise disclosed in writing to the Company on Exhibit A-2 (attached hereto) on or prior to the date of this Agreement, such Investor is not affiliated with any broker dealer registered under Section 15(a) of the Exchange Act, or a member of the FINRA, Inc. or an entity engaged in the business of being a broker dealer.
 
(d) General Solicitation.  Such Investor is not purchasing the Securities as a result of any unlawful advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media, broadcast over television or radio, disseminated over the Internet or presented at any seminar or any other unlawful general solicitation or unlawful general advertisement.
 
(e) Experience of Such Investor.  Such Investor, either alone or together with its representatives has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment.  Such Investor understands that it must bear the economic risk of this investment in the Securities indefinitely, and is able to bear such risk and is able to afford a complete loss of such investment.
 
 
11

 
 
(f) Access to Information.  Such Investor acknowledges that it has reviewed the Disclosure Materials and has been afforded:  (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and each subsidiary and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.  Neither such inquiries nor any other investigation conducted by or on behalf of such Investor or its representatives or counsel shall modify, amend or affect such Investor’s right to rely on the truth, accuracy and completeness of the Disclosure Materials and the Company’s representations and warranties contained in the Transaction Documents.  Such Investor acknowledges receipt of copies of or access to the SEC Reports.
 
(g) No Governmental Review.  Such Investor understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.
 
(h) No Conflicts.  The execution, delivery and performance by such Investor of this Agreement and the consummation by such Investor of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of such Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above, for such that are not material and do not otherwise affect the ability of such Investor to consummate the transactions contemplated hereby.
 
(i) Prohibited Transactions; Confidentiality.  No Investor, directly or indirectly, and no Person acting on behalf of or pursuant to any understanding with any Investor, has engaged in any purchases or sales in the securities, including derivatives, of the Company (including, without limitation, any Short Sales (a “Transaction”) involving any of the Company’s securities) since the time that such Investor was first contacted by the Company, the Agent or any other Person regarding an investment in the Company.  Such Investor covenants that neither it nor any Person acting on its behalf or pursuant to any understanding with such Investor will engage, directly or indirectly, in any Transactions in the securities of the Company (including Short Sales) prior to the time the transactions contemplated by this Agreement are publicly disclosed.  “Short Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, derivatives and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker-dealers or foreign regulated brokers.
 
(j) Restricted Securities. The Investors understand that the Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances.
 
(k) Legends. It is understood that, except as provided in Section 4.1(b) of this Agreement, certificates evidencing such Securities may bear the legend set forth in Section 4.1(b).
 
(l) No Legal, Tax or Investment Advice.  Such Investor understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Investor in connection with the purchase of the Securities constitutes legal, tax or investment advice.  Such Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in con­nection with its purchase of the Securities.  Such Investor understands that the Agent has acted solely as the agent of the Company in this placement of the Securities, and that the Agent makes no representation or warranty with regard to the merits of this transaction or as to the accuracy of any information such Investor may have received in connection therewith.  Such Investor acknowledges that he has not relied on any information or advice furnished by or on behalf of the Agent.
 
 
12

 
 
ARTICLE IV
 
OTHER AGREEMENTS OF THE PARTIES
 
4.1 Transfer Restrictions.
 
(a) The Investors covenant that the Securities will only be disposed of pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act or pursuant to an available exemption from the registration requirements of the Securities Act, and in compliance with any applicable state securities laws.  In connection with any transfer of Securities other than pursuant to an effective registration statement or to the Company, or pursuant to Rule 144, the Company may require the transferor to provide to the Company an opinion of counsel selected by the transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration under the Securities Act.  Notwithstanding the foregoing, the Company hereby consents to and agrees to register on the books of the Company and with its Transfer Agent, without any such legal opinion, except to the extent that the transfer agent requests such legal opinion, any transfer of Securities by an Investor to an Affiliate of such Investor, provided that the transferee certifies to the Company that it is an “accredited investor” as defined in Rule 501(a) under the Securities Act and provided that such Affiliate does not request any removal of any existing legends on any certificate evidencing the Securities.
 
(b) The Investors agree to the imprinting, until no longer required by this Section 4.1(b), of the following legend on any certificate evidencing any of the Securities:
 
THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.  THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.
 
Certificates evidencing the Warrant Shares shall not be required to contain such legend or any other legend (i) while a registration statement (including the Registration Statement) covering the resale of the Warrant Shares is effective under the Securities Act, (ii) following any sale of such Securities pursuant to Rule 144 if the holder provides the Company with a legal opinion (and the documents upon which the legal opinion is based) reasonably acceptable to the Company to the effect that the Securities can be sold under Rule 144, (iii) if the Securities are eligible for sale under Rule 144, or (iv) if the holder provides the Company with a legal opinion (and the documents upon which the legal opinion is based) reasonably acceptable to the Company to the effect that the legend is not required under applicable requirements of the Securities Act (including controlling judicial interpretations and pronouncements issued by the Staff of the SEC).  The Company shall cause its counsel to issue the legal opinion included in the Transfer Agent Instructions to the Transfer Agent on the Effective Date.  Following the Effective Date and provided the registration statement referred to in clause (i) above is then in effect, or at such earlier time as a legend is no longer required for certain Securities, the Company will no later than three (3) Trading Days following the delivery by an Investor to the Company or the Transfer Agent (if delivery is made to the Transfer Agent a copy shall be contemporaneously delivered to the Company) of (i) a legended certificate representing such Securities (and, in the case of a requested transfer, endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect transfer), and (ii) an opinion of counsel to the extent required by Section 4.1(a), deliver or cause to be delivered to such Investor a certificate representing such Securities that is free from all restrictive and other legends.  The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section.
 
 
13

 
 
If within seven (7) Trading Days after receipt by the Company or its Transfer Agent of a legended certificate and the other documents as specified in Clauses (i) and (ii) of the paragraph immediately above, the Company shall fail to cause to be issued and delivered to such Investor a certificate representing such Securities that is free from all restrictive and other legends, and if on or after such Trading Day the Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Investor of shares of Common Stock that the Investor anticipated receiving from the Company without any restrictive legend (the “Covering Shares”), then the Company shall, within seven (7) Trading Days after the Investors request, pay cash to the Investor in an amount equal to the excess (if any) of the Investor’s total purchase price (including brokerage commissions, if any) for the Covering Shares, over the product of (A) the number of Covering Shares, times (B) the closing bid price on the date of delivery of such certificate and the other documents as specified in Clauses (i) and (ii) of the paragraph immediately above.
 
(c) The Company will not object to and shall permit (except as prohibited by law) an Investor to pledge or grant a security interest in some or all of the Securities in connection with a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement, and if required under the terms of such arrangement, the Company will not object to and shall permit (except as prohibited by law) such Investor to transfer pledged or secured Securities to the pledgees or secured parties.  Except as required by law, such a pledge or transfer would not be subject to approval of the Company, no legal opinion of the pledgee, secured party or pledgor shall be required in connection therewith (but such legal opinion shall be required in connection with a subsequent transfer or foreclosure following default by the Purchaser transferee of the pledge), and no notice shall be required of such pledge.  Each Investor acknowledges that the Company shall not be responsible for any pledges relating to, or the grant of any security interest in, any of the Securities or for any agreement, understanding or arrangement between any Investor and its pledgee or secured party.  At the appropriate Investor's expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities.  Provided that the Company is in compliance with the terms of this Section 4.1(c), the Company’s indemnification obligations pursuant to Section 6.4 shall not extend to any Proceeding or Losses arising out of or related to this Section 4.1(c).
 
4.2 Furnishing of Information.  Until the date that any Investor owning Warrant Shares may sell all of them pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 of the Securities Act (or any successor provision) and without volume or manner-of-sale restrictions , the Company covenants to use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.  The Company further covenants that it will take such further action as any holder of Securities may reasonably request to satisfy the provisions of this Section 4.2.
 
4.3 Integration.  The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate thereof shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Investors or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market.
 
4.4 Reservation of Securities.  The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the Transaction Documents in such amount as may be required to fulfill its obligations to issue such Shares under the Transaction Documents, which reservation of shares shall initially be set at 150 million shares of Common Stock, but which such reservation may be adjusted accordingly upon partial exercises by Holder, or eliminated upon full exercise of this Warrant.  In the event that at any time the then authorized shares of Common Stock are insufficient for the Company to satisfy its obligations to issue such Shares under the Transaction Documents, the Company shall promptly take such actions as may be required to increase the number of authorized shares.
 
4.5 Securities Laws Disclosure; Publicity.  The Company shall, at or before 9:30 a.m., New York time, on the first Trading Day following execution of this Agreement by all of the Investors party to this Agreement, issue a press release disclosing all material terms of the transactions contemplated hereby.  On the Closing Date, the Company shall file a Current Report on Form 8-K with the SEC (the “8-K Filing”) describing the terms of the transactions contemplated by the Transaction Documents and including as exhibits to such Current Report on Form 8-K the Transaction Documents (including the schedules and the names, and addresses of the Investors and the amount(s) of Securities respectively purchased) and the form of Warrant in the form required by the Exchange Act.  Thereafter, the Company shall timely file any filings and notices required by the SEC or applicable law with respect to the transactions contemplated hereby and provide copies thereof to the Investors promptly after filing.  The Company shall not, nor shall any of their respective officers, directors, employees and agents, provide any Investor with any material nonpublic information regarding the Company from and after the issuance of the above referenced press release without the express written consent of such Investor.
 
4.6 Use of Proceeds.  The Company intends to use the net proceeds from the sale of the Securities for working capital and general corporate purposes.  The Company also may use a portion of the net proceeds, currently intended for general corporate purposes, to acquire or invest in technologies, products or services that complement its business, although the Company has no present plans or commitments and is not currently engaged in any material negotiations with respect to these types of transactions.  Pending these uses, the Company intends to invest the net proceeds from this offering in short-term, interest-bearing, investment-grade securities, or as otherwise pursuant to the Company's customary investment policies.
 
 
14

 
 
ARTICLE V
 
CONDITIONS
 
5.1 Conditions Precedent to the Obligations of the Investors.  The obligation of each Investor to acquire Securities at the Closing is subject to the satisfaction or waiver by such Investor, at or before the Closing, of each of the following conditions:
 
(a) Representations and Warranties.  The representations and warranties of the Company contained herein shall be true and correct in all material respects as of the date when made and as of the Closing as though made on and as of such date; and
 
(b) Performance.  The Company and each other Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.
 
(c) No Suspensions of Trading in Common Stock; Listing. Trading in the Common Stock shall not have been suspended by the SEC, DTC (and the Company shall not have received any notice from DTC to the effect that a suspension of electronic trading or settlement services by DTC with respect to the Company’s Common Stock is being imposed or is contemplated) or any Trading Market (except for any suspensions of trading of not more than one Trading Day solely to permit dissemination of material information regarding the Company) at any time since the date of execution of this Agreement, and the Common Stock shall have been at all times since such date listed for trading on a Trading Market.
 
(d) Absence of Litigation. No action, suit or proceeding by or before any court or any governmental body or authority, against the Company or pertaining to the transactions contemplated by this Agreement or their consummation, shall have been instituted on or before the Closing Date, which action, suit or proceeding would, if determined adversely, have a Material Adverse Effect.
 
(e) Form S-1 effectiveness.  The Company shall have filed a registration statement by the Filing date, and such Registration Statement covering the resale of the Warrant Shares shall have bee declared effective on or before the Required Effectiveness Date.
 
(f) Material Adverse Effect.  No Material Adverse Effect relating to the Company shall have occurred.
 
(g) Current SEC Reports.  The Company shall be current in its required filings with the SEC, including all material required to have been filed pursuant to Section 13(a) or 15(d) of the Exchange Act.
 
5.2 Conditions Precedent to the Obligations of the Company.  The obligation of the Company to sell the Securities at the Closing is subject to the satisfaction or waiver by the Company, at or before the Closing, of each of the following conditions:
 
(a) Representations and Warranties.  The representations and warranties of the Investors contained herein shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made on and as of such date; and
 
(b) Performance.  The Investors shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Investors at or prior to the Closing.
 
 
15

 
 
ARTICLE VI
 
REGISTRATION RIGHTS
 
6.1 Registration Statement.
 
(a) As promptly as possible, and in any event on or prior to the Filing Date, the Company shall prepare and file with the SEC a Registration Statement covering the resale of all Registrable Securities.  The Registration Statement shall be on Form S-1.
 
(b) The Company shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective by the SEC as promptly as possible after the filing thereof, but in any event prior to the Required Effectiveness Date, and shall use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act until the earlier of the date that all Warrant Shares covered by such Registration Statement have been sold or can be sold publicly pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions (the “Effectiveness Period”); provided that, upon notification by the SEC that a Registration Statement will not be reviewed or is no longer subject to further review and comments, the Company shall request acceleration of such Registration Statement within five (5) Trading Days after receipt of such notice and request that it become effective on 4:00 p.m. New York City time on the Effective Date and file a prospectus supplement for any Registration Statement, whether or not required under Rule 424 (or otherwise), by 9:00 a.m. New York City time the day after the Effective Date.
 
(c) The Company shall notify the Investors in writing promptly (and in any event within two Trading Days) after receiving notification from the SEC that the Registration Statement has been declared effective.
 
(d) Should an Event (as defined below) occur, then upon the occurrence of such Event, and on every monthly anniversary thereof until the applicable Event is cured, the Company shall pay to the Investor an amount in cash, as liquidated damages and not as a penalty, equal to one-half of one percent (0.5%) of (i) the number of Warrant Shares held by such Investor as of the date of such Event, multiplied by (ii) the purchase price paid by such Investor for such Warrant Shares then held; provided, however, that the total amount of payments pursuant to this Section 6.1(d) shall not exceed, when aggregated with all such payments paid to the Investor, ten percent (10%) of the aggregate purchase price of the Securities purchased pursuant to this Agreement.  The payments to which an Investor shall be entitled pursuant to this Section 6.1(d) are referred to herein as “Event Payments.”  Any Event Payments payable pursuant to the terms hereof shall apply on a pro rated basis for any portion of a month prior to the cure of an Event.  In the event the Company fails to make Event Payments in a timely manner, such Event Payments shall bear interest at the rate of one percent (1.0%) per month (prorated for partial months) until paid in full.  All pro rated calculations made pursuant to this paragraph shall be based upon the actual number of days in such pro rated month.  Notwithstanding the foregoing, the maximum payment to an Investor associated with an Event in the aggregate shall not exceed (i) in any 30-day period, an aggregate of 1.0% of the purchase price paid by such Investor for its Warrant Shares then held (plus interest accrued thereon, if applicable) and (ii) 10.0% of the purchase paid by such Investor for its Warrant Shares then held.
 
For such purposes, each of the following shall constitute an “Event”:
 
(i) the Registration Statement is not filed on or prior to the Filing Date;
 
(ii) the Registration Statement is not declared effective on or prior to the Required Effectiveness Date;
 
(iii) except as provided for in Section 6.1(e) (the “Excluded Events”), after the Effective Date and during the Effectiveness Period, an Investor is not permitted to sell Registrable Securities under the Registration Statement (or a subsequent Registration Statement filed in replacement thereof) for any reason (other than the fault of such Investor or if such Investor is in possession of material non-public information or during a customary blackout period) for five (5) or more Trading Days (whether or not consecutive);
 
(iv) except as a result of the Excluded Events, the Common Stock is not listed or quoted, or is suspended from trading, on an Eligible Market for a period of three Trading Days (which need not be consecutive Trading Days) during the Effectiveness Period;
 
 
16

 
 
(v) with respect to an Investor, the Company fails for any reason to deliver a certificate evidencing any Securities to such Investor within five Trading Days after delivery of such certificate is required pursuant to any Transaction Document or the exercise rights of the Investors pursuant to the Warrants are otherwise suspended for any reason; or
 
(vi) during the Effectiveness Period, except as a result of the Excluded Events, the Company fails to have any Warrant Shares listed or quoted on an Eligible Market.
 
(e) Notwithstanding anything in this Agreement to the contrary, after 60 consecutive Trading Days of continuous effectiveness of the initial Registration Statement filed and declared effective pursuant to this Agreement, the Company may, by written notice to the Investors, suspend sales under a Registration Statement after the Effective Date thereof and/or require that the Investors immediately cease the sale of shares of Common Stock pursuant thereto and/or defer the filing of any subsequent Registration Statement if the Company is engaged in a material merger, acquisition or sale and the Board of Directors determines in good faith, by appropriate resolutions, that, as a result of such activity, (A) it would be materially detrimental to the Company (other than as relating solely to the price of the Common Stock) to maintain a Registration Statement at such time or (B) it is in the best interests of the Company to suspend sales under such registration at such time.  Upon receipt of such notice, each Investor shall immediately discontinue any sales of Registrable Securities pursuant to such registration until such Investor is advised in writing by the Company that the current Prospectus or amended Prospectus, as applicable, may be used.  In no event, however, shall this right be exercised to suspend sales beyond the period during which (in the good faith determination of the Company’s Board of Directors) the failure to require such suspension would be materially detrimental to the Company.  The Company’s rights under this Section 6(e) may be exercised for a period of no more than 20 Trading Days at a time and not more than three times in any twelve-month period, without such suspension being considered as part of an Event Payment determination.  Immediately after the end of any suspension period under this Section 6(e), the Company shall take all necessary actions (including filing any required supplemental prospectus) to restore the effectiveness of the applicable Registration Statement and the ability of the Investors to publicly resell their Registrable Securities pursuant to such effective Registration Statement.
 
6.2 Registration Procedures.  In connection with the Company’s registration obligations hereunder, the Company shall:
 
(a) Not less than three Trading Days prior to the filing of a Registration Statement or any related Prospectus or any amendment or supplement thereto, furnish via email to the Investor copies of all such documents proposed to be filed, which documents (other than any document that is incorporated or deemed to be incorporated by reference therein) will be subject to the review of such Investors.  The Company shall reflect in each such document when so filed with the SEC such comments regarding the Investor and the plan of distribution as the Investors may reasonably and promptly propose no later than two Trading Days after the Investors have been so furnished with copies of such documents as aforesaid.
 
(b) (i) Subject to Section 6.1(e), prepare and file with the SEC such amendments, including post-effective amendments, to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective, as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the SEC such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible, and in any event within 15 Trading Days (except to the extent that the Company reasonably requires additional time to respond to accounting comments), to any comments received from the SEC with respect to the Registration Statement or any amendment thereto; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by the Registration Statement during the applicable period in accordance with the intended methods of disposition by the Investors thereof set forth in the Registration Statement as so amended or in such Prospectus as so supplemented.
 
(c) Notify the Investors as promptly as reasonably possible, and (if requested by the Investor confirm such notice in writing no later than two Trading Days thereafter, of any of the following events:  (i) the SEC notifies the Company whether there will be a “review” of any Registration Statement; (ii) the SEC comments in writing on any Registration Statement; (iii) any Registration Statement or any post-effective amendment is declared effective; (iv) the SEC or any other Federal or state governmental authority requests any amendment or supplement to any Registration Statement or Prospectus or requests additional information related thereto; (v) the SEC issues any stop order suspending the effectiveness of any Registration Statement or initiates any Proceedings for that purpose; (vi) the Company receives notice of any suspension of the qualification or exemption from qualification of any Registrable Securities for sale in any jurisdiction, or the initiation or threat of any Proceeding for such purpose; or (vii) the financial statements included in any Registration Statement become ineligible for inclusion therein or any Registration Statement or Prospectus or other document contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
 
 
17

 
 
(d) Use its commercially reasonable efforts to avoid the issuance of or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of any Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as possible.
 
(e) If requested by the Investor, provide the Investor without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial statements and schedules, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the SEC.
 
(f) Promptly deliver to each Investor, without charge, as many copies of the Prospectus and each amendment or supplement thereto as such Person may reasonably request. The Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by the selling Investor in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto to the extent permitted by federal and state securities laws and regulations.
 
(g) (i) If applicable, in the time and manner required by the applicable Trading Market, prepare and file with such Trading Market an additional shares listing application covering all of the Registrable Securities; (ii) take all steps necessary to cause such Warrant Shares to be approved for listing on the Trading Market as soon as possible thereafter; (iii) provide to the Investor evidence of such listing; and (iv) except as a result of the Excluded Events, during the Effectiveness Period, maintain the listing of such Warrant Shares on each such Trading Market or another Eligible Market.
 
(h) Prior to any public offering of Registrable Securities, use its Best Efforts to register or qualify or cooperate with the selling Investor in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions within the United States as any Investor requests in writing, to keep each such registration or qualification (or exemption therefrom) effective for so long as required, but not to exceed the duration of the Effectiveness Period, and to do any and all other acts or things reasonably necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by a Registration Statement; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.
 
(i) Cooperate with the Investor to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by this Agreement and under law, of all restrictive legends, and to enable such certificates to be in such denominations and registered in such names as any such Investors may reasonably request.
 
(j) Upon the occurrence of any event described in Section 6.2(c)(vii), as promptly as reasonably possible, prepare a supplement or amendment, including a post-effective amendment, to the Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither the Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
 
(k) Comply with all rules and regulations of the SEC applicable to the registration of the Securities.
 
(l) It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of any particular Investor or to make any Event Payments set forth in Section 6.1(c) to such Investor that such Investor furnish to the Company the information specified in Exhibits B-1, B-2 and B-3 hereto and such other information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it (if different from the Plan of Distribution set forth on Exhibit D hereto) as shall be reasonably required to effect the registration of such Registrable Securities and shall complete and execute such documents in connection with such registration as the Company may reasonably request.
 
(m) The Company shall comply with all applicable rules and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investors in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to make available a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.
 
6.3 Registration Expenses.  The Company shall pay all fees and expenses incident to the performance of or compliance with Article VI of this Agreement by the Company, including without limitation (a) all registration and filing fees and expenses, including without limitation those related to filings with the SEC, any Trading Market and in connection with applicable state securities or Blue Sky laws, (b) printing expenses (including without limitation expenses of printing certificates for Registrable Securities), (c) messenger, telephone and delivery expenses, (d) fees and disbursements of counsel for the Company, (e) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement, and (f) all listing fees to be paid by the Company to the Trading Market.
 
 
18

 
 
6.4 Indemnification
 
(a) Indemnification by the Company.  The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless the Investor, its officers, directors, partners, members, agents and employees of each of them, each Person who controls any such Investor (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, partners, members, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, arising out of or relating to (i) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (ii) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (iii) any cause of action, suit or claim brought or made against such Indemnified Party (as defined in Section 6.4(c) below) by a third party (including for these purposes a derivative action brought on behalf of the Company), arising out of or resulting from (x) the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (y) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (z) the status of Indemnified Party as holder of the Securities (unless, such action, suit or claim is based, including in part, upon a breach of the Investor’s representations, warranties or covenants under the Transaction Documents or any conduct by the Investor that constitutes fraud, gross negligence or willful misconduct) or (iv) any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any Prospectus or any form of Company prospectus or in any amendment or supplement thereto or in any Company preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent that (A) such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such Investor furnished in writing to the Company by the Investor  for use therein, or to the extent that such information relates to the Investor or the Investor's proposed method of distribution of Registrable Securities and was reviewed and expressly approved by such Investor in writing expressly for use in the Registration Statement, or (B) with respect to any prospectus, if the untrue statement or omission of material fact contained in such prospectus was corrected on a timely basis in the prospectus, as then amended or supplemented, if such corrected prospectus was timely made available by the Company to the Investor, and the Investor seeking indemnity hereunder was advised in writing not to use the incorrect prospectus prior to the use giving rise to Losses.
 
In no event shall the liability of the Company hereunder be greater than the dollar value of the cash proceeds in amount received by the Company from the Investor under the terms of this Agreement giving rise to such indemnification obligation.
 
(b) Indemnification by Investor.  The Investor shall, indemnify and hold harmless the Company and its directors, officers, agents and employees to the fullest extent permitted by applicable law, from and against all Losses (as determined by a court of competent jurisdiction in a final judgment not subject to appeal or review) arising solely out of any untrue statement of a material fact contained in the Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, but only to the extent that (i) such untrue statements or omissions are based solely upon information regarding such Investor furnished to the Company by the Investor in writing expressly for use therein, or to the extent that such information relates to such Investor or the Investor’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by the Investor expressly for use in the Registration Statement (it being understood that the information provided by the Investor to the Company in Exhibits B-1, B-2 and B-3 and the Plan of Distribution set forth on Exhibit D, as the same may be modified by the Investor and other information provided by the Investor to the Company in or pursuant to the Transaction Documents constitutes information reviewed and expressly approved by the Investor in writing expressly for use in the Registration Statement), such Prospectus or such form of prospectus or in any amendment or supplement thereto.  In no event shall the liability of the selling Investor hereunder be greater in amount than the dollar amount of the net proceeds received by the Investor upon the sale of the Registrable Securities giving rise to such indemnification obligation.
 
(c) Conduct of Indemnification Proceedings.  If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party.
 
 
19

 
 
An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless:  (i) the Indemnifying Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of separate counsel shall be at the expense of the Indemnifying Party).  It shall be understood, however, that the Indemnifying Party shall not, in connection with any one such Proceeding (including separate Proceedings that have been or will be consolidated before a single judge) be liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified Parties, which firm shall be appointed by a majority of the Indemnified Parties.  The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld.  No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.
 
All reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within 20 Trading Days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder).
 
(d) Contribution.  If a claim for indemnification under Section 6.4(a) or  (b) is unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations.  The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission.  The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section 6.4(c), any reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.
 
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 6.4(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph.  Notwithstanding the provisions of this Section 6.4(d), the Investor shall not be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Investor from the sale of the Registrable Securities subject to the Proceeding exceed the amount of any damages that such Investor has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.  No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.
 
 
20

 
 
The indemnity and contribution agreements contained in this Section  are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.
 
6.5 Dispositions.  The Investor agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement and shall sell its Registrable Securities in accordance with the Plan of Distribution set forth in the Prospectus.  The Investor further agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Sections 6.2(c)(v), (vi) or (vii), such Investor will discontinue disposition of such Registrable Securities under the Registration Statement until such Investor is advised in writing by the Company that the use of the Prospectus, or amended Prospectus, as applicable, may be resumed.  The Company may provide appropriate stop orders to enforce the provisions of this paragraph. The Investor agrees that the removal of the restrictive legend from certificates representing Securities is predicated upon the Company’s reliance that the Investor will comply with the provisions of this subsection. Both the Company and the Transfer Agent, and their respective directors, officers, employees and agents, may rely on this subsection.
 
6.6 Piggy-Back Registrations.  If at any time during the Effectiveness Period there is not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to the Investor not then eligible to sell its Registrable Securities pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions in a three-month period, written notice of such determination and if, within ten days after receipt of such notice, the Investor shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities the Investor requests to be registered.  Notwithstanding the foregoing, in the event that, in connection with any underwritten public offering, the managing underwriter(s) thereof shall impose a limitation on the number of shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Investor has requested inclusion hereunder as the underwriter shall permit; provided, however, that (i) the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not contractually entitled to inclusion of such securities in such Registration Statement or are not contractually entitled to pro rata inclusion with the Registrable Securities and (ii) after giving effect to the immediately preceding proviso, any such exclusion of Registrable Securities shall be made pro rata among the Investors seeking to include Registrable Securities and the holders of other securities having the contractual right to inclusion of their securities in such Registration Statement by reason of demand registration rights, in proportion to the number of Registrable Securities or other securities, as applicable, sought to be included by each such Investor or other holder.  If an offering in connection with which an Investor is entitled to registration under this Section 6.7 is an underwritten offering, then the Investor is Registrable Securities are included in such Registration Statement shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in an underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock included in such underwritten offering and shall enter into an underwriting agreement in a form and substance reasonably satisfactory to the Company and the underwriter or underwriters. Upon the effectiveness the registration statement for which piggy-back registration has been provided in this Section 6.7, any Event Payments payable to an Investor whose Securities are included in such registration statement shall terminate and no longer be payable.
 
ARTICLE VII
 
MISCELLANEOUS
 
7.1 Termination.  This Agreement may be terminated by the Company or any Investor, by written notice to the other parties, if the Closing has not been consummated by the third Trading Day following the date of this Agreement; provided that no such termination will affect the right of any party to sue for any breach by the other party (or parties).
 
7.2 Fees and Expenses.  Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.  The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of the applicable Securities.
 
 
21

 
 
7.3 Entire Agreement.  The Transaction Documents, together with the Exhibits and Schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.  At or after the Closing, and without further consideration, the Company will execute and deliver to the Investors such further documents as may be reasonably requested in order to give practical effect to the intention of the parties under the Transaction Documents.
 
7.4 Notices.  Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section  prior to 6:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section on a day that is not a Trading Day or later than 6:30 p.m. (New York City time) on any Trading Day, (c) the Trading Day following the date of deposit with a nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given.  The addresses, facsimile numbers and email addresses for such notices and communications are those set forth on the signature pages hereof, or such other address or facsimile number as may be designated in writing hereafter, in the same manner, by any such Person.
 
7.5 Amendments; Waivers.  No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and each of the Investors or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
 
7.6 Construction.  The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.
 
7.7 Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.  The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investors.  Any Investor may assign its rights under this Agreement to any Person to whom such Investor assigns or transfers any Securities, provided (i) such transferor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company after such assignment, (ii) the Company is furnished with written notice of (x) the name and address of such transferee or assignee and (y) the Registrable Securities with respect to which such registration rights are being transferred or assigned, (iii) following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and applicable state securities laws, (iv) such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions hereof that apply to the “Investors” and (v) such transfer shall have been made in accordance with the applicable requirements of this Agreement and with all laws applicable thereto.
 
7.8 No Third-Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that each Indemnified Party is an intended third party beneficiary of Section 6.4 and (in each case) may enforce the provisions of such Section directly against the parties with obligations thereunder.
 
7.9 Governing Law; Venue; Waiver of Jury Trial.  THE CORPORATE LAWS OF THE STATE OF NEW YORK SHALL GOVERN ALL ISSUES CONCERNING THE RELATIVE RIGHTS OF THE COMPANY AND ITS STOCKHOLDERS.  ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.  THE COMPANY AND INVESTORS HEREBY IRREVOCABLY SUBMIT TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY OR ANY INVESTOR HEREUNDER, IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY THE COMPANY OR ANY INVESTOR, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER.  EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF.  NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.  THE COMPANY AND INVESTORS HEREBY WAIVE ALL RIGHTS TO A TRIAL BY JURY.
 
 
22

 
 
7.10 Survival.  The representations and warranties, agreements and covenants contained herein shall survive the Closing.
 
7.11 Execution.  This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission or email attachment, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or email-attached signature page were an original thereof.
 
7.12 Severability.  If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.
 
7.13 Rescission and Withdrawal Right.  Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any Investor exercises a right, election, demand or option owed to such Investor by the Company under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then, prior to the performance by the Company of the Company's related obligation, such Investor may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.
 
7.14 Replacement of Securities.  If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company for any losses in connection therewith.  The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities.
 
7.15 Remedies.  In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Investors and the Company will be entitled to seek specific performance under the Transaction Documents.  The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action for a temporary restraining order) the defense that a remedy at law would be adequate.
 
7.16 Payment Set Aside.  To the extent that the Company makes a payment or payments to any Investor hereunder or any Investor enforces or exercises its rights hereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company by a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.
 
7.17 Adjustments in Share Numbers and Prices.  In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference in any Transaction Document to a number of shares or a price per share shall be amended to appropriately account for such event.
 
7.18 Independent Nature of Investors' Obligations and Rights.  The obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction Documents.  The decision of each Investor to purchase Securities pursuant to this Agreement has been made by such Investor independently of any other Investor and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company which may have been made or given by any other Investor or by any agent or employee of any other Investor, and no Investor or any of its agents or employees shall have any liability to any other Investor (or any other person) relating to or arising from any such information, materials, statements or opinions.  Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Document.  Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no other Investor will be acting as agent of such Investor in connection with monitoring its investment hereunder.  Each Investor shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any Proceeding for such purpose.
 
[SIGNATURE PAGE TO FOLLOW]
 

 
23

 
 
IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
 
 
TAURIGA SCIENCES, INC.
 
       
 
By:
/s/ Stella M. Sung, Ph.D  
  Name: Stella M. Sung, Ph.D
  Title:  Chief Executive Officer
       
 
Address for Notice:
 
 
Tauriga Sciences, Inc.
39 Old Ridgebury Road, Suite C4
Danbury, CT 06180
Attn:  Stella M. Sung, Ph.D
Telephone: 514-840-3697
Fax:  514-221-3336
 
     
 
With a copy to:
 
 
Nixon Peabody LLP
437 Madison Avenue
New York, New York 10014
Attn: Theodore J. Ghorra, Esq.
Telephone: 212-940-3072
Fax:  855-856-7298
 
 
 
[COMPANY SIGNATURE PAGE]
 

 
 

 
 
Investor Signature Page
 
By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the Securities Purchase Agreement dated as of March 7, 2014 (the “Purchase Agreement”) by and among Tauriga Sciences, Inc. and the Investor (as defined therein), as to the number of shares of Common Stock exercisable under the Warrant as set forth below, and authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof.
 
 
 
  Name of Investor:
     
   ______________________________________________________________   
     
   By: __________________________________________________________
   Name:
   Title:
     
  Address:    ___________________________________________________
  ___________________________________________________________
  ___________________________________________________________
  Telephone No.: ______________________________________________
  Facsimile No.:    _____________________________________________
  Email Address:  _____________________________________________
 
Number of Shares Valued up to $1 Million USD
 
Aggregate Purchase Price: $1 Million USD
 
Delivery Instructions (if different than above):
 
c/o: _________________________________________________________
 
Address: ________________________________________________________
 
________________________________________________________
 
Telephone No.: _______________________________________________________
 
Facsimile No. : _______________________________________________________
 
Other Special Instructions: ___________________________________________
 
 
 

 
[Investor Signature Page]
 
 
 

 
 
Exhibits:
 
A           Form of Warrant
B           Instruction Sheet for Investors
C           Opinion of Company Corporate Counsel
D           Plan of Distribution
E           Company Transfer Agent Instructions
 

 
 

 
 
 
Execution Copy

 
EXHIBIT A
 
FORM OF WARRANT
 
NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.  THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.
 

 
TAURIGA SCIENCES, INC.
 
WARRANT
 
Warrant No. [__] Dated:  [__________], 2014
 
     
Tauriga Sciences, Inc., a Florida corporation (the “Company”), hereby certifies that, for value received, Hanover Holdings I, LLC or its registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of up to that aggregate number of shares of the common stock, par value $0.00001 per share, of the Company (the “Common Stock”) having an aggregate value of up to $1,000,000 (which aggregate amount issuable upon exercise or otherwise shall collectively be referred to herein as the “Warrant Shares”, and each such share, a “Warrant Share”) at an exercise price per share equal to the lower of (i) $0.05 per share or (ii) the average of the Volume Weighted Average Price (“VWAP”) for the five (5) trading days immediately prior to such exercise, with a discount of no greater than 35% of such 5-day VWAP (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any time and after [CLOSING DATE], 2014 (the “Initial Exercise Date”) and through and including the date that is twenty-four (24) months from the Initial Exercise Date (the “Expiration Date”), and subject to the following terms and conditions.  This Warrant (this “Warrant”) is issued pursuant to that certain Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Purchaser identified therein (the “Purchase Agreement”).
 
1. Definitions.  In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement.
 
2. Registration of Warrant.  The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time.  The Company may deem and treat the registered Holder of record of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.
 
3. Registration of Transfers.  The Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached hereto duly completed and signed, to the Transfer Agent or to the Company at its address specified herein.  Upon any such registration of transfer, a new warrant to purchase Common Stock, in substantially the form of this Warrant (any such new warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder.  The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.
 
4. Exercise and Duration of Warrants.
 
(a) This Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the Initial Exercise Date and including the Expiration Date.  At 6:30 P.M., New York City time on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. Notwithstanding anything to the contrary herein, the Expiration Date shall be extended by one day for each day following the Effective Date that the Registration Statement is not effective.
 
(b) A Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached hereto (the “Exercise Notice”), appropriately completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the Exercise Notice and only if a “cashless exercise” may occur at such time pursuant to Section 10 below), and the date such items are delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.”  The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder.  Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.
 
 
 

 
 
5. Delivery of Warrant Shares.
 
(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than five (5) Trading Days after the Exercise Date) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate, a certificate for the Warrant Shares issuable upon such exercise, free of restrictive legends unless a registration statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not then effective or the Warrant Shares are not freely transferable without volume restrictions pursuant to Rule 144 under the Securities Act (without regard to the current public information requirements and volume or manner-of-sale restrictions thereunder) or by electronic book entry utilizing the Depository Trust Corporation’s DWAC delivery system to an account of the Holder or its prime broker.  The Holder, or any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date.  The Company shall, upon request of the Holder, use its best efforts to deliver Warrant Shares hereunder electronically through The Depository Trust Company or another established clearing corporation performing similar functions.
 
(b) This Warrant is exercisable, either in its entirety or, from time to time, for a portion of the number of Warrant Shares.  Upon surrender of this Warrant following one or more partial exercises, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.
 
(c) In addition to any other rights available to a Holder, if the Company fails to deliver to the Holder a certificate representing Warrant Shares by the fifth Trading Day after the date on which delivery of such certificate is required by this Warrant, and if after such fifth Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within five Trading Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such certificate (and to issue such Common Stock) shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Common Stock and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Closing Price on the date of the event giving rise to the Company’s obligation to deliver such certificate.
 
(d) The Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares.  Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of this Warrant  as required pursuant to the terms hereof.
 
6. Charges, Taxes and Expenses.   Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder.  The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.
 
7. Replacement of Warrant.  If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable bond or indemnity, if requested.  Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe.
 
8. Reservation of Warrant Shares.  The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (after giving effect to the adjustments and restrictions of Section 9, if any), which reservation of shares shall initially be set at 150 million shares of Common Stock but which such reservation may be adjusted accordingly upon partial exercises by Holder or eliminated upon full exercise of this Warrant. The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable.  The Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed.
 
 
 

 
 
9. Certain Adjustments.  The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.
 
(a) Stock Dividends and Splits.  If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event.  Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.
 
(b) Fundamental Transactions.  If, at any time while this Warrant is outstanding, (i) the Company effects any merger or consolidation of the Company with or into another Person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock owning more than 50% of the outstanding shares of Common Stock (not including  any shares of Common Stock held by the Person or Persons making or affiliated with the Persons making the tender or exchange offer) tender or exchange their shares for other securities, cash or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”), then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the “Alternate Consideration”).  The aggregate Exercise Price for this Warrant will not be affected by any such Fundamental Transaction, but the Company shall apportion such aggregate Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.  If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.  At the Holder’s request, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to purchase the Alternate Consideration for the aggregate Exercise Price upon exercise thereof.  The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this paragraph (c) and insuring that the Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.
 
(c) Number of Warrant Shares.  Simultaneously with any adjustment to the Exercise Price pursuant to paragraph (a) of this Section, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be adjusted proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.
 
(d) Calculations.  All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th of a share, as applicable.  The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Common Stock.
 
 
 

 
 
(e) Notice of Adjustments.  Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will promptly compute such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based.  Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent.
 
(f) Notice of Corporate Events.  If the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including without limitation any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any Subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction, at least ten calendar days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in order to insure that the Holder is given the practical opportunity to exercise this Warrant prior to such time so as to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice.
 
10. Payment of Exercise Price.  The Holder shall pay the Exercise Price in immediately available funds; provided, however, that if at any time after the Required Effective Date a Registration Statement covering the resale of the Warrant Shares is not effective on the Exercise Date (taking into account any necessary extension of such time under the Purchase Agreement for up to 60 days for comments by the SEC to the Registration Statement, or the like), the Holder may satisfy its obligation to pay the Exercise Price through a “cashless exercise,” in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows:
 
 
X = Y [(A-B)/A]
where:
 
 
X = the number of Warrant Shares to be issued to the Holder.
   
 
Y = the number of Warrant Shares with respect to which this Warrant is being exercised.
   
 
A = the average of the Closing Prices for the five Trading Days immediately prior to (but not including) the Exercise Date.
   
 
B = the Exercise Price.

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued pursuant to the Purchase Agreement.
 
 
 

 
 
11. Limitation on Exercise.
 
(a) The Holder shall not have the right to exercise this Warrant, to the extent that immediately after giving effect to such exercise, such Person (together with such Person’s affiliates) would beneficially own in excess of 4.99% (such percentage, as may be adjusted pursuant to this Section 11, the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise.  Such Holder’s delivery of an Exercise Notice shall constitute a representation that, upon delivery of the Warrant Shares to be issued to it pursuant to the Exercise Notice, such Holder and its affiliates will not own more than the Maximum Percentage applicable to such Holder immediately after giving effect to such exercise.  The Company shall be entitled to rely on such representation deemed made by the Holder and shall not be deemed to have violated the Maximum Percentage by issuing to such Holder no more than the number of shares of Common Stock provided for in an Exercise Notice.  For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and its affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein.  Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.  For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form 10-K or Form 10-Q with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Business Day (as defined in the Purchase Agreement) confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Warrants, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported.  By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% or less than 4.99% specified in such notice; provided that (i) any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to the Holder and not to any other holder of the Warrants.  For the avoidance of doubt, to the extent the limitation set forth in this Section 11 applies, the determination (i) of whether the exercise of this Warrant may be effected (vis-à-vis other options or convertible securities owned by the Holder or any of its affiliates) and (ii) of which of such options or convertible securities shall be convertible, exercisable or exchangeable (as the case may be, as among all such securities owned by the Holder) shall, subject to such Maximum Percentage limitation, be determined on the basis of the first submission to the Company for conversion, exercise or exchange (as the case may be).  The provisions of this paragraph shall be construed and implemented in a manner other than in strict conformity with the terms of this Section 1(g) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.
 
12. Fractional Shares.  The Company shall not be required to issue or cause to be issued fractional Warrant Shares on the exercise of this Warrant.  If any fraction of a Warrant Share would, except for the provisions of this Section, be issuable upon exercise of this Warrant, the number of Warrant Shares to be issued will be rounded up to the nearest whole share.
 
13. Notices.  Any and all notices or other communications or deliveries hereunder (including without limitation any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in the Purchase Agreement prior to 6:30 p.m. (New York City time) on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in the Purchase Agreement on a day that is not a Trading Day or later than 6:30 p.m. (New York City time) on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.  The address for such notices or communications shall be as set forth in the Purchase Agreement.
 
14. Warrant Agent.  The Company shall serve as warrant agent under this Warrant.  Upon 30 days' notice to the Holder, the Company may appoint a new warrant agent.  Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholder services business shall be a successor warrant agent under this Warrant without any further act.  Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder's last address as shown on the Warrant Register.
 
 
 

 
 
15. Miscellaneous.
 
(a) Subject to the restrictions on transfer set forth on the first page hereof, this Warrant may be assigned by the Holder.  This Warrant may not be assigned by the Company except to a successor in the event of a Fundamental Transaction.  This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns.  Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.  This Warrant may be amended only in writing signed by the Company and the Holder and their successors and assigns.
 
(b) The Company will not, by amendment of its governing documents or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment.  Without limiting the generality of the foregoing, the Company (i) will not increase the par value of any Warrant Shares above the amount payable therefor on such exercise, (ii) will take all such action as may be reasonably necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares on the exercise of this Warrant, and (iii) will not close its stockholder books or records in any manner which interferes with the timely exercise of this Warrant.
 
(c) Governing Law; Venue; Waiver Of Jury Trial.  all questions concerning the construction, validity, enforcement and interpretation of this warrant shall be governed by and construed and enforced in accordance with the laws of the state of new york.  each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the city of new york, borough of manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the transaction documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper.  each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.  the company hereby waives all rights to a trial by jury.
 
(d) The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.
 
(e) In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.
 
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,
SIGNATURE PAGE FOLLOWS]
 
 
 

 
 
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.
 
 
TAURIGA SCIENCES, INC.
 
       
 
By:
_________________________________________  
  Name:  _________________________________________  
  Title:  _________________________________________  
       
 
 
 
 

 
 
FORM OF EXERCISE NOTICE
 
(To be executed by the Holder to exercise the right to purchase shares of Common Stock under the foregoing Warrant)
 
To Tauriga Sciences, Inc.:
 
The undersigned is the Holder of Warrant No. _______ (the “Warrant”) issued by Tauriga Sciences, Inc., a Florida corporation (the “Company”).  Capitalized terms used herein and not otherwise defined have the respective meanings set forth in the Warrant.
 
1.  
The Warrant is currently exercisable to purchase a total of ______________ Warrant Shares.
 
2.  
The undersigned Holder hereby exercises its right to purchase _________________ Warrant Shares pursuant to the Warrant.
 
3.  
The Holder intends that payment of the Exercise Price shall be made as (check one):
 
____           “Cash Exercise” under Section 10
 
____           “Cashless Exercise” under Section 10
 
4.  
If the holder has elected a Cash Exercise, the holder shall pay the sum of $____________ to the Company in accordance with the terms of the Warrant.
 
5.  
Pursuant to this exercise, the Company shall deliver to the holder _______________ Warrant Shares in accordance with the terms of the Warrant.
 
6.  
Following this exercise, the Warrant shall be exercisable to purchase a total of ______________ Warrant Shares.
 
     
     
Dated:  ________________________ , ______________    
 
Name of Holder:
     
   
(Print) ______________________________________________                                                            
     
   
By:  ______________________________________________                                                             
   
Name:  _____________________________________________                                                          
   
Title: ______________________________________________                                                              
     
   
(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
     
ACKNOWLEDGED AND AGREED TO this ___ day of ___________, 201[_]
Tauriga Sciences, Inc.
 
 
By:
Name: _______________________
Title:________________________
   
 
 
 
 
 

 
 
FORM OF ASSIGNMENT
 
[To be completed and signed only upon transfer of Warrant]
 
FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto ________________________________ the right represented by the within Warrant to purchase  ____________ shares of Common Stock of Tauriga Sciences, Inc. to which the within Warrant relates and appoints ________________ attorney to transfer said right on the books of Tauriga Sciences, Inc. with full power of substitution in the premises.
 
   
   
Dated: ______________________ , ______     
 
   
   ______________________________________________________
 
(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
   
   ________________________________________________
 
Address of Transferee
   
   ________________________________________________ 
   
   ________________________________________________ 
   
   
In the presence of:
 
   
   
 ________________________________________________   

 
 
 

 

 
Exhibit B
 
INSTRUCTION SHEET FOR INVESTOR
 
(to be read in conjunction with the entire Securities Purchase Agreement)
 
A.  
Complete the following items in the Securities Purchase Agreement:
 
1.  
Complete and execute the Investor Signature Page.  The Agreement must be executed by an individual authorized to bind the Investor.
 
2.  
Exhibit B-1 - Stock Certificate Questionnaire:
 
Provide the information requested by the Stock Certificate Questionnaire;
 
3.  
Exhibit B-2 - Registration Statement Questionnaire:
 
Provide the information requested by the Registration Statement Questionnaire.
 
4.  
Exhibit B-3 - Investor Certificate:
 
Provide the information requested by the Investor Certificate.
 
5.  
Return, via facsimile, the signed Securities Purchase Agreement including the properly completed Exhibits B-1 through B-3, to:
 
Facsimile:
Telephone:
Attn:
 
6.  
After completing instruction number five (5) above, deliver the original signed Securities Purchase Agreement including the properly completed Exhibits  B-1 through B-3 to:
 
 
Address:
 
 
B.  
Instructions regarding the wire transfer of funds for the purchase of the Securities will be telecopied to the Investor by the Company at a later date.

 
 
 

 
 
Exhibit B-1
 
Tauriga Sciences, Inc.
 
STOCK CERTIFICATE QUESTIONNAIRE
 

 
Please provide us with the following information:
 
     
1.
The exact name that the Securities are to be registered in (this is the name that will appear on the stock and warrant certificate(s)).  You may use a nominee name if appropriate:
 
     
2.
The relationship between the Investor of the Securities and the Registered Holder listed in response to item 1 above:
 
     
3.
The mailing address, telephone and telecopy number and email address of the Registered Holder listed in response to item 1 above:
 
     
     
     
     
4.
The Tax Identification Number of the Registered Holder listed in response to item 1 above:
 
 
 
 
 

 

 
Exhibit B-2
 
Tauriga Sciences, Inc.
 
REGISTRATION STATEMENT QUESTIONNAIRE
 
In connection with the Registration Statement, please provide us with the following information regarding the Investor.
 
1.             Please state your organization’s name exactly as it should appear in the Registration Statement:
 
______________________________________________________________________
 
Except as set forth below, your organization does not hold any equity securities of the Company on behalf of another person or entity.
 
State any exceptions here:
 
 
______________________________________________________________________
 
 
If the Investor is not a natural person, please identify the natural person or persons who willhave voting and investment control over the Securities owned by the Investor:
 
 
______________________________________________________________________
 
2.  Address of your organization:
 
______________________________________________________
 
______________________________________________________
 
Telephone:  __________________________
 
Fax:  ________________________________
 
Contact Person:  _______________________
 
 
 

 
 
3.  Have you or your organization had any position, office or other material relationship within the past three years with the Company or its affiliates?  (Include any relationships involving you or any of your affiliates, officers, directors, or principal equity holders (5% or more) that has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.)
 
 
_______                      Yes                                _______                      No
 
If yes, please indicate the nature of any such relationship below:
 
4.  Are you the beneficial owner of any other securities of the Company?  (Include any equity securities that you beneficially own or have a right to acquire within 60 days after the date hereof, and as to which you have sole voting power, shared voting power, sole investment power or shared investment power.)
 
 
_______                      Yes                                _______                      No
 
If yes, please describe the nature and amount of such ownership as of a recent date.
 

 
5.  Except as set forth below, you wish that all the shares of the Company’s common stock beneficially owned by you or that you have the right to acquire from the Company be offered for your account in the Registration Statement.
 
State any exceptions here:
 
 
6.  Have you made or are you aware of any arrangements relating to the distribution of the shares of the Company pursuant to the Registration Statement?
 
_______                      Yes                                _______                      No
 
If yes, please describe the nature and amount of such arrangements.
 
 
 

 
 
7.  FINRA Matters
 
(a)           State below whether (i) you or any associate or affiliate of yours are a member of FINRA, a controlling shareholder of a FINRA member, a person associated with a member, a direct or indirect affiliate of a member, or an underwriter or related person with respect to the proposed offering; (ii) you or any associate or affiliate of yours owns any stock or other securities of any FINRA member not purchased in the open market; or (iii) you or any associate or affiliate of yours has made any outstanding subordinated loans to any FINRA member. If you are a general or limited partnership, a no answer asserts that no such relationship exists for you as well as for each of your general or limited partners.
 
Yes: __________
No: __________
 

 
If “yes,” please identify the FINRA member and describe your relationship, including, in the case of a general or limited partner, the name of the partner:
 
 
 
 
 
 
 
If you answer “no” to Question 7(a), you need not respond to Question 7(b).
 
 
(b) State below whether you or any associate or affiliate of yours has been an underwriter, or a controlling person or member of any investment banking or brokerage firm which has been or might be an underwriter for securities of the Corporation or any affiliate thereof including, but not limited to, the common stock now being registered.
 
Yes: __________
No: __________
 
If “yes,” please identify the FINRA member and describe your relationship, including, in the case of a general or limited partner, the name of the partner.
 
 
 
 

 
 
ACKNOWLEDGEMENT
 
The undersigned hereby agrees to notify the Company promptly of any changes in the foregoing information which should be made as a result of any developments, including the passage of time.  The undersigned also agrees to provide the Company and the Company’s counsel any and all such further information regarding the undersigned promptly upon request in connection with the preparation, filing, amending, and supplementing of the Registration Statement (or any prospectus contained therein).  The undersigned hereby consents to the use of all such information in the Registration Statement.
 
The undersigned understands and acknowledges that the Company will rely on the information set forth herein for purposes of the preparation and filing of the Registration Statement.
 
The undersigned understands that the undersigned may be subject to serious civil and criminal liabilities if the Registration Statement, when it becomes effective, either contains an untrue statement of a material fact or omits to state a material fact required to be stated in the Registration Statement or necessary to make the statements in the Registration Statement not misleading.  The undersigned represents and warrants that all information it provides to the Company and its counsel is currently accurate and complete and will be accurate and complete at the time the Registration Statement becomes effective and at all times subsequent thereto, and agrees during the Effectiveness Period and any additional period in which the undersigned is making sales of Shares under and pursuant to the Registration Statement, and agrees during such periods to notify the Company immediately of any misstatement of a material fact in the Registration Statement, and of the omission of any material fact necessary to make the statements contained therein not misleading.
 
 
Dated:  ________
______________________________
Name
 
______________________________
Signature
 
______________________________
Name and Title of Signatory
 
 
 

 
 
Exhibit B-3
 
TAURIGA SCIENCES, INC.
 
CERTIFICATE FOR CORPORATE, PARTNERSHIP, LIMITED LIABILITY COMPANY,
 
TRUST, FOUNDATION AND JOINT INVESTORS
 
If the Investor is a corporation, partnership, limited liability company, trust, pension plan, foundation, joint Investor (other than a married couple) or other entity, an authorized officer, partner, or trustee must complete, date and sign this Certificate.
 
 
CERTIFICATE
 
The undersigned certifies that the representations and responses below are true and accurate:
 
(a)           The Investor has been duly formed and is validly existing and has full power and authority to invest in the Company.  The person signing on behalf of the undersigned has the authority to execute and deliver the Securities Purchase Agreement on behalf of the Investor and to take other actions with respect thereto.
 
(b)           Indicate the form of entity of the undersigned:
 
____           Limited Partnership
 
____           General Partnership
 
____           Limited Liability Company
 
____           Corporation
 
____           Revocable Trust (identify each grantor and indicate under what circumstances the trust is revocable by the grantor):     ___________________________________
______________________________________________________________________________________________________________________________________
(Continue on a separate piece of paper, if necessary.)
 
 
____           Other type of Trust (indicate type of trust and, for trusts other than pension trusts, name the grantors and beneficiaries):    ______________________________________
 
____________________________________________________________________________________________________________________________________________
(Continue on a separate piece of paper, if necessary.)
 
 
____           Other form of organization (indicate form of organization  (___________________________).                                                                                                               
 
 
(c)           Indicate the approximate date the undersigned entity was formed: ______________________________.
 
 
 

 
 
(d)           In order for the Company to offer and sell the Securities in conformance with state and federal securities laws, the following information must be obtained regarding your investor status.  Please initial each category applicable to you as an investor in the Company.
 
 
___
1.
A bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity;
 
 
___
2.
A broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934;
 
 
___
3.
An insurance company as defined in Section 2(13) of the Securities Act;
 
 
___
4.
An investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section  2(a)(48) of that Act;
 
 
___
5.
A Small Business Investment Company licensed by the U.S.  Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;
 
 
___
6.
A plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000;
 
 
___
7.
An employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors;
 
 
___
8.
A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
 
 
___
9.
Any partnership or corporation or any organization described in Section 501(c)(3) of the Internal Revenue Code or similar business trust, not formed for the specific purpose of acquiring the Shares, with total assets in excess of $5,000,000;
 
 
___
10.
A trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Shares, whose purchase is directed by a sophisticated person as described in Rule  506(b)(2)(ii) of the Exchange Act;
 
 
___
11.
An entity in which all of the equity owners qualify under any of the above subparagraphs.  If the undersigned belongs to this investor category only, list the equity owners of the undersigned, and the investor category which each such equity owner satisfies: _______________________________________________
 
 

 
 

 
 
_____________________________________________________________________________________________________________________                                                                                       
(Continue on a separate piece of paper, if necessary.)
 
Please set forth in the space provided below the (i) states, if any, in the U.S. in which you maintained your principal office during the past two years and the dates during which you maintained your office in each state, (ii) state(s), if any, in which you are incorporated or otherwise organized and (iii) state(s), if any, in which you pay income taxes.
 
                                                                                                                             ___________________________________________________________
 
                                                                                                                             ___________________________________________________________
 
                                                                            ___________________________________________________________
 
Dated:__________________________, 20[__]
 

____________________________________
Print Name of Investor
 
____________________________________
Name:
Title:
(Signature and title of authorized officer, partner or trustee)
 
 
 

 
 
Exhibit C
 
OPINION OF COMPANY COUNSEL
 
[To be addressed to Investor(s)]
 
 
 

 

 
Exhibit D
 
PLAN OF DISTRIBUTION
 
The selling stockholders may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions.  These sales may be at fixed or negotiated prices.  The selling stockholders may use any one or more of the following methods when selling shares:
 
1.  
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
 
2.  
block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
 
3.  
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
 
4.  
an exchange distribution in accordance with the rules of the applicable exchange;
 
5.  
privately negotiated transactions;
 
6.  
short sales;
 
7.  
broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
 
8.  
a combination of any such methods of sale; and
 
9.  
any other method permitted pursuant to applicable law.
 
The selling stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.
 
Broker-dealers engaged by the selling stockholders, if any, may arrange for other brokers-dealers to participate in sales.  Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated.  The selling stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved.  Any profits on the resale of shares of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act.  Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by a selling stockholder.  The selling stockholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities are imposed on that person under the Securities Act.
 
 
 

 
 
The selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus after we have filed a supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.
 
The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under this prospectus after we have filed a supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.
 
The selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales.  In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.
 
We are required to pay all fees and expenses incident to the registration of the shares of common stock.  We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
 
The selling stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with a proposed sale of shares of common stock by any selling stockholder.  If we are notified by any selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock, if required, we will file a supplement to this prospectus.  If the selling stockholders use this prospectus for any sale of the shares of common stock, they will be subject to the prospectus delivery requirements of the Securities Act.
 
The anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934 may apply to sales of our common stock and activities of the selling stockholders
 
 
 

 
 
Exhibit E
 
COMPANY TRANSFER AGENT INSTRUCTIONS
 
ClearTrust LLC
16540 Pointe Village Dr.
Suite 206
Lutz, Florida 33558
Attention: [________________] Representative
 
Ladies and Gentlemen:
 
 
Reference is made to that certain Securities Purchase Agreement, dated as of March 7, 2014 (the “Agreement”), by and among Tauriga Sciences, Inc., a Florida corporation (the “Company”), and the investors named on the Schedule of Investors attached thereto (collectively, the “Holders”), pursuant to which the Company is issuing to the Holders shares (the “Common Shares”) of Common Stock of the Company, par value $0.00001 per share (the “Common Stock”), and Warrants (the “Warrants”), which are exercisable into shares of Common Stock.
 
In connection with the consummation of the transactions contemplated by the Agreement, this letter shall serve as our irrevocable authorization and direction to you:
 
(i)  to issue an aggregate of [_______] shares of our Common Stock in the names and denominations set forth on Annex I attached hereto. The certificates should bear the legend set forth on Annex II attached hereto and “stop transfer” instructions should be placed against their subsequent transfer.  Kindly deliver the certificates to the respective delivery addresses set forth on Annex I via hand delivery or overnight courier.  We confirm that these shares will be validly issued, fully paid and non-assessable upon issuance.
 
(ii)  to issue (provided that you are the transfer agent of the Company at such time) certificates for shares of Common Stock upon transfer or resale of the Common Shares and receipt by you of certificate(s) for the Common Shares so transferred or sold (duly endorsed or accompanied by stock powers duly endorsed, in each case with signatures guaranteed and otherwise in form eligible for transfer); and
 
(iii)  to issue (provided that you are the transfer agent of the Company at such time) shares of Common Stock upon the exercise of the Warrants (the “Warrant Shares”) to or upon the order of a Holder from time to time upon delivery to you of a properly completed and duly executed Exercise Notice, in the form attached hereto as Annex II, which has been acknowledged by the Company as indicated by the signature of a duly authorized officer of the Company thereon.
 
You acknowledge and agree that so long as you have previously received (a) written confirmation from the Company’s legal counsel that either (i) a registration statement covering resales of the Common Shares and the Warrant Shares has been declared effective by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), or (ii) the Common Shares and the Warrant Shares are eligible for sale in conformity with Rule 144 under the Securities Act without regard to volume or manner of sale restrictions (“Rule 144”) and (b) if applicable, a copy of such registration statement, then, unless otherwise required by law, within three (3) business days of your receipt of certificates representing the Common Shares and the Warrant Shares, you shall issue the certificates representing the Common Shares and the Warrant Shares to the Holders or their transferees, as the case may be, registered in the names of such Holders or transferees, as the case may be, and such certificates shall not bear any legend restricting transfer of the Common Shares and the Warrant Shares thereby and should not be subject to any stop-transfer restriction.  Any certificates tendered for transfer shall be endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect transfer.
 
 
 

 
 
A form of written confirmation from the Company’s outside legal counsel at the Quick Law Group that a registration statement covering resales of the Common Shares and the Warrant Shares has been declared effective by the SEC under the Securities Act is attached hereto as Annex III.
 
Please be advised that the Holders are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each Holder is a third party beneficiary to these instructions.
 
Please execute this letter in the space indicated to acknowledge your agreement to act in accordance with these instructions.  Should you have any questions concerning this matter, please contact our counsel, Theodore J. Ghorra Esq., at 212-940-3072.
 
 
Very truly yours,
 
  TAURIGA SCIENCES, INC.  
 
By:
   
   Name:     
   Title:     
       
 
 
THE FOREGOING INSTRUCTIONS ARE
ACKNOWLEDGED AND AGREED TO
this ___ day of [Month], 20[__]
 
 
CLEARTRUST LLC
 
 
By:  ______________________________________                                                              
Name:  ______________________________                                                        
Title:   ______________________________                                                       
 
 
Enclosures
 

EX-99.1 4 taug_ex991.htm PRESS RELEASE OF TAURIGA SCIENCES, INC., DATED MARCH 11, 2014. taug_ex991.htm
Exhibit 99.1
 
Tauriga Sciences Inc. Signs Definitive Agreement to Acquire California's Leading Manufacturer of Topical and Medicinal Cannabis Based Therapeutic Creams
 
San Francisco, CA -- Tauriga Sciences, Inc. (OTCBB: TAUG) or ("Tauriga" "TAUG" or "the Company"), a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the signing of a Definitive Agreement ("the definitive agreement") with California's leading manufacturer of topical medicinal cannabis products ("Cannabis Manufacturer") since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis creams ("cream" or "lotion" or "topical cannabis products") deliver the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the definitive agreement, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies.

Within the next 10 business days, the Company will fully disclose the details of the Cannabis Manufacturer with which it has entered into this definitive merger agreement. Such details will include: the identity of the manufacturer, the product lines, the technology platform, revenue projections, and the product website.

The above-mentioned definitive agreement signed between Tauriga and Cannabis Manufacturer ("both parties") is a binding agreement that stipulates that the parties have one-hundred twenty ("120") days to close this transaction, subject to continued due diligence, representation and related disclosure schedules and other customary closing conditions. Tauriga has agreed to issue Cannabis Manufacturer's existing members up to 32% of Tauriga's common stock on a fully-diluted basis upon consummation of the merger as of the closing date. Tauriga has also agreed to pay to Cannabis Manufacturer, upon execution of the merger agreement $75,000 USD for working capital purposes, and within ten days ("10") of the execution of this merger agreement an additional $100,000 USD for working capital purposes, which will be credited towards any financing obligations of Tauriga as part of the overall transaction.

In support of this merger, Tauriga is pleased to report that it also signed a definitive Securities Purchase Agreement ("SPA") with an Institutional Investor for the issuance of restricted warrants exercisable for such number of Tauriga's common stock equal to the investor's $1,000,000 USD investment in the newly formed subsidiary to, among other things, help expand the Cannabis Manufacturer's operations, increase revenue and for other working capital and corporate purposes. As a closing condition to the merger with the Cannabis Manufacturer, Tauriga has agreed to file a resale registration statement to register the investor's shares of common stock underlying the investor's warrants. The Institutional Investor's obligation to fund the balance of its $1,000,000 USD investment are subject to the satisfaction of customary closing conditions precedent, including, without limitation, the registration statement being declared effective and the closing of a merger. On March 3, 2014, the institutional investor wired an initial $250,000 USD as a good faith gesture into escrow with the Company's outside counsel.

People around the world have been healing and relieving pain with the cannabis plant for millennia. A common preparation of cannabis was to extract the medicinal elements of the cannabis by soaking the plants flowers in oil or other substances to dissolve the medicinal compounds into the oil. These cannabis extracts were then applied to the skin (topical application) where the medicinal cannabinoids would enter the skin and body tissues, binging the medicine directly to the area of the body that was in need of healing and pain relief from injury, tension, inflammation muscle strain, bruising, and other ailments. Modern scientific researchers have discovered that cannabis interacts with a network of pain regulatory receptors that can be found all over the body, called "CB2" receptors.

 
 

 
 
Cannabinols ("CBNs"), the medicinal molecules produced by the cannabis plant, have been found to bind with the CB2 receptors in the body, activating the body's own systems for reducing inflammation and pain. This topical cannabis lotion combines the medicinal properties of select strains of cannabis into deep penetrating shea butter lotion that quickly and effectively delivers the medicinal cannabinols to injured and painful areas of the body, providing relief within seconds, and lasting for hours. Quick absorption into the skin and tissues means you can re-apply as needed or to increase dosage. As the medicinal cannabis is absorbed and remains substantially in local body tissues, it does not cause the same psychoactive "high" one feels after smoking or ingesting marijuana/cannabis. Preliminary tests have shown that even heavy usage of this medicinal cannabis lotion did not show up in urine-analysis screens for cannabis. However the Cannabis Manufacturer cannot guarantee undetectable amounts of THC in blood or urine samples after use.

The topical/medicinal cannabis lotion absorbs quickly into the skin, and does not leave an oily residue on the skin that stains clothes. One application of the cannabis lotion, when in pain, or every few hours, is usually sufficient. Higher dosages can be achieved by rubbing additional applications to the same location, as the cream absorbs quickly. Many people report great benefits from applying the cream before bed and first thing in the morning. Most patients who use the cream do not report of any psychoactive effects from its use.

Tauriga's CEO Dr. Stella M. Sung commented, "The signing of this definitive agreement is an enormous achievement for Tauriga and positions the Company as a potential leader in the fast growing medicinal cannabis sector. In our opinion, the Cannabis Manufacturer's products harness the medicinal benefits of cannabis through a topical cream without negative psychoactive effects. This may especially benefit people with severe arthritis and other chronic pain conditions, and the Company anticipates that it will conduct rigorous clinical testing in the near future once there is more clarity on the potential regulatory path. Additionally the Company is well attuned to the legal precedents that are rapidly changing with respect to the medicinal cannabis sector and will work diligently to be positioned correctly as legislation becomes better defined on a national level. It has been a pleasure to work with the founders of the Cannabis Manufacturer and we are fortunate to have such talented, knowledgeable, and passionate individuals to build our futures with."

Tauriga Sciences Inc. was represented by The Global 100 law firm, Nixon Peabody LLP ("Nixon Peabody") in completing this definitive merger/acquisition agreement.

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On January 28, 2014 the Company completed its acquisition of Cincinnati, Ohio based Pilus Energy LLC ("Pilus Energy"), a developer of alternative cleantech energy platforms using proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater. The Company's corporate website can be found at (www.tauriga.com).

About NIXON PEABODY LLP

Nixon Peabody LLP is a full-service law firm that helps clients navigate complex challenges in litigation, real estate, corporate law, and finance. With more than 600 attorneys throughout the U.S., Europe, and Asia, the firm has the ability to handle matters anywhere in the world, ensuring that clients get the right attorneys, right where they need them. Our focus is on listening to our clients and working collaboratively to help them achieve their business objectives. We have the experience to anticipate and capture opportunities, prepare for and manage risks, and forecast and overcome obstacles (www.nixonpeabody.com).

 
 

 
 
NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.


Contact:
Tauriga Sciences, Inc.:
Dr. Stella M. Sung
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697
Email: ssung@tauriga.com